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Chapter 1 
Motivation and General Outline 
1.1 Pharmacological Motivation 
1.1.1 Pharmacokinetics 
When studying the characteristics and rational uses of a drug, the intensity 
and duration of action playa vital role. These two parameters are related to 
the concentration of drug at its site of action and the time during which the 
effective amount of drug remains active there. 
As the concentration of drug at its site of action is in most cases un assessable, 
the more accessible measure of blood plasma drug concentration is most often 
used to determine the intensity of drug at its site of action provided that 
there exists a good understanding of the processes involved in the evolution of 
the drug within the body. In determining drug action is, therefore, crucial to 
measure drug blood plasma concentration at different times and to understand 
the processes involved in its evolution. 
Figure 1.1 illustrates the effect of a drug as a function of drug concentration 
in blood plasma over time. For that purpose, a plausible blood plasma drug 
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Figure 1.1: Drug concentration and effect. A typical blood plasma drug con-
centration following a single dose orally administered. The total effect of the 
dose will be determined by the time that drug concentration levels exceed a 
minimum concentration level, Gmin , required in order to produce an effect. 







- - - - - - - - - Effective dose 
~------------~----------------------TIME 
concentration-time relationship is drawn. It is shown that immediately after 
administration, drug concentration in blood rises rapidly as the substance is 
being conducted into the circulatory system. Eventually, when no more drug 
is to enter the circulatory system, peak plasma concentration will be reached, 
and it will start decreasing as the drug is being delivered into other organ and 
tissues and is being removed from the body. 
The rates of absorption and distribution govern the time of onset of drug's 
action; the rates of metabolism and excretion govern its duration; while the 
size of the dose, in combination with these effects, governs the intensity. 
The degree of biological effect produced by a drug is a function of the amount 
2 
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of drug at the target site which, at the same time, is a function of the amount of 
drug found in the circulatory system. Only a fraction of the quantity reported 
in the blood plasma will reach the desired site of action. This last fraction of 
the dose is the only one that will actually be effective for therapeutical pur-
poses and, consequently, the one that will determine the final intensity and 
duration of the aimed effect at the target organ or tissue. For instance, in the 
concentration-time profile presented in figure 1.1, a 'minimum concentration', 
Gmin , has to be encountered in the blood plasma sample for the drug to reach 
the target site at a effective amount. For most drugs a quantity as important 
to determine as this minimum concentration level is the 'maximum concentra-
tion', Gmax • Above this level toxicity may occur as the substance can have side 
effects in different organ and tissues. 
A good understanding of the drug flow within the body would lead to optimal 
doses given that there is a knowledge of the actual effect that certain drug 
concentration profiles produce in different parts of the body. 
Pharmacokinetics is the study of the absorption, distribution and elimina-
tion of drugs with respect to time. The quantitative importance of each of 
these processes for a given drug will determine the ultimate drug concentration 
achieved at the desired site of action and the implied level of toxicity. Gibaldi 
and Perrier (1982) constitutes an excellent introduction to the subject. 
The discipline of pharmacokinetics, and the related discipline of drug metabolism, 
have evolved rapidly from being minor, almost insignificant contributors to the 
drug discovery and development process, to the present situation where they 
playa major, pivotal role in all phases from early discovery through develop-
ment, and beyond. The increasing role of pharmacokinetics in drug discovery 
and development has emerged as a result of maturation of scientific awareness 
of its importance and also advances in analytical and computer technology. 
3 
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By necessity, pharmacokinetics is highly interdisciplinary. These interactions 
reflect the ultimate purpose of pharmacokinetics, which is not merely to math-
ematically describe the time course of drug disposition, but to provide one of 
the critical scientific components that contribute to understanding of drug 
efficacy and safety .. 
1.1.2 Pharmacokinetics and Pharmacodynamics 
It is broadly recognised that drug effect may on occasion be directly asso-
ciated with the time course of drug or drug metabolites in the circulation. 
Nevertheless, the relationship between drug concentration and response can 
be quite complex such that the temporal relationship might be difficult to dis-
cern on first examination. An exhaustive quantitative description of the dose-
concentration-effect-time relationship is required for a better understanding of 
the drug course in the patients' organism. Pharmacodynamic models relate 
some response measurement to the dose or to some function of the plasma 
drug concentration. 
The mathematical modelling activity of the dose-concentration-effect-time re-
lationship stimulates the integration of both pharmacokinetic and pharma-
codyamic behaviour during both preclinical and clinical trials. Pharmacokinetic-
Pharmacodynamic (PK/PD) models can lend substantial support to hypothe-
ses of pharmacological mechanisms of action in complex biological systems 
that would otherwise be in most cases untractable. 
Knowledge that a specific test for pharmacological activity gives rise to expo-
sure values predictive of, but not necessarily the same as, values in humans 
can facilitate initial dose-ranges studies in preclinical animal trials (Collins et 
al. 1990). For example, Unadkat et al. (1986) developed an integrated model 
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antagonists based on canine data. Verotta et al. (1991) generalised the model 
to accommodate possible irreversible blockade and noninstantaneous reversal 
kinetics and illustrated its ability to describe the time courses of edrophonium 
and neostigmine in humans. Thus PK/PD models can facilitate the cross-
species comparisons of pharmacological activity. 
An understanding of the time course of drug effect and how it is influenced 
by formulation, environmental, and patient factors is essential for the efficient 
design of clinical studies and the eventual use in therapy. In early clinical 
studies in humans, relevant dose-concentration-effect-time data are collected 
and analysed. 
Subsequent intensive studies in appropriate patient groups using 'dose titra-
tion' or cross-over studies clarify individual dose-concentration-effect relation-
ships over time, giving estimates of pharmacodynamic parameters. Pharma-
codynamic modelling can provide important clues about the complexities of 
drug effect that only emerge over time such as sensitization, tolerance or the 
contributions of active metabolites. Early recognition of these characteristics 
can prevent irrational study designs that lead to inadequate demonstration of 
efficacy or excessive, unnecessary toxicity. 
The total preclinical and clinical experience obtained during drug development 
should give rise to a reasonable understanding of the dose-concentration-effect-
time relationship such that guidelines for individualisation of dosage regimens 
can be based on patient characteristics, disease intensity, and other risk factors 
(Sheiner, 1991). The power of PK/PD modelling to identify why important 
subpopulations of patients may respond differently has been illustrated for 
different drugs (Stanski and Maitre, 1990, Scott and Stanski , 1987). 
5 
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1.2 Statistical Motivation and General Out-
line 
The ultimate aim of this work is to describe a methodology to construct a 
model that both quantitatively and qualitatively associates drug administra-
tion to changes in complicated biological processes. The particular process we 
are going to focus on is the evolution of leukaemic cell populations. There-
fore, the main goal will be to relate leukaemia treatment to the evolution of 
leukaemic cell populations. A better understanding of this relationship would 
improve current treatments by administering drugs more efficiently and effec-
tively. 
Any effort in trying to establish a direct and precise relationship between a 
drug dose and a number of leukaemic cells at certain time will most proba-
bly be condemned to failure due to the amount of intercorrelated biological 
and physiological processes, most of them unknown, involved. The attempt 
to encompass all these processes within a tractable statistical model without 
loosing its biological essence, is in itself of great interest. 
The modelling approach taken in this work is primarily 'data-oriented' in the 
sense that the starting point of the task is to identify those relevant variables 
for which data can be collected. Blood samples are usually taken from pa-
tients during treatment. Standard techniques allow the measurement of blood 
drug concentration levels and the number of leukaemic cells in blood during 
treatment. 
The structure of this work follows the natural steps required to build such a 
model based on surrogate information derived from blood samples: a phar-
macokinetic model relating doses with blood drug concentration levels, a cell 
kinetic model explaining the evolution of leukaemic cell populations and a 
6 
1.2. Statistical Motivation and General Outline 
pharmacodynamic model describing the effect that certain blood drug con-
centrations initiate in the kinetics of leukaemic cell populations. Necessary 
pharmacological concepts will be followed by the required statistical method-
ology and advances. 
Pharmacokinetics 
All the physiological processes that determine the evolution of administered 
substances within the body should be captured by few manageable processes 
and adequate descriptive mathematical models built. This is discussed in 
chapter 2, where the main pharmacokinetic processes are explained and com-
partmental models introduced. These models aim to explain general trends of 
the corresponding processes. 
Blood concentration levels and dosing histories of different patients are usu-
ally available. These data are usually very sparse both within and between 
individuals. In addition, repeated measures from the same individual are of-
ten correlated and conform to a pattern non-linear in a set of parameters of 
interest. These kind of scenarios have been successfully handled by setting 
appropriate 'non-linear hierarchical population models'. This approach will 
be taken in chapter 3 from a fully Bayesian approach that we advocate due to 
several beliefs and practical reasons that will be exposed. An introduction to 
Bayesian inference will be presented. 
'Markov chain Monte Carlo' techniques facilitate enormously the inference for 
'Bayesian non-linear hierarchical models'. The main algorithms and several 
technical and practical issues will be addressed and discussed. 
The physiological and statistical theory developed in previous chapters will be 




The second step required to build the aimed model is to study the evolution of 
leukaemic cell populations prior to treatment, that is, to study the cell kinetics 
of leukaemic cell populations. This will enable us to identify the drug-specific 
effect in the cell population. 
Two approaches will be taken to model cell populations in chapter 5: the 'Con-
tinuous time Markov Process' approach and the 'Branching Process' approach. 
These two branches of stochastic modelling will be introduced and several new 
population-growth models built. The pros and cons of these models will be 
discussed. An easily tractable novel approximation of one of the main limit 
result of Branching Process theory will be presented. 
Pharmacodynamics 
Lastly, when treatment starts the observed number of leukaemic cells will be 
modelled as a function of, apart from its inherent kinetics, blood drug concen-
tration levels. The underlying processes are known to be drug and individual 
specific. General pharmacodynamic models are introduced in chapter 6. Ob-
served data (number of leukaemic cells in blood samples) are usually very 
sparse and vary between and within individuals. 
Consequently, in order to capture as much variability as possible, the popu-
lation approach will be taken. Different new 'fully Bayesian non-linear pop-
ulation pharmacodynamic models' will be proposed for the special scenario 
we are concerned with, that is, changes in leukaemic cell populations due to 
treatment. 
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Global Model 
The resulting global model constitutes a novel 'fully Bayesian population 
pharmacokinetic-cell kinetic-pharmacodynamic hierarchical model' that, we 
believe, is able to capture the main underlying biological processes that dic-
taminate the effect of drugs. 
This global model will be applied to real data in chapter 7. Unfortunately, as 
we will see, the resolution of the available data set is not the desired one, and 
several simplification the of the general model will be required. Therefore, the 






There are innumberable pharmacokinetic processes that will determine the fate 
of substances introduced in the organism. These can be grouped in three main 
processes: absorption, distribution and elimination. 
The two main complementary approaches to analyse these processes quanti-
tatively (e.g., compartmental and non-compartmental approaches) are briefly 
introduced in the first section of the chapter. A qualitative and quantitative 
description of the absorption, distribution and elimination processes follow in 
sections 2.2, 2.3 and 2.4 respectively, using the language of the compartmental 
approach. Different mathematical models are built to describe the drug con-
centration time course within the body following a rapidly administered single 
dose, either intravenously or by the oral route. 
More generalised dosing schemes are introduced in the pharmacokinetic models 
in the last two sections: infused dosing in section 2.5 and multiple dosing in 
section 2.6. 
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2.1 Introduction 
There are two approaches to analysing pharmacokinetic data -usually blood 
drug concentration samples collected at different times. One is the 'compart-
mental analysis' where an appropriate mathematical model is built to describe 
the transfer of a drug from its absorption site to the blood and the various 
steps involved in the distribution of the drug throughout the body. This phar-
macokinetic model has to be coherent with experimental data in order to use 
the achieved model parameters for prediction of blood plasma concentration 
after dosing. For compartmental pharmacokinetic theory and applications see, 
for instance, Gibaldi and Perrier (1982), Jusko (1992) and Rowland and Tozer 
(1995). 
The second approach is the 'non-compartmental analysis'. Non-compartmental 
analysis does not require the assumption of a specific compartmental model for 
the drug. It rather focuses in the area under a plot of the plasma concentration 
versus time curve. The advantages of this approach are the disadvantages of 
the compartmental modelling approach and vice versa. Non-compartmental 
theory has been mainly developed in the last two decades due to the work 
of Benet and Galeazzi (1979), \Vatary and Benet (1989) and Nakashima and 
Benet (1989). For a discussion of the pros and cons of non-compartmental mod-
els versus compartmental models see, for example, Gillespie (1991), Kumper-
scak and Kozjek (1998) and Rescigno (2001). 
These two approaches are not exclusive but complementary and should be 
used in conjunction for a better understanding of the kinetic processes that 
dictate the time course of the administered substance within the body. In 
what follows, we will concentrate on compartmental models, but considering 
them just as a part of the ultimate task. In fact, basic non-compartmental 
concepts will be introduced briefly within the compartmental framework. 
12 
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Figure 2.1: Main Pharmacokinetic Processes. Schematic representation of the 
interrelationships between absorption, distribution and elimination of drugs 
that are injected or orally administered. 
Dose of Drug 
°nistered admi 
Drug concentration ELIMINATION Drug metabolised 
ABSORPTION in systemic circulation ~ or excreted 
Drug concentration Drug in tissues 
at site of action DISTRIBUTION of distribution 
Therefore, to describe the fate of a drug in the body quantitatively, and even 
qualitatively, a mathematical model for the body is going to be built and 
assumed. To include all known kinetic processes in a pharmacokinetic model 
would be of no practical use because of mathematical difficulties. It is often 
more convenient to construct simple models that take into account only the 
main processes in a meaningful way. In the literature different compartmental 
models have been applied to study the pharmacokinetics of different drugs and 
dosing regimes. For recent applications, see for instance, Wu and Furlanut 
(1998), Lewitt and Lewitt (1998), McCarley and Bunge (2000) and Yukawa et 
al (2001). 
The most important pharmacokinetic processes -e.g., Absorption, Distribution 
and Elimination- are shown schematically in figure 2.1. The administered 
substance needs first to be absorbed by the body before entering into the 
circulatory system. From the circulatory system drugs are both distributed 
to different parts of the body, including the site of action of interest, and 
13 
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excreted irreversibly from the body. In what follows, each of these processes 
will be described in more detail. 
2.2 Absorption 
2.2.1 Introduction 
As drugs are usually xenobiotics (Le., substances that are chemically foreign 
to the body), they have to gain entrance into the body in order to produce 
an effect by the oral or the rectal route, inhalation, injecting it directly (Le., 
intravenously) or indirectly (Le., intramuscularly or subcutaneously) into the 
circulatory system, depending on the specific drug's characteristics and clinical 
targets. All these routes can be classified as 'enteral' (to do with the gastroin-
testinal tract, e.g., the oral and the rectal route) or 'parental' (other than 
intestine, e.g., intravenous, intramuscular or subcutaneous administration). 
'Bioavailability' is defined as the fraction of unchanged or active drug reach-
ing the systemic circulation following administration by any route, that is, 
the fraction which is absorbed by the organism. When drugs arc adminis-
tered parentally, the bioavailability is usually supposed to be equal to unity. 
Nevertheless, when orally administered, the dose is absorbed from the gas-
trointestinal tract into the circulation and, therefore, it can be extensively 
metabolised in the gut and in the liver before reaching the systemic circula-
tion. This is called the 'first-pass effect' and it can be of great importance 
for some substances. This effect is drug dependent, and has to be studied in 
order to decide which drug to use and how to administer it for different specific 
targets. 
Other factors which are of importance for the absorption extent of a drug 
are the chemical form (e.g., salt, ester), the dosage form (e.g., tablet, cap-
14 
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sule), and many irregular pharmacological or physiological processes which 
may complicate enormously the absorption process of a drug before reaching 
the circulatory system. 
In addition to the fraction of the dose gaining entrance into the circulatory sys-
tem, the velocity of the absorption process has to be studied as well. Slowly 
absorbed drugs may not achieve sufficiently high concentrations at the site of 
action to ensure the desired effect even if the entire dose is absorbed (e.g., uni-
tary bioavailability factor). The bioavailability factor of a specific formulation 
of the drug will be one of the determinants of the therapeutic effect. 
The 'Area Under the Concentration-time Curve', AUC, represents the amount 
of drug that is actually being absorbed. Hence, a comparison of these areas 
after equivalent oral and intravenous administration expressed as a percentage 
gives the bioavailability of a drug following oral administration. 
Two typical drug concentration-time curves are shown in figure 2.2 for intra-
venous and oral dosing. Assuming that the administered doses are exactly the 
same in both cases, the bioavailability of this particular drug would be close 
to unity, as the areas under the curve do not seem to differ substantially. 
Note that concepts such as bioavailability and the AUe are purely physiological 
and that they do not rely on any model assumption. 
In the next section a compartmental approach is presented to describe the 
absorption process where modelling assumptions are required and the concepts 
presented therein are, therefore, intrinsically model dependent. 
2.2.2 Compartmental Approach 
For many drugs, when orally administered, the absorption process from the 
gastrointestinal tract may be described by a 'first-order kinetic' process. With 
15 
Chapter 2:Main Pharmacokinetic Processes 
Figure 2.2: Bioavailability of a drug. Comparison of concentration-time curvcs 




first-order kinetics it is meant that the rate of change of drug concentration 
by any process is directly proportional to the drug concentration remaining to 
undertake that process. This concept will be explained with more detail in 
following sections. 
With first-order absorption, the amount of drug in the gastrointestinal tract, 
xo, may be described by the following linear differential equation: 
dxo ) dt = -kaxo(t , (2.1) 
where xo(O) is given by the administered dose and ka > 0 is the 'absorption 
rate constant'. This is the proportion of the remaining amount of drug in 
the gastrointestinal tract that enters into the circulatory system, which in a 
first-order absorption process is assumed to be constant. 
This kinetic behaviour is linear, a simplification that in most applications has 
been done but that by no means should be generalised. Time dependency 
in kinetic variables has been observed for some drugs, and several non-linear 
models have been proposed and used in the literature. For general readings 
16 
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on non-linear kinetic models see, for example, texts such as Lassen and Perl 
(1979), Gibaldi and Perrier (1982) and Levy (1982). 
Equivalently, if we assume for the moment that the drug is not being eliminated 
from the body, the amount of drug in the circulatory system, say Xl, would 
then be given by the following linear differential equation: 
(2.2) 
where Xo is the amount of drug in the gastrointestinal tract and ka is the 
absorption rate constant. The solution of equations (2.1) and (2.2) would 
determine the time course of the amount of drug in the gastrointestinal tract 
and in the circulatory system at any time. 
In addition, in some applications the time course of concentration in blood 
may suggest a 'time-lag' between oral administration and the apparent onset 
of absorption. In this case equation (2.1) can be written as follows: 
dxo { 0 
dt = -kaxo(t -llag) 
where llag is the corresponding time-lag. 
for t < llag 
for t ~ llag 
(2.3) 
For further models and absorption routes see, for instance, Creasy and Jaffe 
(1991), Robinson (1991) and Andersson et al (1994). 
2.3 Distribution 
2.3.1 Introduction 
Once a certain fraction of the administered drug has entered the circulatory 
system, blood samples can be taken and drug concentration in blood plasma 
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reported. A fraction of this drug will be bound to plasma proteins and will 
therefore be pharmacologically inactive. Therefore, all the processes involved 
in protein binding will be crucial for the amount that actually is free to be 
distributed along the tissues and, eventually, reaches the target site of action. 
The volume of distribution, V, for a drug relates the amount of drug in the 
body, say x, to the concentration of drug, C, in blood plasma: 
x 
V=C' (2.4) 
The volume calculated using equation (2.4) is an 'apparent volume of distribu-
tion' because it does not refer to any identifiable physical site in the body. It 
is simply the volume necessary to contain the amount of drug homogeneously 
throughout the body at the concentration found in the blood plasma. Drugs 
with a very high apparent volume of distribution have much higher concentra-
tions in extravascular tissues than in the vascular compartment and, therefore, 
they are not homogeneously distributed. 
From the circulatory system, the drug moves to different anatomical tissues 
and organs following rather complex and sometimes correlated kinetics - distri-
bution, metabolism, excretion. In the compartmental approach each of these 
sites, and even parts of them, are thought of as a single compartment where the 
substance enters at some point, stays in there for a certain period and leavcs 
it reversibly or irreversibly, changed or unchanged, following certain kinetic 
behaviour. Within a compartment the kinetic mechanisms are supposed to 
be equal so that, the-drug fraction that reaches a compartment is distributed 
uniformly along it, and it is eliminated or transferred to other compartments 
following the same kinetics all over it. 
Every attempt for first identifying all the different compartments and second 
assigning specific kinetic patterns to each of them, seems therefore condemned 
18 
2.3. Distribution 
Figure 2.3: One-Compartment Model. The body is treated as a single com-
partment where the drug is intravenously administered. The drug is uniformly 





to failure. Nevertheless, quite often many of the processes involved in the 
evolution of a substance within the body might be fast or not significant for 
a given drug, being reasonable, and sometimes necessary, to model them as a 
single process. 
In a multi-compartment model, drugs first enter into the central compart-
ment, normally comprising the blood plasma, and from there are transferred 
reversibly into all other compartments, called peripheral compartments, fol-
lowing certain kinetic patterns. The actual identification of pharmacokinetic 
compartments with real anatomical tissues or organs is rather complex and, 
at times, impossible. When drugs are administered in a way that do not give 
direct entry into the central compartment (e.g., oral administration) the pre-
liminary absorption phase needs to be introduced in the model as well. The 
absorption phase will take place in the corresponding absorption compartment. 
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Figure 2.4: One-Compartment Mod 1. ub tan 
understood as a single compartment wh r dru ~ 11 win 
uniform kinetic pattern. 
DRUG IN - x 
... IMIN 
-
2.3.2 Single-Compartment Mod Is 
In a one-compartment model, the body is und r t d a a in I 
or liquid container where on e a drug is introdu d it pr ad r idl uni~ rml. 
through all the organs and ti sue. F igur 2.3 r pr 
environment which is meaningful for c rtain dru s £ I' whi h i 
all body compartment ar in rapid quilibrium wi h h 
This means that the drug is uniformly di tribu d thr 1I 
Figure 2.4 describe chemati ally th 
is injected directly into th ntral mpartm nt nd i i di 
taneously and uniformly through th 
whole body. Eventually the drug ha t b liminat fr m hi nl 
ment. 
Even though the one-compartm nt mod 1 might s m t b 
ha be n applied ucce fu lly in sam as (Matu 
1984, Lee et at 1989, Norman 1992) nd work in th In th d I 
(Hoke and Ravis, 1992, Purv ,1993, Br nt tal, 1 6, Wu, 2 ). 




Sometime it i mor cony ni n t th b I a ' w (r m r ) 
different compartm nt . Th fir t mpar m nt far pid 
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Figure 2. 5: Two-Compartment Model. T he body is divided in two different 
compartments. Immediately after intravenous administra tion , the drug enters 
the circulatory system and organs and t issues with high blood-flow. More 








mixing central compartment , usually made up by blood and those organs or 
ti sues that have high blood-flow. The second or peripheral compartment will 
equilibrate with the drug over a longer time period after administration. T his 
is ill ustrated in figure 2.5. 
\ \Then a two-compartment model is assumed , the central compartment has a 
,"olumc referred to as VI or ini t ial volume. The substance will then be dis-
tributed into the second or peripheral compartment , so that th ini t ial volume 
will deer ase as the volume in the second or peripheral compart ment , V2 , in-
cr ases. T he sum of VI and V2 is the total apparent volume of distribution , 1/ . 
Therefore, high drug concentrations in plasma immediately after administra-
tion may be due to the t ime that consumes the delibera tion of the drug into 
t he peripheral compartment. 
\Vh n designing a do e it is important to know whether the target site behaves 
a bel nging to the central compart ment or to the peripheral compartment , 
and to calculate it on the basis of t he total volume of distribution , V. Plasma 
21 
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Figure 2.6: Two-Compartment Model. T hen' axe two cO ll1partllH'llt s wilh 
different kine tic patterns with constant fl ows betw('(' 11 cO lTlpartm (,llt s. 
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concentrations which arc obtained before cii stribu t ion is cornplC'l(' will Il ot r('-
fl ect the peripheral compartment at eq uilibrilllll. 
Figure 2.6 describes a two-compartme tl t model wh('r(' th(' drllg is ('xc illsiwly 
eliminated from the central compartment. Here, kl :l ;)("(,Ol ln ts for (II ' fra '1 ion 
of drug that is distributed from the centra l cO lTlprt rt lll (, ll t to th (' peripheral 
compartment , and k21 for the fraction of drug t hat rct lJrllS from ti1(' pC'ripIH'ral 
compartment to the central compartmell t. s lI a ll y thrse n ws satisfy first 
order kinetics so that all the fractions are co nstall t. 
Two-compartment models are widely used in phanllacok il1 (,t.i ·s H'sc'1Hch. R -
cent applications and developments in Iud Yashiro et al (1904), Illye' alld \Vill 
(1995), Chappell (1995), Artemov et al (1998) , Tso llki as a ile! ('org ' (1 ). 
Yllkawa et al (2001) and Catl in t al (2001 ). 
In the samc way, it is sOII1('times II C 'cssary to cO ll cC' ptu 'lIi s(' t1lrc(' difrc' rC'1l1 C( Ill -
partments within th body wh n mod ' Ilill g plas lll a cOIl c-c ll Lrat ions of certaill 
drug. Again , there wi ll be a central CO lllpart lll C' ll t wit. h rap id dnl l!, !lIixin g. 




Three-compartment models are also being applied in pharmacokinetic studies 
of different drugs. See, for instance, Tingle and Park (1993) , Sabot et al (1995) 
and \ Vu and Furlanut (1998) and ref renc s therein . 
2.4 Elimination 
2.4. 1 Introduction 
Aft r , and during, a drug is distributed within the body it has to be eliminated. 
The fraction of drug that has not been absorbed is not considered as being 
eliminated , a it i con idered to be 'out ide' the body in the first place. There 
are some mechan i m whereby the molecule has its bioactivity terminated 
by biotran formation (metabolism) and is excreted from the body (through 
kidneys, liver , etc .). Otherwise, drug effects would last the lifetime of the 
ho t. 
The two maj or site of drug elimination are the kidneys and the liver. Clear-
anc of unchanged drug in the urine represents 'renal clearance ' . Within the 
liver. drug elimination occurs via biotran formation of parent drug to one or 
mor m taboli te , or ex retion of unchang d drug into t h bil , or both. 
Drug clearance repre ents the volume of blood or plasma that is being com-
pletely clea red (because of elimination from the kidneys) of drug per unit of 
tim. 
C _ RE L --C 
(2 .5) 
where is the plasma concentration and RE is the rate of elimination which 
a count for the t ta l amount cleared from the body per unit of time (not jllst 
from the plasma) . Th greater t he value of plasma clearanc , the greater will 
be the rate at which th drug will be removed from th body. 
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The total body clearance, CL , comprises the renal clearance, the metabolic 
clearance and other possible clearance sites. 
The rest of this section will be devoted to pharmacokinetic compartmental 
models following a single dose with no previous dosing. 
2.4.2 The One-Compartment Model Following Intravenous 
Administration 
Different types of drugs follow distinct kinetic patterns. \Vhen is said that the 
elimination process from the body of a drug follows a 'zero order kinetics' it 
is meant that the plasma concentration decreases at a fixed amount per time. 
A plot of concentration against time would produce a straight line. 
Nevertheless, for many drugs the elimination process follows 'first order ki-
netics'. As said before, in a first-order kinetic process the rate of change in 
drug amount is proportional to the first power of the concentration of a drug. 
Therefore, the concentration of drug in the body will diminish logarithmically 
over time. This assumption implies that the rate of elimination, RE, 
dx 
RE = -- = ke/x, dt (2.6) 
where x is the total amount of drug in the body as illustrated in figure 2.7. The 
rate of elimination is proportional to the drug concentration and, therefore, 
the fraction of the total amount of drug that is removed per unit of time will 
remain constant, independently of the dose administered. This constant is 
called the 'Elimination Rate Constant', kez, and satisfies: 
k RE RE CLC CL 
el = -X = VC = VC = V· (2.7) 
\Ve can now rewrite equation (2.5) and find the relationship between the elim-
ination rate constant and the evolution of drug concentration: 
dx dx de 
kel = - dt Ix = - dt I(VC) = -TtIC, (2.8) 
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Figure 2.7: First order elimination in a one-compartment model follow-
ing intravenous administration. Typical concentration-time and logarithmic 

















This exponential behaviour of the plasma concentration is shown in figure 2.7. 
The elimination rate constant is the constant slope of the logarithm of the 
plasma concentration against time. 
Integrating up equation (2.9), a single exponential equation follows: 
(2.10) 
where A is the dose-dependent constant accounting for the concentration just 
immediately after administration. This constant can be determined by not-
ing that, when no previous doses have been administered, immediately after 
intravenous administration the total amount of drug in the body is the dose 
(bioavailability equals to one when considering intravenous administration), 
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and therefore recalling equation (2.4) , 
D 
V = C(O) C(O) = D 
where D is the administered do 
- k It (2.11) 
For convenience, the elimination rat on t nt i ft n xpr , d in rm r 
the drug's 'elimination half-m ', or '/3 half-lif '. Th /3 half-Iif 
amount of time required for th plasma drug 
half starting from any time point. Thi on p i r lat 
rate constant by the formula: 
C(t) C(t1/ 2) = C(t) k el t l /2 => 2 
In2 k ltl/2 => 
In2 
tl/2 k-; = r lln2, 
where Tel is the time con tant for limination that 'ati fi 
Equation (2.11) an now b xpr d a foIl w , 
D - k It D _.-L D --t '-C(t) = V e = V T. I = V 2 1/2. 
This equation r pr sent the r lation hip b 
the drug concentration. Wh n the liminati n half- im 








predict the drug cone ntration in th b dy t an tim t ft r d in . I will 
take on half-tim to liminat 50% f all 
tim s to eliminat 75o/c , thr h If-tim t !imina 7. rc f ur h< )f- im 
eliminate 93.75% and 0 on. 
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Figure 2.8: One-Compartment Model after oral administration. The substance 
rcaches the circulatory system at a constant rate ka and is eliminated from the 








2.4.3 The One-Compartment Model Following Oral Ad-
ministration 
\Vhen a drug i orally administered it does not reach the circulatory system 
immediately after administration. As mentioned before, the substance has to 
be metaboli ed in the gastrointestinal t ract and other tissues in order to be 
absorbed at orne extent . 
\Ve will assume that drug absorpt ion from the gastrointestinal tract may be 
described bv a first-order kinetic process. That is to say that the amount of 
drug that is bing absorbed by the gastroint stinal tract is proportional to the 
amount of drug remaining to undertake the absorpt ion process (see equation 
2.1). This cons tan t proportion is called the 'absorption rate constant ' ka ) 
already introduced. 
T he differential equations that describe first-order absorption and elimination 
r pr ented in figure 2.8 are the following: 
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where Xo is the total amount of drug that enters the body (e.g., the absorption 
compartment) and Xl accounts for the amount of active drug that enters the 
body (e.g., the circulatory system and all the body organ and tissues within 
the monocompartment assumption). 
From equation (2.17), it follows immediately that, 
(2.18) 
where Al is a constant that can be determined by noting that right after oral 
administration the total amount in the absorption compartment is the fraction 
of the dose that reaches the absorption phase actively. That is, 
Xo(O) = Al = FD, (2.19) 
where F denotes the bioavailability factor and D is the administered dose. 
Sometimes, as it will be shown, is necessary to consider a short delay between 
the intake of a medicine and the onset of the absorption process. 
From equation (2.19), it follows immediately that, 
(2.20) 
It is straightforward now to solve equation (2.16). Substituting xo(t) in equa-
tion (2.16) we get that, 
Xl(t) = FD ka e-kat + A2e-krlt, 
kel - ka 
(2.21) 
where A2 is a constant to be determined. Assuming that at the time of ad-
ministration there is no dru_g in the body (that is to say that no drug has been 






Hence, the solution is given by: 
(2.24) 
The real amount of active medicine in the body, XI, is unobservable. Never-
theless, drug blood concentration levels can be measured and, from equation 
(2.4), it follows that, 
C(t) = Xl(t) = FD ka (e-ke/t _ e-kat ). 
V V ka - kel 
(2.25) 
In figure 2.9 a theoretical drug concentration curve is represented. Generally 
ka > kef, and hence the second exponential of equation (2.25) is usually faster 
than the first one. Therefore, the concentration-time curve starts increasing 
exponentially during the absorption phase, reaches a peak value and finally 
decreases exponentially once most of the drug has been absorbed and is being 
eliminated from the body. This shape is characteristic of first-order absorption 
and elimination kinetics. 
2.4.4 The Two-Compartment Model Following Intra-
venous Administration 
As mentioned in previous sections, sometimes it is too naive to model the body 
as a single, rapidly mixing compartment. Most drugs follow very complicated 
and 'obscure' kinetics within the body. The main difficulty when dealing with 
complicated multi-compartment pharmacokinetic models is that it is very haz-
ardous to draw conclusions on the drug behaviour within several compartments 
from measurements only in plasma, and sometimes urine, compartments. 
Generally it is clinically expensive, and sometimes even impossible, to obtain 
the profile of drug concentration in other body fluids, tissues or organs. How-
ever, the dose-concentration relationship in different body compartments is, for 
many drugs, much more homogeneous than one would expect at first glance. 
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Figm e 2.9: Ollr- om part ll H'1l1 \[odr l aft('r oral adlllillisl ral illll .\ fl ' I adlllill-
istration . the suhstanc is absorbed , .1"0, Hlld 1 Ir l ' r('/"or<' p\;I ~ III H ('(l lll 'I'llt I at IClII. 
,r , o iucrr(l. e until clm g rlimi lmlio ll rx("('('ds dl"1l g ilhsorpl iOIl . 
Xo = X I 
o 
Illne 
In a t\\'o-compartmrnt rnodrl. two diffrr<'llt kill (' ti c pall('r lls arc
' 
1I1Od(' llc'd . O IIC' 
for t he crutra l compar t rn lit all d Oll r for 11](' 1)('ripllC'rid (,O lllpart IIIC' llt . ' [ hi..., i 
represcnted ch matic-ally in fi gure 2.10 . A ssllming [irst ordrr kilH' t i('~ \\ it hill 
and bct\\'c 11 compartm nts t hr dYlIa.rnicsgO\( l"Ilillg III(' l otal Hlll ()ll llt ofd lllg 
in the centra l compartment foll owillg illtraV(' lI oll s ndlllillist ra t iOll ('(\11 h ' d('-
scribcd by the foll owing cq uat ion: 
(:2.:2 » 
wh re Xl i t h total am oul1t of drug ill t lr(' (" Iltral ("o lllj>arl ll lC 'llt alld .J",! I ~ 
t h amou nt of drllg in thr p 'riplt (' ral CO lllP;'ll"LIlH' III . [I is aSS lllll( 'd I hill drug 
elimina ion (eith r by biotrallsform tiOll or h. ('X ("I"C't iOll ) {)c"("llr~ 'xrlll~i\"( ' I ~ 
from t he 'cntral 'ompartlllC'nt at a (" )ll st ;llri rat e k", . This i \ ~~ IIIllP'i ()ll i .... 
u, ually madc, 'lS ill most cas S tire vast lll a,Vori t., of I h(' (1lilllill ill i()n 1> 10("(' .... , 
0(" ' ll r. frolll thr c(,lltral ("om part lll r lll . Tlw sllbst a 11 ( ' (' fl ows frolll I h(' ('(1 11t I ill 
ompartlll r nt to the PNiplH'ra,l OIl(' (1,1. a ('ollsl ,,"I. nIl (' kl 'l ;t ile! il r< I III li S to IIIC' 
cC' ll trrtl compmt mcnt at a COllstallt rat C' k 'l l ' 
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Figure 2.10: Two-Compartment Model. Substances migrate at a constant 
rates kJ2 and k2I between compartments 1, or central, and 2, or peripheral. 
Elimination occurs exclusively from compartment 1 at a constant rate kel · 
kl2 
,[ 
2 I Xl k21 X2 
E 
kel 
T herefore, the amount of drug at the second or peripheral compartment sat-
isfies the following kinetics: 
(2.27) 
Integrating up these equations we end up with the amount of drug at the 
central compartment as a exponential function of time: 
(2.28) 
where the constants At A; , aI , a2, are determin d by the initial conditions. 
As C(t) = XJ (t)/ l 'J , ,,,,,here Vl is the volume of di stribution at the first com-
partment . it follows that : 
(2.29) 
,,,here AI = A 71 ' "1 and A2 = A;/Vj • It is straightforward to se that the 
constant Al :h aI, a2 , in terms of the original parameters are given by: 
Al D(al - k21 ) (2 .30) Vi (al - a2) , 
A2 D(k21 - a2) (2.31) - Vi (al - a2) , 
,,,here al and a2 (al > a2) are the roots of the quadratic equation: r2 + (k12 + 
k 21 + k el)1' + k21kel = O. 
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A typical exponential b haviour f h n- im 'ur I riv I r m 
equation (2.29) i pr In h ari hmi 
conc ntration-tim curv i pr nt d . 
can ee that in a two- ompartm nt mod 1 th 
compartment d creas mor r pi ly imm di 
to drug distribution into th p riph ral 
becomes he dominan pro 
be approximately linear a in h ingJ 
2.4.5 The Two-Compartm nt M 
ministration 
2. 1 
Jl ill bI 
ntrati n- im 
11 WIn 
It ha b n xplain d in ti n 2.2 that wh n lru , ar a Imini 
the ab orption pro es n ds to b m d II d . 
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Figur 2.12: Two- ompartments Model after oral admini . tration. The sub-
stance is ab orbed in the gastrointestinal tract (GI tract) and enters the central 
compartment, "\0 , at a constant rate ka . Distribution and elimination occurs 
at rates k 12 k21 and kel. 
1 k1 2 2 0 
Drug in k a Xl X2 
GI Tract k21 
kel 
the dynamics of the two- ompartment model following oral administration are 
gi ,'en by the following et of differential equations: 









where the notation has already been introduced. This kinetic behaviour is 
schematically hown in figure 2.12. 
oh 'ing equations (2 .34)-(2.36), it follows that, 
(2.35) 
\\'h r th onstant Ar A2 A3 al and a2 in terms of the original parameters 
arc gin'n by: 
A* Dka(k21 - ad (2.36) 1 (al - a2)(a, - ka)' 
A* - Dka(k21 - a2) (2.37) 2 (al - a2)(a2 - k,) ' 
A* Dka(k21 - ka) (2.38) 3 (a2 - ka)(a] - ka)' 
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Figure 2.13: Two-Compartment Model after oral administration. After ad-
ministration, the substance is absorbed and, therefore, plasma concentration 
increases until drug elimination exceeds drug absorption. The substance is 
then distributed between the central and the peripheral compartments. Elim-
ination occurs exclusively from the central compartment. 
c 
where al and a2 (al > a2) are the roots of the quadratic equation: r2 + (kl2 + 
k21 + kel)r + k21 kel = O. 
As the concentration is defined as C(t) = xl(t)/Vi, it follows that, 
(2.39) 
Figure 2.13 shows a typical blood drug concentration - time curve following 
the exponential behaviour derived from equation (2.45). The concentration 
in blood increases exponentially during the absorption phase. Comparing fig-
ures 2.13 and 2.9, notice that after the drug is absorbed, blood concentration 
decreases initially more rapidly in this two-compartment model than in the 
one-compartment model. This is due to the distribution process between the 




In previous sections, drugs have been administered either orally, in tablet form, 
or by rapid intravenous injection, known as a 'bolus' dose. Nevertheless, com-
monly in a hospital setting a patient will receive a drug by intravenous slow 
infusion, usually over 15 or 30 minutes. This will, consequently, alter the 
kinetics of the drug. 
Let TI be the length of infusion. The 'constant infusion rate', R, will be equal 
to the dose divided by the length of infusion. 
In the one-compartment model it is easy to see that (see, for example, Gibaldi 
and Perrier, 1982) the concentration of drug in the blood following a single 
intravenously infused dose is given by: 
C(t) = D _1_(e-ke/tl _ e-ke/t) 
TI Vkel ' 
(2.40) 
where TI is the length of infusion, tf = t - TI for t > TI and tf = 0 otherwise, 
D is the dose, V represents the volume of distribution and kel the elimination 
rate constant. 
\Vhen the kinetics of the drug are not uniform throughout the body and a two-
compartment model is required, the corresponding concentration following a 
single intravenously infused dose will be given by: 
(2.41) 
where TI is the length of infusion, tf = t - TI for t > TI and tf = 0 otherwise. 
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Figure 2.14: Constant-rate infusion. A drug is infused at a constant-rate during 
the length of infusion, Tl, followed by a one-compartment kinetic behaviour 
(left plot) and by a two-compartment kinetic behaviour(right plot}. 
c c 
time time 
where, al and a2 (al > a2) are the roots of the quadratic equation: r2 + (k12 + 
k21 + ket)r + k21ket = O. The rest of the notation has already been introduced 
in previous sections. 
Typical concentration-time plots for one- and two-compartment models follow-
ing a single infused dose are shown in figure 2.14. Drug is being eliminated from 
the start of the infusion, but as the infusion rate exceeds the elimination rate, 
concentration levels increase during the infusion period. \Vhen the infusion 
is stopped, the concentration will decrease according to a. one-compartment 
kinetic (left plot) or to a two-compartment kinetic (right plot) behaviour. 
2.6 Multiple Dosing 
Different pharmacokinetic models that can explain the evolution of a drug in 
the circulatory system following a single dose administered either by nn intra-
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Figure 2.15: Multiple dosing. Six doses of a drug are infused intravenously at 
constant intervals TD. The dosing regime has been designed so that after the 
fifth dose, a steady-state drug concentration is achieved. By 'steady-state' is 
meant that the concentration at any time during any dosing interval is identical 
to the concentration at the same time during any other interval. 
C 
I 
: TD I 







venous bolus or infusion or by the oral route have been described in previous 
sections. Some drugs may be effective as a single dose, for example analgesics. 
Nonetheless, more frequently, drugs are administered on a continuous basis. 
Usually, multiple doses are given at fixed intervals with sufficient frequency 
that significant levels of drug persist in the body at dosing times. The peak 
concentration level following the second and succeeding doses is frequently 
higher than the peak level after the first dose. This is not due to higher doses 
but due to the fact that concentration levels from previous doses accumulate 
in the body. 
In fact, generally the dosing regime is designed in such a way that drug accu-
mulation proceeds at a decreasing rate with increasing number of doses until 
a 'steady-state' concentration level is achieved. At steady state, drug concen-
tration in blood at any time during any dosing interval should be identical to 
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the concentration at the same time during any other dosing interval. 
Figure 2.15 shows a drug concentration time course due to a treatment con-
sisting on multiple doses of a drug at fixed time intervals. The doses are in 
this case calculated in order to achieve steady-state drug concentrations after 
the fifth dose is administered. Therefore, denoting by tD,. the time of the nth 
dose, it follows that: 
C{tDr. + l) = C(tD,. + l), (2.44) 
for all l ~ 0 and n > 5. 
The concept of steady-state drug concentration levels constitutes one of the 
bases of a rational treatment. \Ve are not going to talk any further about it 
because it will not be required in subsequent chapters. For further reading, 
see for instance, the book by Gibaldi and Perrier {1982}. 
2.7 Discussion 
The basic pharmacokinetic processes have been explained to sufficient extent to 
derive the most common compartmental models understanding the underlying 
physiological mechanisms. 
As has been shown, scientists comprise complicated physiological processes 
in tractable mathematical models. The aim is to obtain rigorous explana-
tory, descriptive and/or predictive information about the general trends of the 





In a standard pharmacokinetic study individual dose histories, individual co-
variate information and blood drug concentration measures with associated 
sampling times are usually reported. The aim is to fit the most appropriate, 
both physiologically and statistically, pharmacokinetic model. Pharmacoki-
netic data are usually very sparse both between and within individuals and 
two approaches can be taken to estimate the pharmacokinetic parameters: in-
dividual and population approach. The second is taken in this work due to the 
firm belief that there exists a high correlation structure between individuals' 
parameters. This constitutes valuable information that should by no means 
be omitted when estimating and/or predicting individual parameters. 
All the pharmacokinetic models described in the previous chapter are non-
linear in the parameters and the dimensionality of the parameter space is 
usually large. For these cases, classical inference tools rely on asymptotic 
arguments that can be hazardous to examine for particular data sets. A fully 
Bayesian approach is taken in this work instead. Due primarily to spectacular 
developments in 'Markov chain Monte Carlo' techniques in the last decade, the 
Bayesian approach offers a flexible framework to build and estimate population 
pharmacokinetic models that can be easily used for prediction and, therefore, 
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dose recommendation. In addition, when relevant prior information from other 
studies or from expert advise is available and correctly used, inference can be 
considerably improved. 
Population pharmacokinetic models and Bayesian statistics and Markov chain 
Monte Carlo techniques will be reviewed in this chapter. A fuller treatment 
and results of the former can be found, for instance, in \Vakefield and Racine-
Poon (1995). The review of Bayesian statistics and Markov chain 1\lonte Carlo 
techniques is not at all complete and can be found in general references such 
as Bernardo and Smith (1994) and Gilks et al (1996). 
An introduction to population pharmacokinetic models in section 3.1 is fol-
lowed by a general three-stage hierarchical model that accommodates all the 
models that will be applied in succeeding chapters. In section 3.3 a 'directed 
acyclic graph' is constructed for the general population pharmacokinetic model 
in order to specify the full joint distribution of all model quantities in an in-
tuitive manner. 
The rest of the chapter is devoted to a review of Bayesian inference. Special 
attention is given to Markov chain Montc Carlo tools that havc contributed 
enormously to the applicability of Bayesian inference. Some of these tools will 
be used in following chapters. 
3.1 Introd uction 
Population models have been widely used in biometrical curvc analysis (Berkey, 
1982), in educational research (Novick et al., 1972), econometrics (Swamy, 
1970) and many other fields. The problem of implementing such models at-
tracts methodological attention in the statistical literature both from a non-
Bayesian perspective (Lindstrom and Bates, 1990) and from a Bayesian per-
40 
3.1. Introduction 
spective (Gelfand and Smith, 1990). We adopt the Bayesian methodology due 
to reasons that will be explained in following sections and chapters. 
Population analyses attempt to explain and control the variability observed 
both within and across individuals. Kinetic data are usually very sparse be-
cause of the fact that in clinical trials various doses and/or dosage regimens 
and/or application routes (e.g. oral, intravenous, intramuscular) are generally 
used in different patients and in the same patient at different stages of the 
therapy. Also several responses might be measured (e.g., drug plasma concen-
tration, arterial blood pressure), and diverse administration schedules (single 
dose and chronic dosing) might be considered. 
Population sparse data arise specially in the later phases of drug development 
when the drug is administered to the patient population, usually a highly 
heterogeneous group. In early phases full profiles are available on a small 
number of well controlled individuals who are typically from a well-defined 
population. 
The basic rationale behind population models is that the set of underlying 
structural pharmacokinetic parameters is qualitatively the same for all indi-
viduals and that what vary from individual to individual are the quantitative 
values. 
These special characteristics of typical population data suggest that a popula-
tion mathematical model should encompass a collection of models for hetero-
geneous individual observations. 
The population approach has gained prevalence over the individual pharma-
cokinetic approach during the last two decades both from the Bayesian and 
from the non-Bayesian approach, and has proved enormous potential to deal 
with pharmacokinetic sparse data. The literature in this topic is very vast both 
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in the methodology and in particular applications (sec, for instance, Steimer et 
aI, 1994, \Vakefield and Racine-Poon, 1995, Vozeh et ai, 1996 and Racine-Poon 
and Wakefield, 1996, and references therein). 
3.2 Hierarchical Structure 
3.2.1 Introduction 
Population Pharmacokinetic models fit naturally into a hierarchical structure 
(\Vakefield and Racine-Poon, 1995). At the first stage of the hierarchy we 
model the data (e.g., blood drug concentration levels) from a particular indi-
vidual over time as a function of unknown parameters. 
At the second stage, the pharmacokinetic parameters from a particular indi-
vidual over time as a function of unknown parameters, defining each of the 
individual's curves, are assigned some distributional form after accounting for 
covariate information, if any is going to be considered. A Dayesian model 
then requires a third stage at which prior distributions arc specified for the 
hyperparameters defining the second stage distributional form. 
Such a model acknowledges and estimates both the within-individual concen-
trations variability (at the first stage) and the variability observed between 
different individual's pharmacokinetic parameters (at the third stage). Dy 
doing this, it is possible to determine appropriate subject-specific dosage reg-
imens that will lead to attainment of desirable concentration and response 
levels. 
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3.2.2 The General Population Pharmacokinetic Model 
Each stage of the hierarchy is now described in more detail. We present a 
general model that accommodates most of the drug-specific models (Wakefield 
and Racine-Poon, 1995). The population pharmacokinetic models used in 
following chapters will all be particular cases of this general model. 
The observed drug concentration of an individual within the framework of 
a general pharmacokinetic population non-linear mixed-effects model can be 
described as: 
(3.1) 
where Cij for j = 1, "', ni are the observed data (e.g., ni plasma concentration 
levels measured at time points tij) of the ith subject. An appropriate model of 
this type is defined for all i = 1, .", K, where K is the number of subjects in the 
sample. The function lij is a specified pharmacokinetic function that predicts 
the concentration in the ith subject at time j, ()ij is the vector of unknown 
subject-specific pharmacokinetic parameters (e.g., volume of distribution and 
elimination rate constant), Hij describes the dose history up to time tij (Le. 
amounts and times of administration) and fij accounts for the error between 
the 'true' (unknown) concentration and the corresponding measurement. Usu-
ally these errors are considered to arise from a distribution with zero mean 
and precision parameter Tij' Generally, as discussed in the previous chapter, 
this Pharmacokinetic model will take the form of a sum of exponentials. 
As mentioned before, various doses and/or dosage regimens can be used in 
different patients and in the same patient at different stages of the therapy. 
Accordingly, the functions lij will sometimes differ within and across individ-
uals. 
To complete the first stage of the hierarchy we need to assign distributional 
forms to the errors, fij' 
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At the second stage of the hierarchy, a model relating the paramrtcrs of the 
different individuals is required. Let Xij represent the value of relevant phar-
macokinetic covariates of the individual i at times tij' The population ap-
proach assumes that after conditioning on covariates (in a parametric or non-
parametric fashion), the Pharmacokinetic parameters are drawn from some 
assigned distribution. 
A model commonly assumed at the second stage is given by 
(3.2) 
where J.l represents population pharmacokinetic parameters and g(.) the value 
of these parameters predicted by the specific covariates of the individual, Xij' 
Therefore, we have that 
(3.3) 
The distribution of the 'random-effects' parameters oij is defined by the pop-
ulation pharmacokinetic scale matrix O. 
To complete the specification of a full probability model, we require prior 
distributions for variables without parents or founders (e.g. Tij, It, 0). "'c 
would often like these priors to be not too influential in the final conclusions, 
although if there is external information it may be very useful to be ablc to 
include it. In hierarchical models, it is particularly important to avoid casual 
use of standard improper priors since these may result in improper posterior 
distributions (see, for instance, DuMouchel and Waternaux, 1992). 
The appropriate specification of 'non-informative' priors is an old problem in 
Bayesian statistics, and is particularly important when techniques are to be 
used in a scientific context in which an 'objective' inference is required. This 
will be further discussed in following sections. 
44 
3.3. DAG representation 
In the present work, we will require that a full probability model is defined, and 
this forces all priors to be 'non-informative' but proper. It is, however, vital to 
distinguish parameters of primary interest from those which specify secondary 
structure for the model. The former will generally be location parameters, such 
as regression coefficients, and in many cases a normal prior with an extremely 
small precision (large variance) is adequate. 
More care is required in setting the parameters that constitute secondary as-
pects of a model. The literature has recommended to think carefully about 
reasonable values for such parameters in advance and so specifying fairly infor-
mative priors wherever possible - the inclusion of such external information is 
unlikely to bias the scientific conclusions of a study, although some sensitivity 
analysis should be performed. 
3.3 DAG representation 
Figure 3.1 shows a directed acyclic graph (DAG) that corresponds to the model 
defined by equations (3.1 )-(3.3) (directed because each link between nodes is an 
arrow; acyclic because by following the direction of the arrows, it is impossible 
to return to a node after leaving it). Each quantity in the model appears 
as a node in the graph, and directed links correspond to direct dependencies 
as specified above: solid arrows are probabilistic dependencies, while dashed 
arrowS show functional (deterministic) relationships. The latter are included 
to simplify the graph but are collapsed over when identifying probabilistic 
relationships. Repetitive structures are shown as stacked 'plates'. Rectangles 
denote either quantities assumed to be fixed or observed data, and circles 
represent all unknown quantities. 
It is important to understand that the graph represents properties of the full 
model before any data are observed and forms a convenient basis for the spec-
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Figure 3.1: DAG representation for the General Pharmacokilletic Model. Solid 
and dashed arrows represent probabilistic and deterministic relationships re-
spectively. Circles denote unknown random quantities whereas fixed or ob-




ification of the full joint distribution of all model quantities; see for example 
Lauritzen et al. (1990) or Whittaker (1990) for discussion of how to read off 
independence properties from DAGs. 
It can be shown (Lauritzen, 1996) that a DAG model is equivalent to assuming 
that the joint distribution of all the random quantities is fully specified in terms 
of the conditional distribution of each node given its parents: 
P(V) = IT P(vlparents[v]) (3.4) 
vEV 
where P denotes a probability distribution, v is a node in the graph, V is the 
set of all nodes and a 'parent' of v is any node with an arrow emanating from 
it pointing to v - in identifying parents, deterministic links are collapsed. This 
factorisation not only allows extremely complex models to be built up from 
local components, but also provides an efficient basis for the implementation 
of some forms of MCMC methods that will be introduced in the following 
section. 
3.4 Estimation 
3.4.1 Bayesian Statistics 
Until quite recently Bayesian statistics was undertaken largely by those primar-
ily concerned with contributing to the theory, and the proportion of applied 
work that was formally Bayesian was rather small. There are several reasons 
for this. First, Bayesian statistics demands a prior distribution as well as a 
likelihood function, where non-Bayesian methods do not. Second, a subjective 
prior distribution has to be defended. Third, in most problems posterior dis-
tributions cannot be obtained anyway because the required integrals cannot 
be evaluated. 
~4'L .. _ 
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When no prior information is available, the idea of a 'non-informative' prior 
distribution, representing 'ignorance' and 'letting the data speak for them-
selves' in order to provide objective inferences sounds very seductivc. A lot of 
work has been done to identify 'appropriate' procedures for formulating prior 
representations of ignorance, but no general procedurc has yet been univer-
sally proposed. Bernardo and Smith (1994), provide an overview of some of 
the main directions followed in this controversial topic. 
In many cases, however, prior information does exist. From a theoretical 
perspective discussions of the prior component inevitably focus on stylised 
forms, such as conjugate or reference specifications, which arc amenable to 
a mathematical treatment. However, there is a danger of losing sight of the 
fact that, in real applications, prior specifications should be encapsulations 
of actual beliefs rather than mathematically 'nice' forms. The key task is 
how to process the expert knowledge and opinions in the form of probability 
distribution. There is a very vast literature in Prior Elicitation. Sec, for 
example, Merkhofer (1987), Garthwaite and Dickey (1992) or 'Vest and Crosse 
(1992). 
Bayesian methods are operational only to the extent that posterior distribu-
tions can actually be computed. There are three ways in which this can be 
done. If the posterior distribution and the function of interest arc sufficiently 
simple, the posterior distribution may be obtained analytically. Most results 
in this category may be found in Bernardo and Smith (1994). If the required 
integration takes place in few dimensions, then classical deterministic methods 
of numerical analysis, principally quadrature, arc often practical. A standard 
reference for these methods is in Davis and Rabinowitz (1984). In the remain-
ing cases, which constitute the preponderance of applied work, the approach 
of choice is posterior simulation using methods such as 'Rejection Sampling', 
'Importance Sampling' and 'Markov chain Monte Carlo'. 
48 
3.4. Estimation 
The idea behind rejection sampling is to generate a random vector from a dis-
tribution that is similar, in an appropriate sense, to the posterior distribution, 
and then to accept that drawing with a probability that depends on the drawn 
value of the vector or otherwise repeat. If this acceptance probability function 
is chosen correctly the accepted values will have the desired distribution. 
In importance sampling, however, rather than accept only a fraction of the 
draws from the source density, it retains all of them, and consistently approx-
imate the posterior moments by appropriately weighting the draws. 
The ability to generate draws from non-standard posterior distributions has 
improved enormously in the past ten years, due to the development of Markov 
chain Monte Carlo (MeMe) methods and the dramatic decrease in the cost 
of computing. 
The development of MeMe methods in the last decade enables the simulation 
of samples from high~dimensional joint density functions and, as a result, the 
Bayesian approach offers a flexible and unified way of combining prior and 
sample information to obtain a complete posterior distribution upon which 
to base the inferences 1. MeMe methods will be introduced in subsequent 
sections. 
3.4.2 Bayesian Inference 
This section provides a brief overview of Bayesian inference in order to intro-
duce an explicit context of concepts and notation for following sections. The 
concepts will be very standard and can be found in many reference books, 
including Berger (1985) and Bernardo and Smith (1994). 
1 MCl\IC methods are also valuable in frequentist inference to explore the likelihood 
function. 
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Inference takes place in the context of one or more models. A model describes 
the behaviour of a vector of observables Yt over time 2 units t = 1,2, "" The 
history of the sequence Yt at time t is given by Ye = {Y,}!=t. A 'model' is a 
corresponding sequence of probability density functions: 
(3.5) 
where () is, say, k x 1 vector of unknown parameters, 0 E 9 ~ Rk and t = 1, .... 
\Ve will use 7r(.) to denote both the distribution function and the density. 
The probability density function of YT conditional on the model and parameter 
vector (), is given by: 
T 
7r(YT I(}) = IT 7rt(YtiYe-l, 0). (3.G) 
t=1 
The likelihood function is any function L(O; YT ) ex: 1l'(1'T10). 
If the model specifies that the Yt are independent and identically distributed, 
then it holds that, 
7rt(YtIYe-l, (}) = 1l't(YtIO), 
T 




The objective of Bayesian inference is to make useful inference about 0 using 
the posterior distribution 1l'(OIYT ). Computations for Dayes inference often 
reduce to computing expectations that in general can be expressed as follows: 
E[h(O)IYT], (3.9) 
where h(O) is a 'function of interest'. Droadly speaking, this function of interest 
can be: 
2Subindex t may pertain to cross sections, to time series, or both, but time series mcxlcls 
and language are used here for specificity. Likewise, it is assumed that VI is continuously 
distributed for specificity and brevity. 
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• a parameter or a function of parameters, 
• h(O) = LO(ab 0) - LO(a2' 0) in which Lo(a, 0) is the loss function associ-
ated to taking action a with parameter vector O. 
• h( 0) = Xeo (0) which arises when a hypothesis restricts 0 to a set 8 0 •3 
• a predictive density, h(O) = E[g(Y*)IYT' 0], where y* = (YT+b ... , YT+I). 
Models and functions of interest for which equation (3.9) can be analytically 
evaluated are quite limited. 
The specification of the model in equation (3.8) is completed with a 'prior 
density' 7r(O). It can be shown that given equation (3.8) and a density 7r(YT) 
(Le., a density' for the data unconditional on 0) a prior density must exist 
(Bernardo and Smith, 1996). 








Bayesian inference requires the evaluation of posterior expectations of func-
tions of O. That is, 
E[h(O)IYT] = r h(O)7r(OIYT)dO = Ie h(O)L(Oj YT)7r(O)dO. (3.13) Je Ie L(O; Yr)7r(O)dO 
In most applications, analytic evaluation of E[h(O)IYT] is impossible. Alterna-
tive approaches are needed like Monte Carlo integration. 
3X(·) is the characteristic function. X,(z) = 1 if z E S, X.(z) = 0 if z ~ S. 
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3.4.3 Monte Carlo Integration and Markov Chains 
In this section a brief overview of some elementary Monte Carlo integration and 
Markov chains theory that will be needed to understand the following section 
will be covered. The material presented here can be found, for instance, in 
Meyn and Tweedie (1993). For more specific treatment of Markov chain theory 
relevant to the study of Markov chain Monte Carlo the reader is referred to 
Tierney (1994), Tierney (1996), Mengersen and Tweedie (1990) and Roberts 
and Tweedie (1996). 
Let x be a vector comprising the unknown model parameters, latent variablcs, 
missing values and/or future data with posterior distribution 1r(.). As shown in 
the previous section, the task of Bayesian inference is to evaluate the posterior 
expectation: 
E[h{x)] = J h{x)1r{x)v{dx) , J 1r{x)v(dx) (3.14) 
where 71' is the density of 71' with respect to the measure v (hence, 1r(dy) = 
1r(y)v{dy» and h(.) is the function of interest. 
Monte Carlo integration evaluates E[h(x)] by drawing samples {Xtt t = I, .,,' n} 
from 71'(.) and then approximating the expectation by, for example, 
1 n 
E[h(x)] ~ - 2: h(xt). 
n t=l 
(3.15) 
In general, drawing samples {Xt} independently from 71'(.) is 110t feasible and, 
therefore, laws of large numbers that ensure that the approximation can be 
as accurate as desired by increasing the sample size narc 110t applicable. 
However, the {Xt} need not necessarily be independent. In fact, the {Xt} can be 
generated by any process which, loosely speaking, draws samples throughout 
the support of 1r(.) in the correct proportions. One way of doing this is through 
a Markov chain having 71'(.) as its stationary distribution. 
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A Markov chain is a sequence ofrandom variables (generally vectors), Xo, Xt, X2, ••• , 
such that at each time t > 0, the evolution of the chain on a space 0 ~ RP is 
governed by the 'transition kernel': 
P(x, A) 
where x E O,A c o. 
P(Xt+1 E Alxt = x, Xs, S < t) 
- P(Xt+1 E AIXt = x), 
The assumption that the probability distribution of the next state in the se-
quence, given the current and the past states, depends only on the current 
state is the 'Markov property'. 
That is, given Xt, the next state Xt+1 does not depend further on the history 
of the chain {xo, xl, ... , Xt-d. It will be supposed that the chain is time-
homogeneous (Le., P(.I.) does not depend on t). 
The tth step ahead transition kernel is consequently given by: 
P(Xt+m E Alxs, s < m; Xm = x) = pt(x, A); (3.16) 
that is, pt(x, A) denotes the probability that a chain at x will be in the set 
A after t steps or transitions. The independence of pt on the values of Xs, 
s < m, is the Markov property, and the independence of pt and m is the 
time-homogenei ty property. 
Under certain conditions, which will be briefly discussed later, it can be shown 
that the tth iterate of the transition kernel converges (as t ~ (0) to the 
invariant or stationary distribution, say 7r, that satisfies: 
7r(dy) = In P(x, dY)7r(x)v(dx). (3.17) 
The invariance condition states that if Xt is a sample from 7r then all subsequent 
samples will be from that distribution. Thus, after a sufficiently long 'burn-
in' of say m iterations, points {Xt; t = m + 1, ... } will be dependent samples 
approximately from 7r. 
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A chain is said to be 'reversible' if the transition kernel P(x, y) sntisfies 'de-
tailed balance': 
f(x)P(x, y) = f(y)P(y, x), (3.18) 
for a density, say, f(.). If reversibility holds, it can be shown that f(.) = 1f(.}. 
Hence, a reversible chain has 11' as its invariant distribution. 
A Markov chain is said to be '11' -irreducible' if, for every x E fl, 
If(A) > 0 => P(Xt E Alxo = x) > 0, (3.19) 
for some t ;::: 1. 
A third important property of a chain is 'aperiodicity', which ensures that the 
chain does not cycle through a finite number of sets. 
Now the following (ergodicity) result, which forms the basis for MCMC meth-
ods, can be stated. 
Proposition 3.1. If P(.,.) is If-in'educible and has invariant distribution 11', 
then 1r is the unique invariant distribution of P(., .). Then for If-almost every 
x E n and all sets A, we have the following: 
• For all1r-integrable real-valued functions h, 
t E:=l h(Xi) -t J h(x)7r(x)v(dx) as t -t 00, a.s. 
If P(.,.) is also aperiodic, then it holds, 
• Ipt(x, A) - 1r(A)1 -t 0 as t -t 00. 
The first part of Proposition 3.1 tells us that averages of functions evaluated 
at sample values (ergodic averages) converge (as t -t 00, almost surely) to 
their expected value under the target density. Later, sufficient conditions for 
'If-irreducibility' and aperiodicity will be presented. 
54 
3.4. Estimation 
The second part states that the probability density of the tth iterate of the 
Markov chain is, for large t, very close to its unique, invariant density. Hence, if 
drawings are made from pt(x, dy), then for large t the probability distribution 
of the drawings is the invariant distribution, regardless of the initial values. 
3.4.4 Markov chain Monte Carlo 
Markov chain Monte Carlo (MCMC) methods have a history in mathematical 
physics dating back to the algorithm of Metropolis et al (1953). This method 
was generalised by Hastings (1970), who focused on statistical problems, and 
was further explored by Peskun (1973). A version particularly suited to image 
reconstruction and spatial statistics was then introduced by Geman and Ge-
man (1984) and it was consequently shown to have great potential for Bayesian 
computation by Gelfand and Smith (1990). 
Since 1990 applications of MCMC methods have grown rapidly, specially for 
Bayesian inference. New generic techniques and the mathematical properties 
of different methods continue to attract a huge research effort. For an intro-
duction and overview of the theory implementation and applications of MCMC 
techniques see, for instance, the book by Gilks et al (1996). 
The idea behind most approaches to construct a MCMC method is to gener-
ate a Markov chain that satisfies detailed balance (equation 3.18) and that, 
therefore, is reversible. This is a easy-to-work-with sufficient condition that 
guarantees that the target distribution is going to be the invariant distribution 
of the chain. 
\Ve are going to concentrate on the two most widely used MCMC methods, 
the Gibbs sampler and the Metropolis-Hastings algorithm. 
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3.4.5 Gibbs sampler 
The Gibbs sampler is the most widely applied MCMC tool nfter the work of 
Geman and Geman (1984) which was popularised in statistics by the articles 
by Gelfand and Smith (1990) and Gelfand et al. (1990). 
The value of this algorithm arises from the fact that in many npplicntions the 
full conditional densities take convenient forms to be simulated even though 
the target density is intractable. 
For Bayesian DAG models in particular, the joint distribution of the data and 
parameters is a product of many terms, each involving only a subset of the 
parameters. For such models, the full conditional distribution for any given 
parameter can be constructed from those few terms of the joint distribution 
which depend on it (Lauritzen, 1994, Spiegel halter et al., 1095). 
Let 7r(x) = 7r(Xl, ••• Xk), X ERn, denote a joint density, and let 1T{x'lx-') 
denote the induced full conditional densities for each of the components x', 
given values of the other components X-' = (X'i 1 # 8), 8 = 1, ... , k ~ n. Full 
conditional distribution densities are derived from the joint distribution: 
( ' -') ( 'I -') 7r x , X 7r X X = . J 7r(x',x-')dx' (3.20) 
'Ve start with a partition or 'blocking' of the random vector x = (Xl, ... x,"). 
One important consideration in choosing the level at which the components 
for the conditionals are chosen is the correlation structure of 7r{x). If highly 
correlated scalar components are treated individually, there could be slow COIl-
vergence of the chain to its stationary distribution density as a result of very 
little movement at each conditional random variate generation step. If, how-
ever, correlated scalars are blocked together to form a subvector component 
this problem is avoided, but at the expense of having to perform a draw from 
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a multivariate conditional distribution (see, for instance, Roberts and Sahu, 
1997), 
A systematic form of the Gibbs algorithm proceeds as follows, Start by pick-
ing arbitrary starting values, say Xo = (xA, .. " x~), Then successively make 
random drawings from the full conditional distributions 7r{xS lx-S ), s = 1, .. ,' k, 
as follows: 
xt from 7r(xllxQ"l)j 
x~ from 7r(x2IxLx~, .. "x~)j 
This completes a transition from Xo = (x~, .. " x~) to Xl = (xL .. " xn, Iterat-
ing this cycle of random variate generation from each of the full conditional 
distributions in turn produces a sequence Xo, Xl! .. " Xt, .. , which is a realisation 
of a Markov chain, with transition probability from Xt = x to Xt+1 = Y given 
by: 
k 
Pa(x, y) = I17r(ySlyl, .. " yS-I, xs+1, .. " xk), (3,21) 
s=1 
Suppose that v is the Lebesgue measure 4 j then, 
f Pa{x, Y)7r(x)dx = f ! k (alia-I) ( s+1 kl 1 yS) I1 7r Y Y , .. " Y 7r X , .. " X y, .. " .. , 1 k)d a=1 7r(Xa+ , .. " X X 
X 7r{x1Ix2, .. " Xk)7r(X2, .. " xk)dx, 
by applying Bayes theorem to each term in the transition kernel, letting yO 
denote the empty set, and writing 7r(X) as 7r{x1Ix2, .. "xk }rr(x2 , .. "xk ), The 
calculation is completed by noting that, 
40n the real line (R, B(R» Lebesgue measure v is a positive measure defined for intervals 
(a, b) by v(a, b] = b - a, and for the other sets in B(R) by an obvious extension technique, 
Lebesgue measure on higher dimensional Euclidean space RP is constructed similarly using 
the area of rectangles as a basic definition, 
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• the terms n(y"lyl, ... , y,,-l) are independent of x, so they factor out as 
0!=1 (yslyl, ... , y,,-l) to give n(y)j 
• the integral over Xl is 1; 
• the term n(x2 , ••• , Xk) cancels for s = 1; and 
• cancellation by telescoping occurs because the numerator clement in term 
s -1 is n(xS+l, ... ,sklyl, ... ,y,,-I) after the requisite integration over xt , 
which cancels with the denominator in term s. 
A convenient set of sufficient conditions which ensures that the ~farkov chain 
generated by the Gibbs sampler satisfies the conditions in Proposition 3.1 is 
due to Roberts and Smith (1994). 
Proposition 3.2. Suppose that 
• n{x) > 0 implies there exists an open neighborhood Nz containing x and 
f > 0 such that, for all y E Nx , n{y) ~ f > 0; 
• f n{x)dxS is bounded for all sand y E Nz in an open neighborhood of x; 
and 
• the support of x is arc-connected. 
Then PG{x, y) satisfies the conditions of Proposition 9.1. 
The conditions ensure that each full conditional density is well defined and 
that the support of the density is not separated into disjoint regions so that 
once the chain moves into one such region it never leaves it. Although these 
are only sufficient conditions for the convergence of the Gibbs sampler, the 
conditions are extremely weak and are satisfied in most applications. 
In general, four steps are required to implement the Gibbs sampling: 
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• starting values must be provided for all unobserved nodes; 
• full conditional distributions for each unobserved node must be con-
structed and methods for sampling from them decided upon; 
• the output must be monitored to decide on the length of the burn-in and 
the total run length, or perhaps to identify whether a more computa-
tionally efficient parameterisation or MCMC algorithm is required; 
• summary statistics for quantities of interest must be calculated and ex-
amined from the output, for inference about the true values of the un-
observed nodes. 
3.4.6 Metropolis-Hastings 
The Metropolis-Hastings algorithm is due to the generalisation that Hastings 
(1970) made of the algorithm introduced by Metropolis et al. (1953). 
Following with the notation presented previously, the Metropolis-Hastings al-
gorithm begins with a candidate new value, or 'proposal', y by drawing y E Rn, 
from an arbitrary transition probability density function q(y; x) which gener-
ates transitions for a discreet time Markov chain evolving on Rn. We are going 
to update x in a single block without loss of generality. 
The algorithm will actually accept the proposal with probability, 
{ 
min{1, 7r(y)q(y,x)} if 7T(X)q(X, y) > 0 
a(x, y) = 7r(x)q(x,y) • 
1 if 7T(X)q(X, y) = 0 
(3.22) 
This defines a Markov chain with a transition probability from Xt = x to 
Xt+l = Y given by: 
PMII = { 
q(x, y)a(x, y) if y =/:- x 
f q(x, y)[1 - a(x, y)]dy if y = x 
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Note that the Gibbs sampler is the special case of the MetroJlolis-linstings 
algorithm where the proposal density q(y; x) is the full conditional density 
1r(ylx), so that the proposal is accepted with probability one. 
The sequence Xt generated by the Metropolis-Hastings algorithm satisfies de-
tailed balance (see equation 3.18) by construction of a and, therefore, its equi-
librium distribution is 1r. 
In implementing the Metropolis-Hastings algorithm, the transition probability 
density function must share two important properties: it must be possible to 
generate y from q(.) easily and the acceptance rate should not be so low that 
the time required to generate a sufficient number of different Xc is too great 
(see, for instance, Besag et aI, 1995 and Gelman et aI, 199G). 
The convergence properties of the Metropolis-Hastings algorithm ha\'e been ex-
tensively studied following the work by Roberts and Smith (1094) and ~Iengersen 
and Tweedie (1996) and sufficient conditions found by Tierney (199·1). 
3.5 Performance of MCMC methods 
MCMC methodology relies on the fact that the t-step transition kernel of the 
algorithms converges to the target density as t -+ 00. \Vhen implementing 
any of the MCMC algorithms, there are innumerable strategies affecting the 
'efficiency' of the algorithm. Efficiency consists, broadly speaking, of reducing 
the number of bum in iterations (i.e., the initial iterations which are considered 
not to arise from the target density) and the amount of required calculations 
at each iteration. 
Consequently, there are different techniques and recipes to construct appropri-
ate algorithms in different scenarios that have been, and are being, proposed 
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in the literature. For an overview of different implementation and practical 
issues the reader is referred to the book by Gilks et al (1996). In what follows, 
just a summary of few of these topics, specially those concerning convergence 
of the chains, will be presented. 
Convergence diagnostics are fundamental in order to establish that the sample 
obtained by running any algorithm constitutes a sample from the distribution 
of interest. Much research is being made for diagnosing convergence of Gibbs 
samplers and other Markov chain Monte Carlo algorithms (see, for instance, 
Brooks and Roberts (1995), Cowles and Carlin (1996), and Brooks and Roberts 
(1998)). No particular method of assessing convergence is universally accepted 
as being foolproof and it is recommended using a combination of diagnostics 
in addition to visual inspection of the trace plots in order to be able to assess 
convergence with a reasonable degree of confidence. 
The literature has suggested two methods for generating a sample from a 
MCMC algorithm: the single chain and the multiple chain. In the multiple-
chain method, the value at the end of a 'burn-in' period of, say, n drawings is 
taken as a draw from the target distribution and the process is repeated with 
a new starting value. This method is somehow considered wasteful because 
it generates an independent sample at the cost of discarding n drawings in 
each run. The multiple-run method has been superseded for the most part 
by the single-run method. Even though this scheme usually introduces strong 
correlation between parameter values at successive iterations, the correlation 
often dissipates quickly for moderate n . 
Because the length of the 'burn-in' period seems to be model- and data - de-
pendent, the question of convergence requires considerable care. If the target 
density being simulated is 'well behaved' (as it is in many standard applica-
tions), then the simulated Markov chain usually mixes rapidly and the serial 
correlations die out quickly. But with weak identifiability of the parameters 
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and/or multiple modes the chain can be poorly behaved and slow to produce 
numerically accurate results. Many proposals have been made to she'd light on 
these problems. 
One class of approaches (Ritter and Tanner, 1992; Gelman and Rubin, 1992; 
Geweke, 1992; Zellner and Min, 1995 and Brooks and Gelman, 1998) attempts 
to analyse the output to determine whether or not the chain has converged. 
The Gelman and Rubin (Gelman and Rubin, 1992) and the Brooks, Gelman 
and Rubin approach (Brooks and Gelman, 1998), which is based on multiple-
chain sampling from dispersed starting values, compares the within and be-
tween variation in the sampled values. The Ritter and Tanner approach (Ritter 
and Tanner, 1992), which requires a single run, monitors the ratio of the target 
density (up to a normalising constant) and the current estimate of the target 
density; stability of the ratio indicates that the chain has converged. Gewekc's 
(Geweke, 1992) convergence diagnostic, which is based on standard time series 
methods, is appropriate for the analysis of individual chains when convergence 
of the mean of some function of the sampled variables is of interest. 
Another type of approach (Raftery and Lewis, 1902, and Polson, 199·1) at-
tempts to produce estimates of both the 'burn-in' time prior to sampling by 
analysing the rate of convergence of the Markov chain to the target density 
and the run-lengths needed to accurately estimate quantilcs of functions of the 
variables of interest. 
In addition to different convergence diagnostics, a preliminary visual analysis 
of the obtained chains is strongly recommended. A rapid mixing chain will g('n-
eraIly present rapid fluctuations over the sample space. High autocorrelations 
within chains and substantial correlation between variahles usually indicate 
slow mixing and, therefore, slow convergence. This will be characterised by 
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plots of sample traces which 'snake' slowly up and down. Reparameterisation 
of the model variables can sometimes lead to less correlated chains. space. 
3.6 Discussion 
In this chapter a general Bayesian population pharmacokinetic hierarchical 
model, accommodating different pharmacokinetic models between and within 
individuals, has been built. The DAG representation has allowed to specify the 
full joint distribution of a rather complicated model in an intuitive and sim-
ple manner from local components. This factorisation, in addition, facilitates 
the implementation of MeMC tools that overcome the historical constrain 





A Case Study: Cyclosporin 
After reviewing the main pharmacokinetic models and, we believe, the most ad-
equate inference framework, we are ready to handle real data. A fully Bayesian 
three-stage hierarchical model is going to be fitted to a real data set. The most 
suitable pharmacokinetic model needs first to be chosen following visual inspec-
tion of the data and literature recommendations. Once the structural model 
is built, probabilistic assumptions will be made and estimation performed. 
4.1 Introduction 
Cyclosporin is in routine use in organ transplantation processes as an in-
munosuppressive medication. Fahr (1993) constitutes an excellent summary 
of all the research and literature survey of the clinical pharmacokinetics of 
cyclosporin. Even though it is prescribed by the medical profession on a daily 
basis, its pharmacokinetics are of great importance for a specialised group of 
clinical pharmacologist as standard dosing regimes of cyclosporin do not work 
because its therapeutic range is narrow and the variability of its pharmacoki-
netics are large between different patients and within individual patients. A 
narrow therapeutic range, with the consequent high risk of lethal poisoning, 
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with a poor pharmacokinetic understanding originates conscrvativc doses that 
can be clinically uneffective. 
There are two approaches in designing dose schedules: 
• Administration of standard subtherapeutic, but safe, doses in conjunc-
tion with therapeutic doses of other better understood inmunosupprcs-
sive medications . 
• Individualised administration after monitoring cyclosporin blood con-
centrations that requires a reasonable understanding of the individual 
specific pharmacokinetic characteristics. 
The latter approach has got an increasing statistical interest and will be in-
troduced in this chapter. 
4.2 Pharmacokinetic Variability 
The pharmacokinetics of cyclosporin, as mentioned before, arc vcry variable 
both between and within patients. The sites of action arc rather unknown 
and extremely complex and, even though attempts have been done in order to 
quantify the drug concentration in different sitcs of action, thcy arc all rather 
time-consuming and lack specificity for cyclosporin. Currently, blood concen-
tration monitoring constitutcs the only clinically useful feedback information 
on which dosing decisions can be bascd. 
The first source of pharmacokinctic variability of any drug is related to the 
error associated with the method chosen to measure drug conccntrations in 
blood. Different techniques show diverse dcgrees of accuracy and pr<'Cision. 
This source of variability may diminish in the near future if the rrcommen-
dations of recent consensus documents to monitor hlood concentrations arc 
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followed. Nevertheless, the pharmacokientic parameters are highly variable 
and depend on many individual factors. 
Clinical studies show that the bioavailability of cyclosporin varies dramatically 
between and within individuals depending on a large number of factors such 
as the mixing of the oral formulation with the drink, individual physiological 
characteristics, interactions with other drugs, etc. 
Cyclosporin is not uniformly distributed throughout the body, and the liter-
ature suggests that it is extensively bounded within the blood compartment 
and even more to tissues. Nonetheless, little is known with accuracy about the 
distribution process of cyclosporin due to its complexity and, again, variability. 
Little work has been done up to the present on the pharmacokinetics of cy-
closporin following the population approach using either classical or Bayesian 
tools (Rui et al., 1995, Charpiat et al., 1998, Parke and Charles, 1998, Jensen 
and Dalhoff, 2000). 
Elimination occurs principally by metabolism in the liver, and any factor af-
fecting the liver will influence the extent and rate of elimination. 
4.3 Data 
The data set we are concerned with is presented in figure 4.1. This data set 
was provided by Dr. Stephen Lowis from the Bristol Royal Hospital for Sick 
Children. A group of seventeen patients received different doses of cyclosporin 
intravenously. Logarithmic concentration level observations are plotted against 
time. The doses were administered by infusion during approximately an hour, 
varying between patients. After and during administration, blood samples 
were collected for each patient at different times and blood cyclosporin con-
centration levels determined following the same technique to monitor blood 
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Figure 4.1: Cyclosporin Blood Concentration. Last dose of the treatment is 
given at time O. The logarithm of observed concentration levels for 17 patients 
are plotted against time. 
o 200 400 
minutes 
600 800 
concentrations. They all had previous doses, and that is why the starting 
concentration levels are in all cases positive. 
Figure 4.1 shows how concentration levels increase abruptly during the infu-
sion of the substance. Drug concentration levels reach a peak, shortly after 
the infusion is terminated, approximately in 60 minutes. After r('aching the 
peak, drug distribution and elimination impose an exponential drcay of blood 
logarithmic drug levels, suggesting that a two compartmental model might 
be necessary and sufficient in order to explain the drug blood concentration 
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behaviour. The first rapid decay is probably originated by the distribution 
of the substance from the circulatory system to different organ and tissues in 
addition to the fraction of drug that is being eliminated from the body. Then 
follows a somehow more moderate decrease due to the combination of two 
processes: part of the drug is being expelled from the body and some is being 
redistributed into the circulatory system. 
The data set looks at first sight fairly homogeneous with the possible excep-
tion of a couple of patients. We aim to construct a model flexible enough to 
accommodate this kind of irregularities between individuals. 
4.4 The Pharmacokinetic Model 
The logarithmic concentration - time plots in Figure 4.1 suggest that a two 
compartment model should be first tried to explain the data we are concerned 
with. Blood samples have been taken after the beginning of the administration 
of the last dose, at time zero, of a treatment that so far comprises 20 previous 
doses given at regular intervals of 8 hours. 
Recall that (see section 2.5) for an intravenously administered infusion single 
dose, in a two-compartment model with first order distribution and elimina-
tion, the blood plasma drug concentration at any time is given by the following 
equation: 
(4.1) 
where, defining T{ as the length of infusion, t~ = t - T{ for t > T{ and t' = 0 
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where, al and a2 (al > a2) are the roots of the quadratic equation: r2 + (k12 + 
k21 + kez}r + k21 kel = O. 
As it has been said above, all the patients have been given 20 previous doses, 
so that the pharmacokinetic equation from the beginning of the 21" infusion 
for each individual is given by: 
21 
C(t) = I: Cd(t). (4.4) 
d=1 
4.5 The Probability Model 
Let us denote the jLh observed concentration for patient i (i = 1, ... 1(, where 
K is the number of patients) by Cij and the time at which the associated 
sample was collected by tij • The dosing history for patient i at time tij will 
be described by Hij , and ()i will denote the p x 1 vector of pharmacokinetic 
parameters for individual i. 
As discussed in chapter 3, pharmacokinetic models fit naturally into a three-
stage hierarchical model (Steimer et al., 1994, Wakefield et al., 1994, Dennett 
et al., 1995, \Vakefield and Racine-Poon, 1995). In Figure 4.2. the 'directed 
acyclic graph' (DAG) (see section 3.3 for notation and conventions) represent-
ing the structural assumptions we wiII make below is shown. 
At the first stage of the hierarchical model, the form of the probability distribu-
tion of each observed concentration level, Cij, given the individual pharrnacoki-
netic parameters, ()j = (V, k12' k21' ket) and T needs to be specified, where T, the 
inverse of the residual error variance, is assumed to be a normally distributed 
multiplicative error. Therefore, denoting by C j ; the mean, unobservable, con-
centration level given by equation (4.4), it follows that, 
(4.5) 
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Figure 4.2: DAG representation for the Cyc1osporin Model. Due to the lack of 
relevant covariate information about the patients, the structure of the model 
is more simple than in the general model presented in the previous chapter. 
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where we follow the notation of Gelfand and Smith (1990) for defining prob-
ability densities, i.e., joint, conditional and marginal densities of the random 
variables x and yare denoted by [x, V], [xly] and [xJ, [yJ repectively. A normal 
distribution with mean a and precision parameter b is as usual denoted by 
N(a, b). 
Exploiting the conditional independence property and denoting by c the total-
ity of the observed data and by S = {Ob ... ,OK}, we have that: 
K ni 
[In(c)IS, rJ = IT IT N(ln(qj), T-1). (4.6) 
i=l j=1 
At the second stage of the probabilistic model, assumptions regarding the 
distribution of each patient's pharmacokinetic parameters must be done I: 
[O;lp,rJ = Np(/J,r-1) for i = 1, ... ,](. (4.7) 
And, therefore, due to the conditional independence property, it follows that 
K 
[Sip, rJ = IT Np(p, r-1), (4.8) 
i=l 
where Np(A, B) denotes a p-dimensional multivariate Normal distribution with 
p x 1 mean vector A and p x p matrix of variance-covariance B. Here I' repre-
sents the mean population pharmacokinetic parameters and r-1 the interindi-
vidual variability of the pharmacokinetic parameters. 
The stochastic model is completed by the specification of the third stage, in 
which prior densities are assigned to the parameters 0, rand T. The distribu-
tions we choose are: 
[r] = Ga(a, b), [/l] = Nq(TJ, e), and [rJ = lVp(R, pl. (4.9) 
where lV(A, b) denotes a \Vishart distribution with b degrees of freedom and 
scale matrix A and G(a, b) a Gamma distribution with parameters a and b. 
IThere is no relevant covariate information recorded. 
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The last step is to assign values to the hyperparameters of the model, i. e. a, b, 
11, C, Rand p. The chosen value for both a and b is 0.001. Consequently, T has 
a prior expected value of 1 and prior standard deviation of 1000. This prior is, 
therefore, proper but very vague as there is not any kind of prior information 
to include in the model about the real value of T. 
To represent vague prior knowledge about J.L, we propose 11 = (0,0,0,0) and C 
as a diagonal matrix taking values 10-4 , again, a very uninformative, but still 
proper, distribution. 
Lastly, as there is no available prior information about r, in order to have 
an uninformative prior distribution, we take the degrees of freedom for this 
distribution, p, to be as small as possible (i.e. 4, the rank of r). The scale 
matrix R represents our prior guess of the order of magnitude of the covariance 
matrix. Note that except for cases with very few individuals, the choice of C 
has little effect on the posterior estimate of r u (Lindley, 1970). We set the 
off-diagonal elements to zero, and the diagonal elements are set to 3.1 2. 
Once the distributional assumptions of this three-stage hierarchy are made, 
we are ready to construct the joint posterior distribution. Appealing to Bayes' 
theorem, the joint posterior is proportional to the product of the prior densities 
and the likelihood function (see section 3.4.2) 
4.6 Estimation 
The software PKBUGS(94) has been used to perform the estimation of the 
posterior distributions of the model parameters conditional on the given data. 
PKBUGS uses the Gibbs sampler (Geman and Geman, 1984) to explore the 
posterior distributions of the parameters 0, J.L, T, and r. The components of 
2We follow the recommendations given by the authors of PKBUGS. 
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Table 4.1: Summary: Marginal Posterior Distributions for the Population 
Pharmacokinetic Parameters. 
Iln(Param) I Mean I sd I Me error I 2.5% I median I 97.5% I 
111 = CL -1.769 0.1277 0.003235 -2.021 -1.769 -1.517 
112 = Q -1.073 0.2223 0.005898 -1.492 -1.08 -0.6078 
113 = VI 3.32 0.2312 0.00694 2.868 3.322 3.779 
114 = V2 4.82 0.3463 0.01552 4.212 4.795 5.588 
8 are sampled using a Metropolis-Hastings algorithm (Metropolis et al., 1953, 
and Hastings, 1970). 
All stochastic parameters in the population pharmacokinetic model, i.e. 9, 
7, J.l and f, must be given initial values. The values we choose are the prior 
means. 
After several attempts, the first 20.000 iterations of the Gibbs sampler were 
discarded as 'burn-in', in order to, hopefully, guarantee that the stationary 
distribution was reached. Then, the chains were run for an additional 20.000 
iterations past 'burn-in'. The computation took around 25 minutes. 
In table 4.1, the estimation of the posterior marginal distributions of the pop-
ulation pharmacokinetic parameters is summarised. Here CL represents the 
clearance, Q denotes the distributional clearance, Vi and V2 the volume of 
compartments 1 and 2 respectively. All the variables are on a logarithmic 
scale. To get back the rate constants in equation (4.4) from these parameters, 
we apply: 
(4.10) 
The second column on table 4.1, reports the expected value of the posterior 
marginal distribution of the corresponding parameter in the first column. The 
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third column gives the standard deviation of the distribution. The MC error 
is the standard error of the estimate of the expected value in column 2; it is 
estimated by considering both the sample size and the degree of autocorrelation 
in the sample. The last three columns give the quantiles and the median of 
the distributions. 
The standard deviations and the quantiles of the posterior distributions of the 
population parameters suggest that these distributions are reasonably sym-
metric and concentrated around their mean values, as expected. Therefore, 
and taking in account the small MC errors, these expected values are sta-
tistically good point estimators of the real values. The estimated posterior 
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distributions of population parameters, 0, calculated from the samples of each 
of the variables are shown in figure 4.3. PKBUGS carries out the Kernel den-
sity estimation using the S-Plus 'density' function. This leads to a smooth 
estimate that could hide local features of the density. 
Individual pharmacokinetic parameters' posterior distributions are summarised 
in Appendix A. 
Substituting posterior expected values of JL in equation (4.4), estimations of 
observed concentration levels are calculated. The results that we obtain are 
represented in figures 4.4-4.6. Data points are represented by dots. Individual 
curves are obtained by substituting the individual parameters' posterior dis-
tributions' means, together with the corresponding doses and infusion lengths, 
in model 4.4. These are represented by solid curves. To get an insight into the 
population variability, we can construct a curve (the dotted curves in figures 
4.4 - 4.6) where individual variability is removed by introducing the means of 
the posterior distributions of the population parameters together with individ-
ual doses and infusion lengths in model 4.4. We refer to these as 'population 
curves'. 
In general terms, the individual curves are encouraging and seem to reflect that 
the chosen two compartment model captures in a simplified fashion most of the 
pharmacokinetic processes that cyclosporin induces in the organism within this 
particular scenario (e.g. possible interactions with other drugs administered 
in the personalised treatments, the particular set of patients that enter in our 
study, etc.). 
Differences between individual curves and the population counterparts, give in-
formation about the heterogeneity of the pharmacokinetic profiles of different 
patients. For example, if the population curve lies markedly under the indi-
vidual curve, the concentration levels of the individual are higher than those 
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'expected'. This could be, for example, due to a relatively small body mass of 
the patient (information that is not available). It can be seen that the popu-
lation curve differs substantially from the individual curve for approximately 
half of the patients. Therefore, our data set corroborates what has been im-
plied by previous studies, e.g., that the pharmacokinetics of cyclosporin show 
an important variability between individuals. 
Let us point out that the second observation of Patient 3 seems to be somehow, 
'strange' as the concentration actually decreases during the intake of the drug. 
This could be due to the slow elimination of previous doses. Nevertheless, 
we believe that this observation has been measured with some sort of error. 
The consequences are obvious in figure 4.4 as it influences the estimated curve 
notably due to the small amount of observations. If our suspicion were cor-
roborated, we would probably delete that observation in order to get better 
fittings for the rest of the observations. 
There are relatively few blood samples for Patient 12, but the estimated curve 
explain pretty well the observations. 
Blood concentrations for Patient 13 show a very particular profile and the use 
of a two compartment model without any covariate information seems not to 
be enough to estimate the concentration levels for this patient. Nevertheless, 
comparing the individual curve with the corresponding population one, it can 
be seen that the our model is flexible enough to capture substantial individual 
variability. 
4.7 Convergence diagnostic 
All the analysis presented above requires that the Gibbs sampler and the 
Metropolis-Hastings algorithm have effectively converged to their unique sta-
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Figure 4.4: Patients 1-6, ordered from right to left, top to bottom. Log con-
centration - time. Dots represent observed data, solid lines are the individual 
curves, and dotted lines, the corresponding population curves. D = Dose. TI 
= Infusion Interval. 
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Figure 4.5: Patients 7-12, ordered from right to left, top to bottom. Log con-
centration - time. Dots represent observed data, solid lines are the individual 
curves, and dotted lines, the corresponding population curves. D = Dose. TI 
= Infusion Interval. 
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Figure 4.6: Patients 13-17, ordered from left to right, top to bottom. Log con-
centration - time. Dots represent observed data, solid lines are the individual 
curves, and dotted lines, the corresponding population curves. D = Dose. TI 
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tionary or invariant distributions. Convergence diagnostics are fundamental 
in order to establish that the sample obtained by running the algorithms con-
stitute a sample from the posterior distribution of interest. 
As briefly discussed in chapter 3, much research is carried out for diagnosing 
convergence of Gibbs samplers and other Markov chain Monte Carlo sequences 
(see, for instance, Brooks and Roberts (1995)). No particular method of as-
sessing convergence has universally been accepted as being superior in different 
scenarios. 
The software PKBUGS does not include any tool for analysing convergence. 
In what follows, only a graphical inspection of the chains is going to be per-
81 
Chapter 4:A Case Study: Cyc1osporin 
formed. In figure 4.7 the traces of the generated chains are represented for 
the population mean values. These seem to mix rapidly over the sample space 
of the posterior distributions. Therefore, all four parameters appear to have 
converged to their stationary distribution, so that sampling from the corre-
sponding posterior distributions seems to be achieved. 
Stationarity has been checked visually in the traces for each of the other vari-
ables in the model. All showed a well-mixing behaviour. 
4.8 Conclusions 
The tools introduced in previous chapters have proved to be remarkably appro-
priate to estimate concentration levels of cyc1osporin in blood plasma following 
an infused multi-dose treatment. It has, therefore, been described a framework 
that links drug dosing with drug blood concentration levels over time with sig-
nificant accuracy. 
In what follows, drug concentration levels, and therefore particular dosing 
histories, will be linked to actual drug effect in order to gain further insight 
towards rational treatment. 
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the' proliferation of c~lls in a drug-free context need to b~ studied first. This 
will be performed in"thls Chapter. 
, \ 
Cell populations have historically been analysed in 'Continuous Time Markov 
r '-,' f • '\ • ''''I Processes' theory (Bailey, 1967) and in 'Branching Proces~es' theory,\(Jagers~' 
1975). In this chapter both kinds of stochastic processes will be briefly intra-
duced and corresponding models built.' , 
I •. I If ,,, /\ i , ~ < .J, I ); , " 
Any modelling attempt should start ;by defining the physiological'processes I 
that it is intended to analyse. Section 5.1 constitutes a biological description' 
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of the kinetics of individual cells, so that the foundations and assumptions of 
the models that follow will become apparent. 
In section 5.2 a deterministic approach to model the cell cycle, and therefore 
the cell population, will be taken and discussed. A multi-type cell population 
- \ .~ , 
'0"'-)-'('1"'" , 
model is proposed and the pros and cons expounded. t, ,,, ~~ - i. :., \, .-
Section 5.3 starts by introducing the theory of 'Continuous Time Markov Pro-
cesses'. 'Birth-and-Death' processes are explain¢ 'and 'extend~d:to acComm~ 
~_" ,.,,!Il ,t _.1' ... _. ~ .. ,j.. • ,_,' 
date different kinetic patterns within the population. Different types of cells 
are alowed within the population. The distributional constraints derived from 
vital assumptions required in thi,~ ap~roach will ~e palliated to som~ ,'weak: 
" , ! 1 ' I .', • 
extent in the model proposed in section 5.4 by means of analysing a less am-
,( . , . t, " " , I: ~ f I ~' , • .; 
bitious kinetic ,pattern. , 
, " 
, !: , r .' " , ,. _ , " I •• I I ~ I • 
The theory of 'Branching Processes', discussed in section 5.5, constitutes an 
:' " j •• • • \ , '" I • It 
alternative approach to model cell populations. A population of cells of the 
• • 1)' I' ,,'j: " (J ' 
same type are only considered. The implications of the required assumptions 
are physiologically less restrictive. Unfortunately, these processes are math-
ematically more complicated and rely on asymptotic, results. An interesting 
, • 'r' , .' "f" ' t! • j .'" II \ 
'easy-to-work-with' general approximation of one of,the main limit results will 
• " , • ~ , , ' , ' , I , ., r. 'j ,~ " 1 
be derived,and illustrated. This simplifies considerably the use of the theory 
.. II! • ,,. " ~., I . , ! , 11 .,' .. 
of 'Branching Processes' in the study of the evolution of cell pop,ulations. " 
(I • t " 1,1 
I I 'r 
• I ., t '\ : '1 {~, , .~ , • I I :. ' ; " . t;, Ij;"'li 'I. I{ (I 'I 
5.1;' 'Cell, Cycle 'I' .' I ,'1 
l " t' f . ~. ~ I \"1 " : .f"- ; I " 
The number of cells in a tumour or in the p()pulation of leukaemic, cells in t~~ . 
circulatory system grows because the cell division rate is greater than that of 
death.),They fail to respond effeCtively to the homeostatic control mechanisms 
which maintain the appropriate number of cells in normal renewal tissues (for' 
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a detailed discussion of the cell kinetics of normal tissues see, for instance, 
Burgess and Nicola, 1983, Wright and Alison, 1984, Murakami et al., 1985). 
For decades it has been well known that there is in the life of a cell a well 
defined period during which DNA is synthesised. The concept of cell cycle was 
first introduced by Howard and Pelc (1953). More recently, experiments using 
different sophisticated techniques (Murray, 1993, Vincent, 1990) have led to a 
general model for the cell cycle. This model is represented in figure 5.1. 
Within a cell population, not all the cells follow the kinetics of cell division. 
A new born cell enters in a phase called G1 where the fate of the cell will be 
established. The G1 period is usually longer than a third of the life length. 
During this early phase, three possible directions can be taken. 
• The natural path to follow is to, after some time of maturation, enter in 
the S phase, a very active phase where DNA duplication is undertaken. 
Two identical cells are fertilized during this period of considerable dura-
tion. In the subsequent stage, known as G2 phase, the cell will get ready 
for the last and most dramatic stage of a cell's life, mitosis or M phase. 
During mitosis, the cell will split into two newborn daughter cells, the 
reproducing cell ceasing to exist as such. 
• The cell can enter a 'quiescent' or 'resting' state, known as the Go phase, 
at any time whilst in G1• Cells will return to cycling at some indetermi-
nate later time. 
• The cell can also be terminally differentiated and cease proliferation. In 
this case, even though the death is imminent, the actual disappearance 
will not occur until the cycle is completed, so that the cell will go on with 
the cycle but without any kind of activity. We call this, the I period to 
show that the cells are irreversibly out of the cycle. 
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I .. 
.. I .. 
Gl 
I x 
s G2 M 
r '----------------------------------------, 
GO 
Tc ~ ............................................................................................. ~ 
Tc* ~ ...................................................................................................... ~ 
Figure 5.1: Cell Cycle. A dashed vertical edge or arrow means that the cell 
has got the option to take that path. Solid vertical edges or arrows, instead, 
indicate an unavoidable path. Tc is the total cycle time if the cell is proliferative 
(Le., Gl -+ S -+ G2 -+ !'vI) or is irreversibly differentiated (Le., G1 -+ I). If 
the cell enters a resting phase (Le., G l -+ Go -+ S -+ G -+ M), then the cell 
cycle time will be Tc*' 
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Cells that choose to take the first path are called proliferative, whereas cells 
that enter into a resting phase are known as non proliferative or resting cells. 
Finally, we will say that the cells that are committed to die and leave the cycle 
are irreversibly differentiated. 
If we denote the times spent in each phase by Tal! Ts, Ta2 , TM , Tr and Tao 
respectively, the total cycle time Tc will be given by: 
if proliferative or goes to I 
if goes to Go 
(5.1) 
Each of these quantities is not fixed and varies substantially between cells. 
Therefore, it is natural to treat them as random variables. The variable which 
is known to be the most unpredictable and obscure one is Tao. In some mod-
els, Tao has been considered to be infinity (Steel, 1968, Steel, 1977). The 
consequences of noncycling cells in modelling and analysis of experiments are 
profound (\Vhite and Terry, 2000). 
5.2 Deterministic Approach to model the Cell 
Cycle 
5.2.1 Introduction 
We are concerned with a population of cells following the behaviour described 
in the previous section. Interest lies on understanding both qualitatively and 
quantitatively the growth of such populations. 
A high variability has been acknowledged in most of the mathematical descrip-
tions of biological populations. The work by Elton (1958) was followed by a 
vast literature on modelling the spread of biological populations. For a review 
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of different models applied in different branches of biology see , for example, 
Hengeveld (1989), Renshaw (1991) and references therein. 
The deterministic approach has proved validity in the study and prediction of 
certain large populations where the variability is regarded as relatively small 
enough. Bailey (1967, p. 2) states that there is nothing inappropriate in 
predicting that the present population of, say, 51226 persons in a town will 
have grown to 60863 in ten years' time, provided the latter estimate is correct 
to within a few hundred units. But if, in a small family of four children, one 
of whom develops measles today, we predict the total number of cases in a 
week's time as 2.37, it is most unlikely that this figure will have any particular 
significance. The prediction of small populations like this should, therefore, be 
based on a probabilistic approach. 
Starting with one single cell, the number of cells in a population after certain 
time period will vary substantially between different populations. Neverthe-
less, the first attempt in modelling the fate of large populations has historically 
been to ignore such variation and fix terms such as 'birth rate' and 'death rate' 
as continuous and steady flows. Given these constant rates, as it will be shown 
in what follows, the population size can be determined at any time as the so-
lution of the corresponding set of differential equations. This constitutes the 
deterministic approach. 
The simplest deterministic model to predict the number of individuals in a 
population with one ancestor and with a steady net growth rate of ,\ would be 
the solution of the differential equation 
dX(t) = '\X(t) 
dt ' 
where X{t) is the positive integer-valued variable which counts the number of 
individuals alive at time t ~ O. Therefore, the number of individuals at time 
t will be given by X{t) = e>.t. 
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5.2.2 Cell Populations 
As introduced in the previous section, there are three types of cells depending 
on the role they undertake within the cell cycle. In figure 5.2 a population 
consisting of these three different subpopulations with the corresponding de-
terministic migration rates is drawn. 
Denoting by the positive integer-valued variables Xp(t), Xr(t) and Xi(t) the 
number of proliferative, resting and irreversibly out of cycle cells at time t ~ 0 
respectively, and by kpp, kpr, krp , kpi and kd the migration rates shown in 
figure 5.2, the dynamics of such a population would be given by the following 







kprXp(t) - krpXr(t) 




The solution set of this system specifies exactly the number of cells of each 
type at any instant of time, and therefore, the total number of cells in the 
population: 
(5.5) 
Xr(t) =Cr( a - Al e.\lt _ a - A2 e.\2t) (5.6) krp krp 
k . k . Xi(t) =Ci ( pt e.\lt + pt e.\2t + e-kdt ) (5.7) kd + Al kd + A2 
where a = kpp - kpr - kpi' and defining D = (a - krp )2 + 4krp (kpr + a) > 0, 
Al,2 = a-kr~±v'D respectively. The constants Cp , Cr and Ci are defined by the 
initial values. When analysing population with a single ancestor, these initial 
values are given by: Xp(O) = 1, Xr(O) = Xi(O) = O. 
A deterministic model like the one presented, as discussed above, could be 
of legitimate use in the case of large populations with small variability as an 
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Figure 5.2: Multi-Type cell population. There are three different types of 
cells, the proliferative cells, Xp , the resting cells, X r , and the irreversibly 





Kpr~ III Kpi Krp 
Xr Xi -- Kd 
approximate trend. If we start to model a large population of cells where a 
count of cells of each type is available and there is a good knowledge of the 
migration rates (or are estimated correctly), we could predict fairly safely the 
evolution of the population with equations (5.5)-(5.7) up to a time point where 
the assumed variability becomes considerable in relation to the number of cells. 
At this time more realistic stochastic models should be used instead, as well 
as if we were analysing the early stages of the population. 
It should be kept in mind that stochastic models are not merely generalisations 
of their deterministic counterparts. The properties of each of the models can 
vary substantially. In many cases the means of the stochastic models will turn 
out to be equal to the corresponding exact value of the deterministic growth 
models. But, this is by no means always true. 
90 
5.3. Continuous Time Markov Processes 
5.3 Continuous Time Markov Processes 
5.3.1 Introduction 
\Ve aim to build a statistical model for the growth of cell populations. We 
start by defining the random variable X(t), taking nonnegative integer values, 
representing the size of the population at time t. The time parameter will be 
continuous as changes in the population could happen at any instant. 
There are different stochastic processes that could be applied to study the 
properties and evolution of {X(t), t 2': o}. One of the simplest but still the most 
broadly used are the well known Markov Processes in Continuous Time. Many 
authors have used Markov processes as mathematical models for the growth 
of biological or physical populations (see, for instance, for general references 
Bailey, 1967, Chiang, 1980 and Ross, 1996 and references therein; for particular 
applications, for instance, Lefevre, 1981, Metz et al., 1983, Norberg, 1995, 
Chick et al., 1996, Jaiswal et al., 1997). 
Although too restrictive and simplistic in many cases, they are of great interest 
as they can lead to analytic results that can give important insights about the 
real process underneath. 
\Ve say that the stochastic process {X(t), t ~ o} is a continuous time Markov 
chain if for all s, t 2': 0, and nonnegative integers i,j, x(u), 0 < u ~ s, 
P{X(t + s) = jIX(s) = i,X(u) = x(u),O ~ u < s} 
= P{X(t + s) = jIX(s) = i}. 
(5.8) 
In other words, if the size ofthe population is known at any time, say X(t) = i, 
then given X(t) = i, the subsequent behaviour of the population is assumed 
to be independent of the past history. This is the Markov property. 
If, in addition, P{X(t + s) = jIX(s) = i} is independent of s, then the 
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continuous-time Markov chain is said to have stationary or homogeneous tran-
sition probabilities. 
We aim to find out the probability distribution function of the process {X(t), t ~ 
O} or, at least, to be able to capture some information from it (e.g., the ex-
pected value). Let X(t) be an positive integer-valued random variable. If 
we denote by Pn(t) the probability that X(t) takes the value n at time t, 
the probability-generating function, the moment-generating function and the 
cumulant-generating function are respectively given by: 








- In(M((), t) = L ~r(t)()r Ir! (5.11) 
r=l 
where J-t~(t) is the rth moment about the origin and ~r(t) the rth cumulant. 
We will follow what Bailey (1967, pp. 70 - 74) terms the 'random-variable 
technique' for writing down, in an intuitive way, the corresponding partial 
differential equations for the probability-generating function or the moment-
generating function, and therefore, for the cumulant-generating function of the 
process. 
In some applications these partial differential equations will be straightforward 
to solve, whereas in most of the practical applications this will be a complicated 
or even an impossible t<!-s~. Nevertheless, as we will see below, even though in 
most cases explicit solutions for the distribution at time t can not be found, it 
is relatively simple to find the corresponding moments or cumulants. 
One general method of approximating distributions is first to solve for the 
cumulants of the process and then to find suitable approximating distributions 
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with matching cumulants (see, for instance, Renshaw, 1991, Wehrly et al., 1993 
or Renshaw, 2000). 
Let the change in the population X(t) during the interval 6.t be defined as 
6.X(t) = X(t + 6.t) - X(t). (5.12) 
Usually there is a finite number of possible transitions during 6.t. Hence, let 
us suppose that we can write 
P{6.X(t) = iIX(t)} = h(X)6.t, i f:. 0, (5.13) 
where h(X) are appropriate nonnegative functions of X(t) and j may be 
a positive or negative integer (in most applications h will be very simple 
function). The probability of no change in X(t) during 6.t is therefore given 
by 
P{6.X(t) = 0IX(t)} = 1- Lh(X)6.t. (5.14) 
#0 
Applying expectations in equation (5.12), it is easy to show that for an arbi-
trary function ~{X(t)}, we can write 
EHAt[~{X(t + 6.t)}] = EdEAtlt[~{X(t) + 6.X(t)}]}, (5.15) 
where Et and EHAt are the expectations of the function ~ at time t with 
respect to variations in X(t), and time t + 6.t for variations in X(t + 6.t) 
respectively. And, EAti t is the conditional expectation at the end of the interval 
6.t given the value of X(t) at time t. 
And, in particular, for Al = <P, where M(8, t) is the moment generating func-
tion we get: 
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. M((}, t + ~t) - M((}, t) 
1m --~--~~--~~ 
~t-+O ~t 
- lim ..!-.[EdeOX(t)E~tldeO~X(t)}} - EdeOX(t)}] 
~t-+O ~t 
E [eOX(t) lim E {(eO~X(t) - 1) }]. 




If the limit as ~t --+- 0 of the expectation inside the brackets in equation (5.21) 
is W((}, t,X), then this equation can be written as: 
aM((}, t) 
at Et{ eOX(t)\It((}, t, X)} 
a 
- \It((}, t, a(})M((}, t), 
where the operator ala(} acts only on M((}, t). 
(5.22) 
(5.23) 
In the special case in which the conditional transition probabilities are given 
by equations (5.13) and (5.14), the function \It has the form 
. {1 - 2:#0 !;(X)~t} + 2:#0 !;(X)~tejO - 1 ) 
\It((}, t, X) hm ~ (5.24 ~t-+O t 
I)ei° - 1)!;(X). (5.25) 
#0 
Using equation (5.25), the differential equation (5.23) simplifies to 
aM~:, t) = L:)eiO _ l)!;(X) a~~, t) . 
#0 
(5.26) 
And, therefore, it follows that, 
aK~~, t) = L(eio _ 1)!;(X) aK~;, t) , 
- _ #0 
(5.27) 
ap(x, t) = ~( j _ ) .(X) ap(x, t) 
at ~ x 1 fJ x ax . (5.28) 
#0 
These differential equations can be solved analytically for some stochastic pro-
cesses for which exact analytical solution for the probability distribution at 
time t can not be found. 
94 
5.3. Continuous Time Markov Processes 
In what follows, for all the processes we will present, the corresponding differ-
ential equations (5.26), (5.27) or (5.28) will be calculated in order to capture 
the moments of the underlying distributions. 
5.3.2 Linear Birth and Death Processes 
Let us start with the most familiar time continuous Markov process, the 'Linear 
Birth and Death Process'. First introduced by Yule (1924), this models have 
been used in a diverse variety of scenarios (see, for instance, Harris, 1963, 
Bailey, 1967, Athreya and Ney, 1972, Jagers, 1975, and Chiang, 1980, for 
different applications and further references). 
At time t there is a population of cells whose total number is given by the 
discrete variable Xp(t) 1, where the probability that Xp(t) takes the positive 
integer valuen is given by Pn(t). Each cell lives for certain time and at its 
death it can be either replaced by two new born daughter cells or by none. In 
the former case we will say there has been a birth (twin birth, the reproducing 
cell dying) and in the latter one that there has been a death. If there is a 
birth, the total population will increase by one unit, whereas if there is death, 
it will decrease by one unit. 
Let us start off with the assumption that the probability of a given cell dividing 
in time At is )"At, and that the probability of dying in At is given by JlAt. This 
is equivalent to assuming that the life length u of the cell has an exponential 
distribution with parameter ().. + Jl) so that 
(5.29) 
It is convenient to keep in mind the importance of the property of lack of 
memory of the Exponential Distribution. This means that the probability of 
1 Subscript p refers to proliferative cells. 
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an event occurring in the immediate future is independent of the time of the 
last occurrence. In terms of cell life lengths, this property implies that the 
probability that a cell will be alive at time s + 1 > 0, given that it has survived 
s 2: 0, is the same as the initial probability that it lives at I 2: O. In other 
words, if a cell is alive at time s, then the distribution of its remaining life is the 
original lifetime distribution. Therefore, the lifetime of a cell is considered to 
be completely random. This assumption will be relaxed in following sections. 
The population will be composed of indistinguishable cells. All the events 
that can happen to a cell during the interval (t, t + ~t) are independent of the 
event happening to other cells and of the events that happened to the cell in 
the past. 
As we assume that the lifetimes of the cells are independent, exponentially dis-
tributed random variables, the possible changes in the population size Xp(t) = 
n at time t can be classified as follows: 
• Prob. of one birth = An~t + o(~t) 
• Prob. of one death = Jm~t + o(~t) 
• Prob. of more than one of these events = o(~t) 
• Prob. of no jump = 1 - (An + p,n)~t + o(~t). 
Note that in this process the probability of a jump (either a birth or a death) 
during a short time interval ~t depends on the present population size but 
not on any other function of the time. Thus the process is homogeneous with 
respect to time. 
Given that Xp(t) = n, the waiting time w between jumps has the exponential 
distri bu tion 
q(w) = (A + p,)ne-(>'+Il)nw 0:5 w < 00. (5.30) 
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If a jump actually occurs, the probability of a birth is AI(A + J-L) (population 
increases in one unit) and that of a death J-LI(A + J-L) (population decreases in 
one unit). 
For this first simple model, the probability distribution function is straightfor-
ward and we do not need to use the 'random-variable technique'. It follows 
immediately'that; , II , I 
, 'I i ~ ,(' 
, ~ 
, , 
- Pn(t)(l- AnLlt:.... ItnLlt) -+- Pn-l(t)(,x(n'- I}Llt) 
+Pn+l(t)(ltnLlt) + o(Llt). 'i' 
, (5.31) 
It is easy to check (see, for instance, Bailey, 1967, pp. 92-97) that, if we start 
! , 'I \ '~-, "1 ,- "'1'.''''' -I 
off with Xp(O) = a, the corresponding probability'distribution is 'given by 
Pn(t) = L.JJ=o J a-I Q Q 1 n - , (5.32) 
{ 
"''?1in(a,n) (~) (o+n-i-1) o-;fln-;(l - - fl); ·r > 1 
~ ffn=O 
where 
, J-L( e(A-p)t - 1) 
Q = '--'--:---,--_-:.. 
Ae(A-p)t - J-L ' 
A(e(~-P)t :-1) 
fl = Ae(A-p)t - J-L • 
In the speCial case where'a'='l, this simplifies to: ' 




where Q and {3 are above. These moments are drawn in Figure 5.3 for different 
values or A and J-L. 
, :. 
The mean and variance of the process for any a > 0 can now easily be calcu-
lated as: 
{ 
ae(A-p)t if oX =fi It 
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Figure 5.3: Mean (left plots) and Standard Deviation (right 1 plots) i~, loga-
rithms for the Birth and Death Process. In the superior plots, straight lines 
correspond to ,\ ,- 0,13 and JL = 0.12, dashed,lines to'\ = 0.125 and,JL = 0.125, 
and dotted lines to ,\ = 0.12 and JL = 0.13. In the inferior plots these values 
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It should be pointed out that the expected value is nothing but the growth 
rate of the corresponding deterministic model and that it will only depend on 
the difference between the instantaneous probabilities A - J..L and the initial 
value. 
In figure 5.3 the expected value and the standard deviation is compared for 
two different life length distributions under three different birth and death 
probability scenarios in a population that starts with 20000 cells. 
In the superior plots, the life length of each of the cells is Exponentially dis-
tributed with parameter A + J..L = 0.25, so that the mean value and the standard 
deviation of the cell length are given by 4. After a cell dies, we have considered 
three different birth and death probabilities: 
• A = 0.13 and J..L = 0.12, so that with probability 0.52 there will be one 
more cell in the population. 
• A = 0.125 and J..L = 0.125, so that the population will be unchanged. 
• A = 0.12 and J..L = 0.13, so that with probability 0.52 there will be one 
cell less in the population. 
In the inferior plots, the life length of each of the cells is Exponentially dis-
tributed with parameter A+ J..L = 10.13+ 10.12 = 20.25, so that the mean value 
and deviation of the cell length are given by 0.049383. In this case, the three 
probability scenarios are given by: 
• A = 10.13 and J..L = 10.12, so that with probability 0.50025 there will be 
one more cell in the population. 
• A = 10.125 and J..L = 10.125, so that the population will be unchanged. 
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• ,\ = 10.12 and f..L = 10.13, so that with probability 0.49975 there will be 
one cell less in the population. 
Figure 5.3 confirms that the expected value of the population only depends on 
the difference ,\ - J..L. 
In this very simple model, where the probability distribution of the stochastic 
process is easily attained, it is straightforward {see, for instance, Bailey, 1967, 
pp.95 - 96)to calculate the extinction probability of the population: 
lim Po{t) = - . {
I if ,\ < J..L 
t~oo (X)a if,\ > J..L (5.37) 
Therefore, the chance of extinction of the population is positive for any value 
of ,\ and J..L. Exctinction will actually be certain unless the birth rate exceeds 
the death rate, in which case it will happen with probability {X)a. 
5.3.3 Multi-Type Birth and Death Processes 
In the previous section, cells within the population were indistinguishable as 
they all followed independently the same probabilistic behaviour with expo-
nentiallife times. Several extensions of this process are possible. 
The first natural generalisation of the birth-and-death process is to allow dif-
ferent probabilistic behaviours for different distinguishable subpopulations. 
These processes are called Multi-Type Brith and Death Processes provided 
that each subpopulation has an exponential life length distribution (see, for 
instance Bailey, 1967, and references therein). 
In this section we are going to propose a new model that will enable us to 
follow the evolution of different cell types. Therefore, two processes which 
remain hidden in simple Birth and Death processes will be taken into account: 
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cells that reversibly enter into a resting phase and cells that are irreversibly 
differentiated but still remain for certain time in the organism. These two 
processes, when relevant, will be of substantial importance when analysing the 
whole population. 
As we have already seen previously in this chapter, within a cell population 
there are three types of different cells depending on the cycle kinetics they 
follow, Le. proliferative, resting and irreversibly out of the cycle. It seems 
therefore, necessary to assign different probabilistic behaviours to each of these 
cell groups. 
At time t, there are three subpopulations of different cell types. The advantage 
of this model is that at any time t we will be able to count the number of cells in 
each of these subpopulations that follow different kinetics. Therefore, we will 
be able not only to get better insight of the evolution of the whole population 
but also to introduce changes in the kinetics of a particular subpopulation (for 
instance, by increasing the ratio of proliferative cells that get differentiated 
irreversibly introducing drugs). The deterministic counterpart of the model 
we propose has been presented in figure 5.2. 
There is a pool of proliferative cells, Xp(t). Given the migration and splitting 
rates shown in Figure 5.2, during the short period D.t, each proliferative cell 
can move towards mitosis, and therefore split into two new born daughter 
cells with probability kppD.t, can decide the leave the cycle reversibly, i. e. go 
resting, with probability kPT~t or can leave the cycle irreversibly so that it will 
eventually disappear, with probability kpiD.t. 
The number of resting cells at time t is given by the random variable Xr(t). 
\Vithin the interval D.t a resting cell will become proliferative again with prob-
ability krpD.t. 
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Finally, Xi(t) is the total number of cells which are irreversibly differentiated. 
Cells in this subpopulation, will be expelled from the organism during tlt with 
probability kdtlt. 
All the events that can happen to a cell within a subpopulation during the 
interval (t, t + tlt) are assumed to be independent of the events happening 
to other cells of the same subpopulations and of the event that happened to 
the cell in the past. This implies that life lengths within a subpopulation are 
independent and identically distributed exponential random variables. 
From the assumptions above, it follows that there are five possible types of 
changes over a short time period tlt in the subpopulation sizes. The instanta-
neous probabilities that these changes occur in the interval (t, ~t) are conse-
quently given by: 
• Prob. Xp increases by one unit (cell division) = kppXp(t)tlt + o(tlt). 
• Prob. Xp decreases by one unit and Xr increases by one unit (a prolif-
erative cell goes resting) = kprXp(t)tlt + o(tlt). 
• Prob. Xp increases by one unit and Xr decreases by one unit (a resting 
cell returns to the cycle) = krpXr(t)~t + o(tlt). 
• Prob. Xp decreases by one unit and Xi increases by one unit (cell differ-
entiation) = kpiXp(t)tlt + o(tlt). 
• Prob. Xi decreases by one unit (cell death) = kdXi(t)tlt + o(tlt). 
If the joint probability distribution of Xp(t), Xr(t) and Xi(t) at time t is given 
by: 
P{Xp(t) = np,Xr(t) = nr,Xi(t) = nil = Pnpnrni(t), (5.38) 
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the probability generating function, the moment generating function and the 
cumulant generating function are, respectively, given by: 
P(Xp, Xr, Xi) - I: (t) np nr n, Pnp,nr,n, Xp Xr Xi , (5.39) 
np,nr,ni 
Af((}p, (}n (}j, t) 
-
P(eOp , eOr , eO,) (5.40) 
- I: P . (t)enpOp+nrOr+n;O, np,nr,n, (5.41) 
np,nr,n; 
K((}p, (}r, (}j, t) 
-
logM((}p, (}r, (}j, t) (5.42) 
Expanding K((}p, (}r, (}j, t) in powers of Op, (}r and (}j we get it in terms of joint 
moments or cumulants, i.e. 
(5.43) 
where kooo = o. 
Now, let us suppose that the joint probability distribution of relevant transi-
tions in the interval Llt is given by: 
= /;piri' (xp, X r , xj)Llt, 
(5.44) 
where jp, jr, ji are not all zero and that the only possible transitions are: 
Extending the results presented on section 5.3.1, to the present multi- dimen-
sional case, it is easy to see that the differential equation for the cumulant-
generating function given in equation (5.27) can be now written as follows. 
a;~ = ([eOp _ l]kpp + ([e-Op+Br _ l]kpr + [e-9p+B, - l]kpi) ~: 
p 
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9 9 ] aK [9. ] 8K + [e p- r - 1 k - + e- , - 1 kd -rp aer aej (5.45) 
Differentiating equation (5.43) with respect to t: 
(5.46) 
Equating coefficients of ep , er and OJ on both sides of equations (5.45) and 
(5.46) we get the following set of differential equations for the expected values 










Therefore, the expected values of the number of cells of each type in this process 





where the constants a, AI, A2, Cp , Cr and Cj have been already defined for the 
deterministic model. 
In a similar manner, equating coefficients of 0;, 0;, Ol, OpOr, OpOj and OrOi in 
equations (5.45) and (5.46), second order moments of the process can be easily 
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obtained as the solution of the following set of differential equations: 
+ 2Krp Kno, 
dK020 = k k dt kprKlOO + rp K010 + 2 prKllO - 2krpK020, 
dKo02 _ 
-;It - k pi K 100 + 2kpiKlOl + kdKOOl - 2kdK002, 
dKllO 
-;It = - kprKlOO - k rpK010 + (kpp - k pi - kpr)KllO + kprK200 
+ k rp (K020 - K010), 
dK101 = k (k k k) dt - pi K100 + pp - pi - pr K101 + k pi K200 + krpKOll 







In figure 5.4, the expected values of the number of cells of each type for differ-
ent multi-type birth and death processes are represented. In the top-left plot 
proliferative cells can only either die or split. As the instantaneous probability 
of dividing (kpp = 0.06) is greater than the probability of irreversible differ-
entiation (kpi = 0.03) with a short delay prior to actually dying (kd = 0.1), 
the population grows rapidly. In this first case, the population is basically 
constituted by proliferative cells. 
In the remaining plots, fixing k pi and kd as before, cells are allowed to enter 
into a resting phase. In all cases kpr = 0.01 but with different resting times. 
In the top-right plot, cells rest for a relatively short time (krp = 0.5), so that 
the proportion of resting cells is very small. However, note that even with 
short resting periods, the whole population grows considerably slower than in 
the previous case. Longer resting times are considered in the remaining plots 
(actually, the resting time is infinity in the last case) and, as one would expect, 
the population growth decreases as the resting subpopulation increases due to 
this pool of non-proliferative cells. 
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Figure 5.4: Multi-Type Birth and Death Processes. Four different processes 
with kpp, kpr and krp as indicated. In all cases, kpi = 0.03 and kd = O.l. 
Cumulative plots of the expected number of cells of each type in logarithms 
over time, starting with one proliferative cell. Straight lines correspond to 
proliferative cells, dotted lines to resting cells and dashed lines to irreversibly 
differentiated cells. 






.!!l .!!l Qj LO Qj 0 0 .... g, .... Cl) 





0 200 400 600 800 1000 0 200 400 600 SOO 1000 






o ~ __ ~ ________________ ~ o 
o 200 400 600 800 1000 o 200 400 600 800 1000 
106 
5.3. Continuous Time Afarkov Processes 
Figure 5.5: Multi-Type Birth and Death Processes. Four different processes 
with kd as indicated. In all cases, kpp = 0.06, kPT = krp = 0 and k pi = 0.05. 
Cumulative plots of the expected number of cells of each type in logarithms 
over time, starting with one proliferative cell. Straight lines correspond to 
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Figure 5.5 intends to illustrate that the time spent by irreversibly differentiated 
cells before they actually leave the organism can originate appreciable changes 
in the expectation of the total number of cells in the whole population. Longer 
times waiting for death (that is, smaller kd' which would mean that cells get 
irreversibly differentiated in earlier phases of the cell cycle) originate bigger ir-
reversibly differentiated supopulation without altering the pool of proliferative 
cells. 
5.4 Multiple-Phase Birth and Death Processes, 
The cell cycle is known to be a compound of stochastic phases. All the models 
considered above rely on the assumption of random transitions from phase 
to phase imposing exponential distribution waiting times between transitions. 
Even though this kind of models could be realistic in many cases, some real 
processes demand less restrictive assumptions. Exponential generating times 
would not be appropriate to model the cell cycle if there is an evidence that, 
for instance, a new born cell requires some minimum maturation time before 
splitting. 
The Markovian property simplifies the tractability of all the stochastic pro-
cesses analysed before. This property will be lost if we consider a general dis-
tribution for the life-time, making the stochastic processes more complicated 
and, sometimes, intractable. 
We could easily generalise the exponential generation time to a X2 distribution 
with even degrees of freedom (note that the exponential distribution is a X2 
distribution with 2 degrees of freedom)by appropriately applying and general-
ising the model presented in Bailey (1967, pp. 131 - 135). This approach was 
first used by Kendall (1948). 
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In what follows, the life cycle is artificially divided in pseudophases (without 
biological counterpart) imposing transition probabilities such that transitions 
from phase to phase occur at random so that the Markovian property holds. 
Let us imagine that the life-time of each cell consists of k consecutive pseu-
dophases. At each time t, Xl (t), ... , Xk(t) represents the number of cells in 
each of these k pseudophases. When transitions from phase to phase occur at 
random, the Markovian property holds. But, more importantly, as we will see, 
if the life lengths are exponentially distributed, then the overall life length will 
have the more general X2 distribution with 2k degrees of freedom. 
In Figure 5.3 the life of a cell is, artificially, divided in k = 2 compartments. 
A new born cell enters the first compartment or youth phase, Xl. During the 
period ~t, a young cell will be transferred to the second phase with probability, 
let us say, 2/3~t. Hence, the distribution of stay in the first phase is the 
exponential distribution with parameter 2/3, which apart from a scale factor is 
essentially a X2 distribution with two degrees of freedom. Imposing that a cell 
in the second or maturity phase X2 has the same 2/3~t probability of dying, 
the distribution of stay will be the same as in the first phase. Consequently, as 
the life of the cell is divided in two exponentially distributed phases, i. e. two 
X2 with 2 degrees of freedom, the overall life length will be distributed as a X2 
with 2 x 2 degrees of freedom. 
The rate /3 will be designed so that the model acknowledges the different 
behaviours of each of the three cell types described in Section 5.1). 
'Ve assume that a young cell cannot die and that will eventually become ma-
ture. It can then choose to go on as a proliferative cell, to go resting or to 
leave the cycle irreversibly. The decision that cells take will determine the fate 
of the population. If the dead cell is replaced by two new born cells, the cell 
is proliferative. If it is replaced by just one new born cell, the cell decides not 
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Figure 5.6: Cell Cycle for the Multiple-Phase Birth and Death Process. 2('\ + 
v + J-L) is the ratio of young cells that become mature and 2'\, 2v and 2J-L are 
the ratio of mature cells that split into two daughter cells, the ratio of cells 
that go resting and the ratio of cells that die respectively. 
2A 
YOUNG 2 (A+U+J.t) OLD 2u YOU NG 
Xl X2 2Jl Xl 
to follow the cycle but to rest. Finally, if there is not any new cell, then the 
cell chooses to die. 
Therefore, in this process during Llt there are four possible types of changes 
in the subpopulations with the following probabilities: 
• Prob. Xl increases by two and X2 decreases by one (cell division): 
2,\X2 (t)Llt + o(Llt). 
• Prob. Xl increases by one and X 2 decreases by one (a proliferative cell 
goes resting): 2vX2(t)Llt + o(Llt). 
• Prob. Xl does not change and X 2 decreases by one (cell death): 2J-LX2(t)Llt+ 
o(Llt). 
• Prob. Xl decreases by one and X 2 increases by one (a cell becomes 
mature): 2('\ + v + J-L)XILlt + o(Llt). 
Note that the last probability has been assigned so that the life length distri-
butions of both subpopulations are the same, i. e. exponential with parameter 
2j3, where j3 = ,\ + v + J-L. Consequently, the time spent from birth to death 
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has essentially a X2 distribution with 4 degrees of freedom, and expected value 
1/ (3. 
By an straightforward extension of equation (5.27), the corresponding differ-
ential equation for the joint cumulant-generating function can be written as 
8K 
at 
where the same notation as in previous sections is used. 
Equating coefficients on both sides of equation (5.59), we obtain the following 





Solving this system gives the first order moments of X 1(t) and X2(t): 
_ !e-2(.8-~)t + !e-2(.B+~)t 
2 2 






where f3 = ,\ + v + JL and cp = 2,\ + v. Therefore, the expected total number of 
cells at time t will be given by: 
m(t) - KlO(t) + KOl(t) (5.65) 
e-2(.B-~)t v<P +..fiJ + e-2(.B+~)t fo - ..fiJ (5.66) 
2v<P 2fo 
In figure 5.7 the multiple-phase birth and death process is compared to the 
simple birth and death process with parameters ,\ = 0.05 and JL = 0.04 (there-
fore, with expected life length of 11.11). The expected number of cells of the 
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Figure 5.7: Multiple-Phase and Standard Birth and Death Processes. Dashed 
lines represent the expected number of cells in a simple birth and death process 
with ,\ = 0.05 and J.L = 0.04. The expected number of cells in a multiple-phase 
process with the indicated instant probabilities are represented by dotted lines, 
where straight lines account for the corresponding subpopulation of young cells. 
In all cases the populations start with only one cell. 
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5.5. Branching Processes 
simple birth and death process in all four plots by dashed lines. In all the cases 
the expected life length of each cell is fixed at 11.11 with different instant prob-
abilities. Straight lines represent the expected number of young cells, whereas 
dotted lines account for the total multiple-phase population. 
A comparison of the plots in figure 5.7 shows that the rate of cells that rest 
plays a vital role in determining the evolution of the expected size of the 
population. 
5.5 Branching Processes 
5.5.1 Introduction 
In this section another kind of stochastic processes will be introduced: Branch-
ing Processes. Bellman and Harris (1952) first introduced and studied the 
theory of Branching Processes and an extensive literature has followed (see 
general references as, for instance, Harris, 1963, Athreya and Ney, 1972, and 
Jagers, 1975, and references therein; and Christensen and Shonkweiller, 1978, 
Cowan, 1985, Cowan and Morris, 1998, and Jagers and Klebaner, 2000, for 
more recent developments). 
5.5.2 The General Model 
'Ve are interested on a population with one ancestor composed by individual 
cells, x, characterised by the pairs (Ax, ~x), where Ax is the life length of x and 
~x the reproduction point process of x, which are supposed to be i.i.d 2 with 
probability distribution Q, known as the individual law, measured on the space 
R+ x N{R+). 
2Therefore, we will omit subscript x. 
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These kinds of processes are called Branching Processes. For a full summary of 
the theory see, for instance, the books by Athreya and Ney (1972) and Jagers 
(1975). vVe shall follow the notation and conventions of the latter one, and 
details and the proofs of the theorems should be consulted there. 
The margin of Q on R+ is the life-length distribution and the margin on N(R+) 
the reproduction law. If ax is the birth time of x and a ~ 0, the variable 
a { 1 if t - a < 0' x ~ t < ax + Ax 
Zt (x) = 
o otherwise 
will be one if x is alive and is younger than a at time t. Therefore, 
zf = LZf(x) ~ 00 (5.67) 
x 
counts all the individuals younger than a that are alive at time t. The stochas-
tic process {zf, t, a ~ O} is the general branching process. When, there is 
no interest on the age distribution of the cells, e.g. a = 00, we will write 
{Zt, t ~ o}. Similarly, if Yt{x) takes value one when x has been born (i.e., 
ax ~ t), 
Yt = LYt{x) (5.68) 
x 
will be the total number of individuals that have been born up to time t. 
Some more notation will be needed in what follows. The life-length distribution 
function and the expected value of the process will be denoted as L(u) = P[A ~ 
u), and m~ = E[zf] respectively. The reproduction generating function will be 
given by: 
f(s) = E[s~(oo)) (5.69) 
and we define the reproduction function as, p{t) = E[~(t)), and the reproduction 
mean as m = /'(1) = Jl{oo). 
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\Ve can classify the z(t), t > 0 according to the corresponding reproduction 
mean, m, as: supercritical ( m > 1 ), critical: (m = 1 ) or subcritical: ( m < 1 
). 
On the other hand, a process is called Malthusian when there is a number 0 
(the e.g. Malthusian parameter) such that: 
/1(0) = 100 e-otJL(dt) = 1. (5.70) 
The Malthusian parameter will be positive, zero or negative according as m > 
=, or < 1 respectively. The Malthusian parameter will always exist for 
supercritical processes. This will not always be true in the subcritical cases. 
The process will be lattice if there is a number d > 0 such that 
00 
LJL({kd}) = JL(oo). (5.71) 
k=O 
We can now state some important theorems. Theorems 5.1 and 5.2 are taken 
from the book by Jagers (1975, Theorems 6.5.1 and 6.3.3 3). 
Theorem 5.1. 
If the reproduction function is finite, then so is E[Ytl and therefore also mt = 
E[ztl for all t. Further, mi = E[ztl satisfies 
m~ = l[o,a)(t){l - L(t)} + lt m~_uJL{du). 
If m = JL(oo) < 1 (the subcritical case), then as t -t 00 then mt -t o. 
If m = 1 (the critical case) and JL is non-lattice, then for 0 < a < 00 
a Joa {1 - L(u)}du 
mt -t roo 
Jo uJL{du) 
If further, 
100 tL( dt) < 00, 
3There are obvious lattice analogs. 
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then also 
1000 uL(du) 
mt ---* It uj-t( du) . 
When m > 1 (the supercritical case), j-t is not lattice, and a > 0 is the Malthu-
sian parameter defined by j7(a) = 1, then for 0 ~ a ~ 00, 
a otJoa e-0 1.l{1- L(u)}du 
m t IV e roo Jo ue-0 1.lJL(du) 
In the lattice cases corresponding assertions hold. 
Theorem 5.2. 
In a non-lattice, subcritical process admitting the Malthusian parameter 0, 
(5.72) 
for 0 ~ a < 00, as t ---* 00. For a = 00 the relation still holds, provided 
(5.73) 
Therefore, we have that under certain conditions, the total expected number 
of cells of all ages in a population, mr = mt, will be given by: 
(5.74) 
A particular case of the general model will be now described in more detail, the 
Bellman-Harris Process, suitable to study the evolution of cell populations. 
5.5.3 Bellman-Harris Processes 
Splitting processes or Sevast' yanov processes were introduced by Sevast' yanov 
(1964) and the Bellman-Harris process processes are known since the forties 
(Bellman and Harris, 1952). 
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Definition 5.1. 
When P(€{A} = €{oo}) = 1, the process is called splitting or Sevast' yanov 
process, and if in addition, A and € are independent, is known as the 'Bellman-
Harris' or the 'age dependent' process. 
In other words, in a splitting process, new cells are only born at the death 
of their mother. If further, the reproduction process is independent of the 
life-span we will talk about Bellman-Harris processes. 
We are concerned with a stochastic model for the cell proliferation. As dis-
cussed above, at the end of their lifes cells can either die or split no matter the 
length life (note that cells that have been resting when back in the cycle they 
become proliferative again and, therefore, when they reach mitosis can either 
die or split). 
Therefore, given the characteristics of cells' behaviour, the stochastic process 
that we will construct for the population will be a Bellman-Harris process. 
This fact will simplify the reproduction function of the process to: 
p(u) = lot f~(l)L{du) = lot m(u)L(du) = mL{u). (5.75) 
From equation (5.70), the Malthusian parameter a satisfies, 
(5.76) 
and applying logarithms it follows that, 
-lnm = In! e-oYl{y)dy. (5.77) 
Noting that In f e-OYl{y)dy = K( -e), where K is the cumulant generating 
function, using the Taylor expansion we get: 
I (_~r ~ 3 In e-OY1(y)dy = 2:>~r-,- = -ap + -2 2 + O(a ), r=l r. a (5.78) 
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where J-L and (72 denote the mean and variance of l(y) respectively. Setting 
m = 1 + f and solving for a in terms of f, it follows that 
(5.79) 
Empirically, restricting our attention to first and second order moments, and 
after testing multiple expressions, the best approximation for the Malthusian 
parameter for the distributions we have considered is the following one: 
(5.80) 
Directly expanding equation (5.76), setting m = 1 + f, it follows immediately 
equation (5.80), where the error will be of O(€3) if the third moment is finite. 
On the other hand, recalling equation (5.74), for the Bellman-Hams process 
we have that: 
k(y) = J e-oY (1 - L(y))dy 
m J ye-oYl(y)dy 
Now, differentiating with respect to m in equation (5.76), 
8a 1 
8m - m2 J ye-oYl(y)dy' 
and therefore, it follows that 
where the last approximation is due to equation (5.80). 
On the other hand, 
! e-oY (1 - L(y))dy = - ~ J (1 - L(y))d(e-oy ) 
= [-.!.(1 - L(y))e-oy]~ + .!.! e-OYd(1 - L(y)) 
a a 
1 1 f -0 Ilm-l 
= - - - e Yl(y)dy = -(1 - -) = . 
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Consequently, k can be approximated as: 
0'2 
m -1 mj;2" ...... 
k':::!. ~ -- =k, 
am J.l 
(5.87) 
and therefore, combining the approximations to the malthusian parameter and 
to the constant k, it follows that: 
(5.88) 
This expression constitutes a simple approximation to the expected number 
of cells alive at time t. The main advantage of this result is that it does not 
depend on the particular life distribution of cells. The first and second order 
moments fully characterise this expectation. 
If p E [0,1] denotes the probability of cell division, the reproduction mean 
of the process will be given by m = 2p E [0,2]. Dots in figure 5.8 represent 
the real values of C¥, k and mt at time t = 30 for ten different values of the 
reproduction mean m. Three different life length distributions are considered: 
• Exponential distribution with parameter 0.03333. 
• Gamma distribution with parameters 0.06666 and 2 with a minimum life 
length of 2 (that is to say that the probability of dividing or splitting is 
zero in the first 2 time units of life of cells). 
• Gamma distribution with parameters 0.2 and 2 with a minimum life 
length of 20. 
In all cases the approximations given by equations (5.80), (5.87) and (5.88) 
are very close to the real values (note that in the exponential case the approx· 
imations equal the real values). This simplifies enormously the calculation of 
the expected number of cells in a population for large populations. Informa· 
tion about the mean and the variance of the distribution of cell life lengths 
comprises enough information to characterise the limit result for the expected 
number of cells. 
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Figure 5.8: Approximations. Real values of the malthusian parameter, a, the 
constant k and the expected number of cells in the population, mh at time 
t = 30 are represented by dots. Three different life length distributions are 
considered, one exponential and two gamma distributions with a minimum 
time length for either division or death. The obtained approximations are 
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5.6 Conel us ions 
In this chapter we have studied the kinetics that govern the proliferation of 
cell populations. After introducing the cell cycle, we have presented several 
deterministic and stochastic models. 
Two different stochastic processes have been considered in this chapter in or-
der to build models for cell growth: 'continuous time Markov processes' and 
'Branching processes'. The underlying assumptions and the pros and cons of 
each of these processes have been detailed and discussed. Three novel models 
have been derived: the 'Multi-Type Birth and Death Process', the 'Multiple-
Phase Birth and Death Process' and the 'General Life Length Process'. With-
out a particular data set or a research interest in mind, these three models 
should be considered as complementary as both the underlying assumptions 
and the degree of detail of results are different in each of them. 
In what follows, cell populations will be exposed to drugs that alter their kinetic 






In chapters 2 and 3 various models to estimate the concentration of drugs in 
different body compartments containing certain cell, tissues and/or organs, 
have been introduced. The next step is to try to quantify, and therefore un-
derstand, the effects that a certain amount of drug induce within the body 
during treatment. 
In the first sections of this chapter we are going to present a brief summary of 
some of the most widely used pharmacodynamic models linking plasma drug 
concentration with response. Our main interest lies on analysing the fate of 
cell populations which are exposed to drugs. The aim is to both qualitatively 
and quantitatively describe the effect that certain blood drug concentration 
levels have in the evolution of cell populations. 
In section 6.2.3, we construct a new general model that links pharmacoki-
netic, pharmacodynamic and cell kinetics processes. An additional crucial 
phenomenon will be introduced in the model in section 6.2.4: 'drug resis-
tance' . It is well known that treatment-resistant cells can arise at any time 
during treatment. These cells can in time come to comprise subpopulations of 
cells that will not be affected by the original treatment. 
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\Ve are going to perform toy examples in order to see how the models we 
propose in this chapter behave in a deterministic world, free of measurement 
error. The evolution of leukaemic cell populations will be analysed under four 
different treatment scenarios. 
The population approach, already introduced in chapter 3 to deal with phar-
macokinetic data, will be then adopted to, hopefully, handle the variability 
that in most cases clinical data present. 
6.1 Introduction 
Pharmacodynamics is the study of the biochemical and physiological effects 
of drugs and their mechanisms of action. It studies the interactions between 
plasma drug concentration and the caused effects in the targed cells, tissues 
and/ or organs. 
Physiological effects of drugs can be divided into two groups: 'continuous' 
and 'quantal' or 'dichotomous'. A continuous response can be evaluated as a 
continuous function of dose, concentration and time (e.g. blood pressure and 
heart rate). A quantal effect, on the other hand, is a discrete variable, there 
is either a response or not, nothing in between (e.g. death and remission). In 
what follows, we are going to concentrate on continuous effects. 
In addition, the type of relationship between the plasma drug concentration 
and a given response can generally be determined by two factors: whether 
concentration is directly or indirectly related to response, and whether the 
drug interacts with the receptor reversibly or irreversibly. 
Lastly, the relationship between effect and concentration can be either 'ago-
nistic' or 'antagonistic'. The effect is said to be agonistic when its magnitude 
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increases with higher drug concentrations and antagonistic when there is an 
inverse relationship between the magnitude of the effect and the levels of con-
centration. In what follows, we will only consider agonistic effects. 
There are innumerable specific models for the interactions between particu-
lar drugs and the different effects they cause. Ross (1996) gives account of 
most of the pharmacodynamic models that have been used in clinical appli-
cations and research. Particular models can be found in Levy (1966), Jusko 
(1971), Matthews (1993), Jusco and Ko (1994), Levy (1994) and Jenkinson et 
al (1995). An exploratory analysis of the data set will in most cases provide 
hints about the most adequate model in each case. 
6.2 Main Pharmacodynamic Models 
6.2.1 Introduction 
It has already been mentioned that the type of relationship between the plasma 
drug concentration and a given response can be either direct or indirect. In 
the first case the intensity of a given pharmacological response is due to a 
direct effect of the drug on the receptor. When the relationship is indirect, 
the intensity of the response may be the net result of several processes, only 
one of which is influenced by the drug. If this is the case, the process that 
is influenced by the drug must be identified and an attempt made to relate 
plasma drug concentrations to changes in this process. 
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6.2.2 Direct Pharmacodynamic Models 
Introduction 
In a direct pharmacodynamic model, by definition, the drug concentration at 
the receptor site will be a function of the drug concentration in the plasma. 
The form of the relationship will depend on the location of the site of action. 
Following the compartmental approach taken in chapter 2 the site of action 
may be located either in the central compartment or in one of the peripheral 
com partments. 
The site of action may be determined by examining the relationship between 
the intensity of response and the concentration of drug in the plasma or the 
estimated amount of drug in the corresponding peripheral compartment. 
One-Compartment Models 
When the drug concentration over time in the plasma can be described by a 
one-compartment model, the drug concentration at the receptor site, CT! will 
be proportional to the drug concentration in the plasma, C, as the receptor is 
believed to be located in the same compartment as the circulatory system. 
The simplest relationship between concentration and an agonistic pharmaco-
logical effect, E, can be described by a linear function of the form, 
E(t) = Eo + qC(t), (6.1) 
where the intercept, Eo, and the slope, q, are constants to be determined. 
However, a linear and direct proportionality between concentration and ef-
fect rarely applies to actual cases. Nevertheless, in a number of instances, 
a linear proportionality between the effect and the log-transformation of the 
126 
6.2. Main Pharmacodynamic Models 
concentration has been applied successfully: 
E{t) = E~ + q'lnC{t) , (6.2) 
where the intercept E~ and the slope q', are constants to be determined. In 
this model, the pharmacologic response can not be estimated when the con-
centration is zero because of the logarithmic function. 
In addition, in both (6.1) and (6.2) the effect tends to infinity as the con-
centration increases. This violates a widely accepted pharmacologic principle 
which under certain biological conditions states that there is a drug-induced 
'maximal effect'. 
A widely used relationship between concentration and an agonistic effect has 
the following form: 
E(t) = EMAXC(t)m 
ECf:o + C{t)m' (6.3) 
where EMAX is the drug induced maximum effect and EC50 represents the 
'potency' of the drug, and m > 0 is known as the 'sigmoidicity factor'. A 
baseline effect could be added if necessary. 
Potency is an expression of the activity of a compound in terms of the concen-
tration needed to produce a defined effect. The variable EC50 is the concen-
tration of the drug that produces 50% of the maximal possible effect. The 
sigmoidicity parameter m does not necessarily have a direct biological in-
terpretation but it provides a degree of flexibility in the sensitivity of the 
response-concentration relationship. This equation is known as the Sigmoid 
EMAX Model or the Hill equation. This equation was first used by Hill (191O) 
and introduced in pharmacodynamics by Wagner (1968). 
The Hill equation will quantitatively and fully characterise the typical sig-
moid curve resulting from a effect versus concentration plot on a logarithmic 
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Figure 6.1: Hill Equation.The dashed line represents the Hill equations with 
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concentration scale as shown in figure 6.1. The solid line has a small sigmoidic-
ity factor, whereas the dashed line is the result of a higher sigmoidicity factor. 
Both lines have the same potency and maximal effect. A high exponent results 
in an all-or-nothing effect. 
When treatment consists in more than one drug, the most common generalisa-
tion of the Hill equation (see, for example, Gero, 1971, and Ebling et ai, 1991) 
is given by: 
E(t) = L EMAX"c,(t)ml 
l ECW,l + c,(t)ml ' (6.4) 
where I = 1, ... , L, L being the number of different drugs administered. This 
model assumes that there are no significant interactions between drugs and 
that the effect they all produce is agonistic. For interaction pharmacodynamic 
models, see for instance, Kenakin (1993) and Matthews (1993). 
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Multi-Compartment Models 
The time course of drug action in multicompartment systems depends on the 
location of the site of action. When the site of action is associated with the 
central compartment, a plot of effect versus the log-concentration should yield 
the same sigmoid-type curve as that shown in figure 6.1. 
A similar relationship should also be observed when the effect is associated 
with the concentration in a peripheral compartment when the effect is plot-
ted against the estimated log-concentration of the corresponding peripheral 
compartment. 
However, when the effect is plotted against the plasma log-concentration, re-
sponse will increase with decreasing plasma concentration during the distribu-
tion phase, reach a peak and then decrease during the postdistribution phase. 
Since plasma drug concentration during the distribution phase in a multicom-
partmental model does not decline in a simple exponential fashion, one would 
not expect the effect to decline in a linear manner. 
In some circumstances, there is no a priori reason to assume that the response 
site corresponds, kinetically, with a site receiving a large amount of drug. In 
these cases, there is little reason to assume that the kinetics of drug in the 
plasma compartment, or another determined compartment, will paralell those 
at the effect site. Sheiner et al (1979) and Whitting et al (1980) proposed that 
the effect compartment should be modelled as a separate compartment linked 
to the plasma compartment by, for instance, a first-order process receiving a 
negligible amount of drug. Consequently, there is no need to add an additional 
exponential term into the n-compartmental pharmacokinetic model to account 
for the effect compartment. 
The model presented by Sheiner et al (1979) is illustrated in Figure 6.2. The 
rate constants from the central to the n - 1 peripheral compartments have 
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Figure 6.2: Multi-compartment Model. There is a central compartment from 
where drug is delivered into all other compartments, including the ffect com-
partment, at rates kIn and k1e respectively. Subtances return to th c ntral 
compartment from the peripheral compartments at rates knl and is liminated 
at rate klO • It is assumed that elimination occurs directly from the ffect 
compartment at rate keo. 
PERIPHERAl 
(n-I) 
kin ~ I 
-
CENTRAL k1e EFFECT ~o 
klO 
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already be int roduced in Chapter 2. The novelty of t his model is t hat a 
fir t order rat e constant k1e connect s the central to the effect compar t ment. 
If " 'e a ume k1e to be very small rela tive to the m agnit ude of any other 
rate constant in t he model, t he drug transfer from the centra l compart ment 
to the effe t ompartm ent is negligible, and therefore does not influence t he 
pl asma concentra tion versus t ime plot. As the amount of drug in the eft"ect 
compartm nt will be negligible , it can be eliminated directly from the eft"ect 
compartment. wi th rate constant ,say, keo. 
T he c n entra tion of d rugs in t he different compartments can easily be ob-
tained following the techniques presented in chapter 2 (see, for inst ance, Sheiner 
t al. 1979). For a two-compartment model (n = 2 in Figure 6.2) , the concen-
trat ion Icyel in the ent ral and effect compartment following a single intra-
,"enoll admini tration are given by: 
( ) = D ((k I2 - a )e-
o t (k12 - (3 )e- fi t ) (6.5) 
c
t
" B + (3 ' 1 - a a-
( ) keoD (k12 - a) - ot keoD (k21 - (3) -fi t vt = , e + e + 
, 11(B-a)(keo - a) V1((3 -a)(keo - (3 ) (6. 6) 
keo D(k12 - keo) - k t + , e eo , 
, 1 (a - keo) ((3 - keo) 
wh ere ' 'I i t he ,"olume of di t ribu t ion in the central compartment , D t he 
a Im inistcr I illtra\' nou dose , and a and (3 are given by: 
3 
T h r forc. wc ha\' obtained an expres ion for the amount of drug reaching 
t he (' ffec t compartmnt luring t reatment. This fraction of the total do e will 
det rmine the effrc t f intere t . An estimation of t he substance that actu-
a lly cut r. in to th e effrc t compart ment is of great importance when choosing 
opt imal doscs. 
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6.2.3 Indirect Pharmacodynamic Models 
Introduction 
The intensity of a pharmacologic response may not be caused by a direct effect 
of the drug but it may be the net result of several processes, only one of which is 
influenced by the drug. Under such circumstances a direct relationship between 
the plasma concentration of the drug and the effect can not be obtained. 
This class of models is typically based on some biological principles with prior 
knowledge about the mechanisms of drug action in that the variables and 
parameters have a physiological meaning. In contrast, the previous direct 
models rely on empirical concepts. 
The particular process that is altered by the drug must first be identified and 
then the relationship between plasma drug concentration and this process must 
be modelled. Applications of indirect pharmacodynamic models can be found , 
for instance, in Jusco (1971) , Jusco (1990) and Dayneka et al (1993). 
Our interest will lie on the cell kinetic processes analysed in the previous chap-
ter. The effect that drugs will originate in the cell cycle need to be modelled 
in order to establish the effect that treatment has in the evolution of cell pop-
ulations. 
Cell Death 
Although most drugs produce a response that is reversible, certain antibiotics 
and anticancer agents cause cell death, an irreversible effi ct , by attacking the 
cell cycle. It is appropriate to classify two different types of drugs , each of 
which affects the cell cycle in a different manner: cell cycle pha e- p cific and 
non-phase-specific drugs. Each type requires a different model as th aft ct d 
population of cells differs from one type to the other. 
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Figure 6.3: Pharmacokinetic-Pharmacodynamic-C -ll-Kill t i s ~I leI. T here 
are three types of cells, t he proliferative cell s, Xp the resti ng 'e ll s .Yr , and 
the irrC'versibly differentiated cells, X i, with migration rates kp1' k rp 1 k'l1 ' kd and 
splitting rate kpp . \Vhen treatment starts, the pharma ok in tic model wi ll 
determine the concentration of drugs in the effect compartment e(i) , that 
will have an effect on the cell population by altering t he cell cycle. In particular. 
we assume that a fra ction kpid (t) of the proliferativ cell s will not clivi Ie during 















In ",hat follow , we are going to introduce phasc-spe ifi drug ' in to the de-
termini tic c ·1l kineti model int roduced in chapter 5. Ke p in mind that thr 
re li lts in this model equal the expected values for the orrespondin g stochastic 
model that as urnes exponential life times in each ph ase of t he cell cycle. \i r 
are going to link the pharmacokinetic and pharmacod nami mod L with t he 
cell population model. A global view of all the processes involved in drtr rmin-
ing t he C'ffect of treatment will be therefore constructed . 
:\. eli 'C ussed in chapter 5 depending on the role th y und rtake within thr 
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cycle, there are three different types of cells: proliferative, resting and differen-
tiated cells. In figure 6.3, these three different types are represented with the 
corresponding deterministic flows between them. The notation is the same as 
the one used in chapter 5. The model is the same as represented in figure 5.2 
with the only difference that drugs are interfering with the cell cycle. 
In this particular model we propose, drugs have effect on the death rate of 
proliferative cells. Cells that otherwise would go into mitosis are being killed 
as an effect of drug action. It is assumed that drugs can only affect proliferative 
cells, leaving the resting and differentiated subpopulations unchanged directly. 
Within the proliferative population, though, drug action is supposed to be 
uniform in the sense that it can occur at any phase (e.g. All, S, A12 or 
mitosis phase) with equal probability. 
The drug-induced death rate of cells is given by kpid(t) which will be a function 
of drug concentration and, therefore, will change over time. Let us suppose 
that the adequate pharmacodynamic model is given by: 
(6.7) 
where Ce(t) is the calculated drug concentration at the site of action and 
CMAX the maximum possible concentration. When Ce(t) = CMAX , the drug-
induced death rate, kpid , will be equal to k, which accounts for the maximum 
response. As discussed earlier, the site of action could either be in one of the 
pharmacokinetic compartments or in a separate effect compartment. 
This particular pharmacodynamic model that we are proposing here will obvi-
ously be adequate only for certain drugs and when looking at certain effects. 
An exploratory analysis should be done to determine the most adequate phar-
macodynamic model to link particular drug concentration levels and a chosen 
response. However, the global approach presented here does not rely on any 
particular pharmacodynamic relationship. 
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When more than one drug is administered, we could easily generalise equation 
(6.7), so that, 
L C;,(t) 
kpid(t) = L k, C2 ' 
l=l MAX,' 
(6.8) 
where L is the number of different drugs that constitute treatment. 
It follows that when treatment starts, the dynamics of the cell population 
changes as concentration levels vary. The model we propose, based on equa-








- kprXp(t) - krpXr(t), 
- (kpi + kpid(t))Xp(t) - kdXi(t), 
(6.10) 
(6.11) 
where kpid(t) is given by equation (X) and Ce,(t) needs to be estimated tak-
ing into account the pharmacokinetic characteristics of each of the drugs 
1 == 1, ... , L. 
Example 
\Ve are going to perform a toy experiment in order to see how the model 
above would behave in a deterministic world, free of measurement error. The 
evolution of a cell population with the same kinetics will be compared for four 
different treatment schedules in three different drug potency scenarios. 
Let us assume that the population starts with one ancestor at time t = 1 
and treatment starts at t = 100, when the population of leukaemic cells has a 
critical size. The cell population will be followed up to time t = 325. 
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Figure 6.4: Effect of Drugs 1 and 2, kpid , plotted against time for four different 
treatments (in rows) and three different pair of values of 'maximum effect' 
of drugs (in columns). Straight lines correspond to the effect of Drug 1 and 
dashed lines to the effect of Drug 2. 
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Treatment consists of two different drugs, Drug 1 and Drug 2. The following 
four doses of each of the drugs must be administered intravenously during 
treatment: 
• Drug 1: DI(1) = 40000, Dd2) = 10000, DI(3) = 5000 and D1(4) 
2500 . 
• Drug 2: D2(1) = 60000, D2(2) = 10000, D2(3) = 5000 and D2(4) = 
2500. 
Let us assume that after the first intravenous dose of each of the drugs, the 
concentration of substances 1 and 2 in the corresponding effect compartment, 
C1(t) and C2 (t) satisfy the following kinetic behaviours: 
C1 (t) - DI (1 )0.5e-O.005(t-TDl (1» 
C2(t) - D2(1)0.2e-o.003(t-TD2(1» 
for t > TD1 (1) and t > TD2 (1) and zero otherwise, where Dl (1) and D2(1) are 
the initial doses of Drugs 1 and 2 and TD1(1) and t > TD1(I) the corresponding 
dosing times. 
Note that these concentrations are understood to correspond to the site of 
response. The concentration in other body compartments has not been speci-
fied. The proportion of the dose that actually reaches the corresponding effect 
compartment is higher for Drug 1 than for drug 2. 
Next, the additive pharmacodynamic model described by equation (6.8) is 
applied to relate the drug-induced cell death rate to the assumed concentration 
of drugs in the corresponding effect compartment. It is supposed that for Drug 
1, CMAX,l = 30000 and that for Drug 2, CMAX ,2 = 20000. 
Four different dosing schedules will be considered in this illustration: treat-
ments A, B, C and D. In Treatment A, all four doses of Drug 1 are administered 
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at times t = 100, 125, 150 and 175, followed by the four doses of Drug 2 at times 
t = 200,225,250 and 275. 
In Treatment B drugs 1 and 2 are administered alternatively, starting with 
a dose of drug I 1 at time t = 100, at 25 time unit intervals. Lastly, Treat-
ments C and D combine both drugs and doses of both substances are given 
simultaneously at every 50 time unit intervals, starting at time t = 112.5 in 
Treatment C and at time t = 100 in Treatment D. 
In figure 6.4, the effect kpid(t) satisfying equation (6.8), is plotted against 
time for all four different treatments for three different pair of values of the 
maximum effect of the drugs. In the left column the same potential efficiency 
is assigned to both drugs, in particular, it is assumed that kl = 0.4 and 
k2 = 0.4. Higher potential efficiency is given to Drug 2 in the plots in the 
middle column, fixing kl = 0.3 and k2 = 0.5. Lastly, in the right column is 
assumed that kl = 0.5 and k2 = 0.3. Straight lines correspond to the effect of 
Drug 1 whereas dashed lines correspond to the effect of Drug 2. 
Note that the chosen response variable, kpid, due to the assumed pharmaco-
dynamic equation (6.8), is proportional to the drug concentration in the effect 
compartment. Proportionality with respect to the concentration in the central 
compartment, which is observable, by no means should be presupposed. The 
relationship between drug concentration in the central compartment and the 
effect variable will be characterised by the location of the effect compartment 
and the kinetics between them, as already discussed. 
As mentioned before, the origins of the population are to be found at time t = 1 
with one ancestor. Before treatment starts, based on the model described in 
figure 6.3, it is assumed that the evolution of the cell population is governed 
by the following rate constants: 
kpp = 0.4, kpr = 0.2, krp = 0.1, kpi = 0.2, kd = 0.3. 
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Figure 6.5: Evolution of cell subpopulations under four different treatments (in 
rows) and three different pair of values of 'maximum effect'(in columns). The 
rate constants are fixed at kpp = 0.4, kpr = 0.2, krp = 0.1, k pi = 0.2 and kd = 
0.3. Straight lines represent the number of reproductive cells, the difference 
between dotted and straight lines accounts for the number of cells reversibly 
resting, and the difference between dotted and dashed lines represents the 
number of irreversibly differentiated cells in the population. 
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In the plots in figure 6.5 are represented the amount of cells over time in 
the three subpopulations that constitute the cell population. Straight lines 
represent the number of reproductive cells. The difference between dotted 
lines and straight lines accounts for the number of cells that are reversibly 
resting at each time. Lastly, the difference between dotted and dashed lines 
represents the number of differentiated cells that will eventually disappear from 
the organism. 
Due to the values assigned to the constant rates, the population of cells in-
creases exponentially prior to treatment. When treatment starts, over 20000 
cells constitute the whole population, where approximately half of them are of 
the reproductive type. As the reproductive subpopulation increases, so does 
the resting subpopulation, as the fixed constant rate kpr is greater than k rp• 
When treatment starts, drugs start acting on the reproductive subpopulation, 
killing cells which otherwise would split. Both the resting and the differentiated 
subpopulations will eventually decrease accordingly, provided that the total 
death rate exceeds the splitting rate. 
The first conclusion that can be derived from figure 6.5 is that the treatment 
that best performs in all four scenarios is Treatment D. It should be pointed 
out that under treatment D not only the total concentration of drugs is higher 
when the population is bigger, but also that the overall exposure of drugs is 
greater due to greater total 'areas under the curve'. Superiority of Treatment 
D could have been predicted since both drugs are administered earlier and, 
therefore, the total drug exposure is greater. 
In Treatment C both drugs are administered simultaneously but treatment 
starts 25 time units after diagnosis. This time gap can be crucial as the size 
of the population could reach lethal levels before treatment starts. However, 
when drug administration begins the number of cells decreases rapidly. 
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In Treatment A new doses are administered when high amounts of previously 
administered doses have not yet been eliminated from the body so that drug 
concentration levels reach high levels but with a shorter exposure length than 
with other treatments. With Treatment B patients have longer exposure to 
Drug 2 as its administration starts sooner and the concentration levels of both 
drugs in the blood are more homogeneous. The performances of Treatments 
A and B are rather similar. Minor differences arise depending on the efficacy 
of the drugs, suggesting that the more efficient a drug the better to introduce 
it sooner in treatment. 
Let us imagine that Drug 1 is highly toxic with a high probability of lethal toxi-
city above certain level. Figure 6.5 shows that under Treatment A, Drug 1 con-
centration levels are higher than in Treatments B, C and D due to shorter dos-
ing intervals and, therefore, the probability of toxicity higher. Consequently, 
in this particular setting, the least effective treatment in terms of cell killing 
rate, would originate the highest probability of lethal toxicity. 
Therefore, the model we are considering shows that when setting treatments 
two intuitive factors need to be considered. First, treatment should start as 
soon as possible after diagnosis. And, second, the most effective drugs should 
be administered in early phases of treatment. 
The deterministic models that we have built in this toy experiment constitute 
a good approximation of the evolution of real cell populations in early phases of 
treatment as it will be shown in chapter 7 for the particular case of leukaemic 
cell populations. 
6.2.4 Drug-Resistant Population 
In the model above we have been concerned with the response of subpopu-
lations present in the malignant cell population at the initiation of therapy. 
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It is well known, however , that the drug re pons patt rn is not n 
static. New resistant variants may arise du to mutations and oth r g n tic 
alterations at any time during treatment. Th variants , if proli~ rativ , rna 
in time come to comprise new subpopulations within th volving p pula ion 
and influence therapeutic effectiveness. 
In figure 6.6 a model that accommodates drug r sistant c 11 pr nt d . W 
start with the model presented in chapt r 5 to d s rib th volu tion of 11 
populations consituted by proliferative, r sting and lIs that ar 
out of the cycle, denoted by X p, Xr and Xi r p tiv ly, with th orr pond-
ing migration rates. When treatment starts, th pharma okin i m d I will 
determine the concentration of drugs in the :ffi ct ompartm nt , (t). a 
result of these concentration levels, a fraction kpid( t) of th proli~ r tiv 
that otherwise would split into two daughter cells at rat kpp , will 1 av th 
cell cycle irreversibly, so that the new splitting rate will b kpp - kpid{t). v-
ertheless, a fraction of the original proli£ rativ 11s will om r i tan to 
some or all the drugs involved in treatment. For simpli it , in figur 6.6 it 
is supposed that only one resistant variant ari s during tr atm nt , an hat 
they do it at rate kppl. Therefore, the splitting rat of th pro1i£ rativ 
now kpp - kppl - kpid (t). 
The number of proli£ rative resistant c lIs at tim tid no d b ' pl(t) and 
the corresponding number of resistant cell whi h d id to r t r v r ibl 
Xr/(t). It is assumed that th migration rat within th r i tant ub pu-
lation are the same as in the original ubpopulation b f r tr atm n. Th 
concentration of drugs in the r sponse it , d t rmin d b th pharma ki-
netic characteristics of each of the drugs, i d not (t). 
drug-induced death rate of th resistant lIs diff r inal 
subpopulation. In fact , kpidl(t) < kpid(t) for all t. Wh n 
to all drugs involved in tr atment, kpidl (t) = O. plittin ra f 
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Figure 6.6: Pharmacokinetic-Pharmacodynami - ell-K inetics ~lodr l witil a. 
Drug-Resistant Subpopulation. The populat i n before trcatmrl1 t is cOll sti -
tuted by three types of cells, proliferative cells , X p , rrsti ng . li s, Sr, a.l1<1 c(' lI s 
which are irreversibly out of the cycle Xi, with the 'orrrsp nelin g migration 
rates given by kpr' krp , kpi' kd and splitting rat kp. Whrn tr atm nt starts til<' 
pharmacokinetic characteristics of the d w gs wi II c1eterlll i ne t he CO IlC('1\ t ra t iOIl 
of drug in the effect compartm -nt , Ce(t) , that will have all H'c t on til e' (:r ll 
population by killing proliferative cells that oth rwisr wOllld sp li t. In pi:Htic-
ular, we assume that a fraction kpid(t) of the pr liferative cell s will not divide' 
during mitosis. In add ition, a fraction kppl i a sum d to becoll1e n'sistall L to 
some of the drugs involved in the treatm nt. Thes rrsistant SUbPOPlll Rtio ll 
will follow the same kinetics as the original subpopul atioll with th diffC'rr l1cr 
that only a fraction kpicdt) will b e killed by treatment , where kpidl(t) < kPld(t). 
Kpp-Kpp' -Kpid(t) 
Xp 





Kpp' Kpi : Kpid' (t)--oo.C · .... . . . .. .. . .. . 
\ 
Xp' 
Kpr Krp Kp-Kpid'(t) 
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resistant proliferative cells is given by kp - kpid' (t) which is going to be smaller 
than that of the original population. 
To make the exposition simpler, let us assume that treatment consists of two 
groups of drugs, II = 1, ... , Ll and 12 = 1, ... , L2, such that L = Ll + L2, where 
L is the total number of drugs being administered during treatment. 
At any time, a proliferative cell from the original population whose predecessor 
has been exposed to the action of all L drugs, due either to a mutation or to 
any other genetic alteration, may get resistant to drugs 12 = 1, ... , L2• This cell, 
if proliferative, will consequently become the founder of a new subpopulation 
of cells which follow the same kinetic patterns as the original population but 
with the difference that drugs 12 = 1, ... , L2 will not be able to affect them. 
Within this setting, if the concentration levels of drugs II = 1, ... , Ll are not 
high enough to kill off the new supopulation of resistant cells, treatment will 
eventually fail to extermine the growing population comprising mainly the new 
resistant variant of cells. 
The following set of equations characterise the whole model based on the as-
sumptions above: 
dXp(t) 








- (kpi + kpid(t))Xp(t) + (kpi(t) + kpid' )Xp,(t) - kdXi(t), 
kpp,Xp(t) + (kpp - kpid,(t) - kpr - kpi - kpid' (t))Xp' (t) 
+krpXr,(t), 
kprXp,(t) - kr,Xr,(t), 
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where the pharmacodynamic equations are assumed to be: 
where the notation has already been introduced in the previous section. 
Example 
We are going to continue with the example in the previous section by intro-
ducing the possibility of proliferative cells becoming drug resistant. Treatment 
specifications and migration rates have already been defined in the previous 
section. The only novelty in this case is that proliferative cells which are being 
exposed to Drugs 1 and 2 will become resistant to Drug 1 at rate kpp' = 0.00003. 
Therefore, Drug 1 will not be able to kill these resistant cells, so that the split-
ting rate of the proliferative resistant cells will be higher than in the original 
population. 
As in the previous section, four different treatments under three different sce-
narios will be considered with the difference that some of the cells will become 
drug resistant during treatment. Figure 6.7 is the equivalent to figure 6.5. 
Four different treatments are considered in columns under three different pair 
of values for the 'maximum effect' of Drugs 1 and 2 in columns as specified. 
Straight lines represent the amount of proliferative cells, the difference be-
tween straigh and dotted lines account for the number of resting cells and the 
diference between dotted and dashed lines represent the number of cells that 
have been irreversibly differentiated. Finally, the distances between the top 




Figure 6.7: Evolution of cell subpopulations under four different treatments 
(in rows) and three different pair of values of 'maximum effect' (in columns), 
with a drug resistant subpopulation. The rate constants are fixed at kpp = 0.4, 
kpr = 0.2, krp = 0.1, kpi = 0.2, kd = 0.3 and kpp' = 0.00003. Straight lines 
represent the number of reproductive cells, the difference between dotted and 
straight lines accounts for the number of cells reversibly restings, and the 
difference between dotted and short dashed lines represents the number of 
irreversibly differentiated cells in the population. The distances between the 
top three dashed lines account for the number of resistant proliferative cells 
and the number of resistant resting cells respectively. 
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In this new setting, it is again Treatment D the one that performs the best, as 
initial high concentration levels of Drug 2 manage to avoid the growth of the 
resistant subpopulation. This should not be a surprise as this treatment is the 
one that introduces both drugs right after diagnosis. 
Remember that under Treatment A Drug 2 is not administered until t = 200. 
The resistant population manages to grow rapidly to probably lethal levels 
-. when the efficacy of Drug 1 is not high enough (left and center plots). 
In all four cases, when Drug 2 is introduced in treatment, the resistant popu-
lation will decrease rapidly, but this might already be too late as the resistant 
population might have already reached lethal levels. 
As in the previous section under Treatment C, which does not administer any 
drug until t = 112.5, cell populations can reach a lethal size before treatment 
starts. 
6.3 Population Pharmacodynamic Models 
6.3.1 Introduction 
Recall that in contraposition to pharmacokinetics, the study of what the body 
does to a drug over time, pharmacodynamics is the study of what the drug 
does to the body. Substantial variability in effect in a group of similarly treated 
patients motivates pharmacodynamic investigations. Variability in drug effect 
may be the result of pharmacokinetic and/or pharmacodynamic factors, and 
although theoretically of differing biological mechanisms, these factors may 
not be easily distinguished. 
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6.3.2 Variability in Data 
As occurs with pharmacokinetic data, pharmacodynamic data are usually very 
sparse, both between and within patients, due to different factors. First of 
all, the effect variable that is being monitored is believed to be a function of 
the pharmacokinetic processes. These processes, as discussed in earlier chap-
ters, are highly heterogeneous both between and within patients. Even after 
accounting for most of this variability with an appropriate pharmacokinetic 
model, the pharmacodynamic model will inheritage the remaining variability. 
On the other hand, patients with similar observed drug concentration lev-
els may exhibit substantial differences in the response of their leukaemic cell 
populations to drug exposure. Interpatient variability that persists after ac-
counting for drug exposure indicates that further statistical modelling with 
pharmacodynamic factors needs to be done. 
On top of that, the response originated by a given drug concentration level 
may change over time within patients due to, for instance, prior treatments or 
biological changes in patients' organisms. 
The reasons for studying variability in effect are mainly twofold: biologic rel-
evance and clinical applicability. Identification of the biologic factors that 
cause variability in similarly treated patients has great importance on its own. 
Directly linked to the biological knowledge arc the widespread clinical appli-
cations of pharmacodynamic analyses. When pharmacokinetic and/or phar-
macodynamic variation leads to an appreciable risk of lethal toxicity at what 
is assumed to be a safe dose, a modification in administration is warranted. 
Pharmacodynamic models are being employed to individualise drug doses such 
that a safe and effective dose can be given to an individual patient. Ideally, a 
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pharmacodynamically guided dose will yield improved efficacy while simulta-
neously decreasing the risk of unacceptable toxicity. 
6.3.3 Direct Population Pharmacodynamic Models 
The population approach to deal with sparse data has been introduced in chap-
ter 3 applied to pharmacokinetic data. As discussed in the previous section, 
variability in pharmacodynamic data is closely related to that in pharmaoki-
netic data. Therefore, it seems natural to design a model that embraces both 
data sets at the same time. 
For each patient we have two series of measurements taken over time, one 
of drug concentration levels observed in blood samples and one of the cho-
sen response variable. Records of the treatment history are usually kept as 
well. Further individual information that might be relevant in explaining the 
observed variability is in some cases available. 
Following equivalent arguments to those in Chapter 3 for pharmacokinetic 
models, we are going to build up a model that combines both the pharma-
cokinetic and the pharmacodynamic processes when no relevant covariate in-
formation is available. 
A detailed specification of a Pharmacokinetic-Pharmacodynamic model, and 
a description of alternative methods of estimation of the three stage hierar-
chical model we briefly present in this section, can be found in \Vakefield and 
Racine-Poon (1995). They apply this methodology to a data set of the drug 
Recombinant Hirudin. 
Let Cij be the lh measured concentration for patient i at time tij, and Yij 
the reciprocal of the measured effect variable, i, j = 1, ... , n. Note that ob-

















Figure 6.8: DAG representation for the General Pharmacokinetic-Direct-
Pharmacodynamic Model. Solid and dashed arrows represent probabilistic 
and deterministic relationships respectively. Circles represent unknown ran-
dom quantities whereas fixed or observed quantities are represented by rect-
angles. Stacked 'plates' represent repetitive structures. 
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be missing values at some time points, as pharmacokinetic and pharmacody-
namic data can be collected at different time points. Let Oi and ¢i be the 
individual specific vectors of pharmacokinetic and pharmacodynamic parame-
ters respectively. Denoting by Ci and Yi the concentration and effect data vector 
of individual i and by Te and Ty the corresponding intra-individual precision 
parameters, the likelihood function for the pharmacokinetic and pharmacody-
namic parameters of individual i is then given by: 
l(Oi, ¢i, Te , Ty) - 7r(e;, YilOi, ¢i, Te , Ty) 
- 7r(ciIOi, Yi, ¢i, Te )7r(YiIOi, ¢i, Ty)) 




where 7r denotes a density function and the last equality holds because the 
concentration measures depend only on the pharmacokinetic parameters. 
At the first stage of the hierarchy, individual observations are described as 
follows: 
lne;j = lnh (Oi' tijl Hi) + f Iij, 
InYij = In!2(¢i, Oi, tij) + f2ij, 
(6.15) 
(6.16) 
where hand 12 are the corresponding pharmacokinetic and pharmacodynamic 
models respectively, the treatment history is described by Hi, and fl and f2 
account for zero mean measurement errors. 
Following the population approach, at the second stage, it is assumed that 
both Oi and cPi arise from multivariate distributions with mean vectors, say, JLo 
and JLtP and precision matrices r 0 and r tP respectively. 
Finally, the Bayesian approach requires a third stage where prior distributions 
need to be assigned to the population parameters JLlh JLtP' ro, and r tP' and to 
the intra-individual precision parameters Te and Ty • 
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Figure 6.8 shows the Directed Acyclic Graph (Lauritzen, 1996) which represents 
this model. DAG representation has already been explained in section 3.3. 
Priors have not been included in the graph. 
Within the Bayesian framework, inference about the posterior distributions 
of the unknown parameters of the model is targeted. In this case, defining 
() = (()t, ... , ()n) and 4> = (4)1, ... , 4>n), the posterior distribution is given by: 
n 
7r((), 4>, 7e, 7y, /-lo, /-It/>' r o, r 4» ex IT 7r(Ci!()i, 7e)7r(Yd()i, 4>i, 7y) 
i=l 
n 
X IT 7r(()i!JiO, r u)7r(4)i!/-l4>' r 4»1r(JiO, J-l4>, ro, r 4>, 7e, 7y), 
i=l 
where the notation is the usual. 
In Chapter 3 some MCMC techniques which allow sampling from posterior 
distributions, have been introduced. A Gibbs sampling approach, for instance, 
would require sampling from the following posterior conditional distributions: 
7r( ()i !()j, j =J. i, cP, 7e, 7y, Jio, /-lIP' r 0, rIP' c, y), 
7r(4)i!4>j,j =J. i, (), 7e , 7y, JiO, /-l4>, r O, r 4>, c, V), 
7r(70!(), 4>, 7IP , /-lo, /-l4>' r O, r 4>, c, V), 
7r( 74>!(), 4>, 70, Jio, /-lIP' r 0, r 4>, c, y), 
7r(JiO!(), 4>, 7o, 74>, /-l4>, r 0, r 4>' c, Y), 
7r(/-l4>!(), cP, 70,74>, Jio, r O, r 4>, c, V), 
7r(r ol(), cP, 7o, 74>, Jio, J-l4>' rIP' c, v), 
7r(r IP!()' 4>, 7(J, 74>, Ji(J, J-l4>, r(J, c, v), 
where y = (Yb ... , Yn) and z = (zt, ... , zn). The prior densities and the particular 
forms given to the pharmacokinetic and the pharmacodynamic functions will 
determine the most convenient sampling technique to be used for each of the 
posterior distributions of the model parameters. 
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6.3.4 Indirect Population Pharmacodynamic Models 
In the previous section the population pharmacokinetic/pharmacodynamic 
methodology has been described when the pharmacological response, y, was 
directed linked to the concentration levels. In this section, a similar hierarchi-
cal model will be presented for the case when the response is indirect, that is 
to say that the response is a result of several processes, only one of which is 
al tered by drugs. 
The exposition will be very brief as the methodology will be similar to the one 
explained in the previous section. The effect variable we will concentrate on 
will be the effect of drugs on a population of malignant cells. The population-
approach will be adopted so that variability of pharmacokinetic, pharmacody-
namic and cell population processes will be aknowledged and correspondingly 
treated. 
Let Cij and Zij be the measured concentration and the number of malignant 
cells respectively for patient i at time tij, where i, j = 1, ... , n. Let 11 be 
the pharmacokinetic equations, with parameters (}i. The unobservable direct 
effect of drugs for patient i at time tij will be denoted by Yij. In the case 
that concerns us, this direct effect would be the function kpid;j introduced in 
previous sections and, for example, based on equation (6.5), it could be given 
by: 
d· 
InYij = lnkpid;j = h; + €2;j = In(kir) + €2;j MAX; (6.17) 
where we allow for zero mean measurement error with precision parameter 
Tyand h is the pharmacodynamic model with parameters ¢>i = (ki' CMAX/). Fi-
nally, let h be the function that describes the cell population, with parameters 
6i which includes the effect variable Yi = kpid;. 
Consequently, the first stage of the hierarchical model, where individual ob-
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servations are described, is given by: 
InCjj = In!t(()i,tij,Hi) + fIji' 
lnzij = lnh(c5jI 4>j, ()j, 'Ty) + f3ij' 
(6.18) 
(6.19) 
where the multiplicative zero mean error f3ij has precision parameter 'Tz • 
At the second stage of the model, it is assumed that the individual parameters 
parameters ()i, 4>i and c5i are samples from the corresponding population pa-
rameters 0, 4> and c5 with mean vectors Po, Pcp and P6, and precision matrices 
r 0, r cp and Cs. 
The model is completed with the third stage of the hierarchy, where prior 
distributions must be assigned to the population parameters Po, Pcp, P6, ro, r cp 
and ra and to the interindividual precision parameters 'Te , 'Ty and 'Tz • 
The corresponding Directed Acyclic Graph (Lauritzen, 1996) of this three stage 
hierarchical model is shown in Figure 6.9. Recall section 3.3 where DAG 
representation has been introduced. Priors have not been included. 
The joint posterior distribution of the parameters of the model from where 
samples should be taken, using the most appropriate MCMC techniques, is 
given by: 
n 
7r((), 4>, c5, 'Te, 'Ty, 'Tz , Po, PcpP6, r o, r cp, r6) ex: II 7r(CiI()i, 'Te)7r(zil c5i, 4>i, ()i, 'Ty , 'Tz) 
i=1 
n 
X II 7r(()jlpo, r O)7r(¢>ilpcp, r cp][c5i lp6, r6) 
i=1 
X 7r(Po, Pcp, P6, ro, r cp, r6, 'Te, 'Ty , 'T,}, 
where () = (()ll ... , ()n), 4> = (4)1, ... , 4>n) and c5 = (c5I , ... , c5n ). The prior densities 
and the particular forms given to the pharmacokinetic, pharmacodynamic and 
cell kinetic functions will determine the most convenient sampling technique 
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Figure 6.9: DAG representation for the General Pharmacokinetic-Indirect-
Pharmacodynamic Model. Solid and dashed arrows represent probabilistic and 
deterministic relationships respectively. Circles represent unknown random 
quantities whereas fixed or observed quantities are represented by rectangles. 




The main pharmacokinetic processes and models have been described in section 
6.2. A differentiation between direct and indirect models has been done in the 
exposition. Our main interest is to analyse the effect that drugs originate in 
cell populations and, therefore, considerable time has been spent on indirect 
models. The relationship between drug concentration levels and the death rate 
of cells plays a vital role in determining the efficacy of a particular treatment. 
Following the approach taken in chapter 3 to model pharmacokinetic processes, 
a compartmental model has been designed to describe cell populations as a 
compound of subpopulations with different roles within the cell cycle. The mi-
gration rates within and between these compartment have been linked to drug 
concentration levels in the corresponding effect compartments. Therefore, a 
threefold model has been built. First, a pharmacokinetic model defining the 
amount of drug that reaches different parts of the body, including the corre-
sponding effect compartment. Besides, a cell kinetic model describing the evo-
lution of cell populations has been constructed. Thirdly, a pharmacodynamic 
model has allowed to link drug concentration levels in the effect compartment 
with the cell kinetic model. 
Therefore, a new compartmental Pharmacokinetic-Pharmacodynamic-Cell-Kinetic 
Model has been constructed. This new approach that we advocate allows to 
link the evolution of cell populations to particular treatments. \Ve believe 
that this global view that we have taken can help when designing rational and 
efficient individual and disease intensity specific treatments. 
A fully Bayesian general population three-stage hierarchical model has been 




A Case Study: Leukaemia 
Treatment 
7 .1 Introduction 
In what follows we will study the evolution of a population of leukaemic cells 
in the circulatory system. Figure 7.1 illustrates a plausible evolution of a 
leukaemic cell population before and during treatment. 
When leukaemia is first diagnosed, the number of malignant cells in the blood 
ascends to around 50 x 109 cells per blood liter. Immeditely after diagnosis 
treatment is initiated. Leukaemia treatment consists of a cocktail of different 
drugs. Each drug attacks the malignant cells in a particular way. An effective 
and efficient treatment requires first of all a good understanding of the indi-
vidual pharmacokinetics of each of the drugs and of the possible intereactions 
between them. 
Once the pharmacokinetic profile of each drug is predicted, the effect of these 
concentration levels on the leukaemic population should be anticipated in order 
to administer optimal doses within admissible ranges of toxicity. The current 
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Figure 7.1: Population of Leukaemic Cells. The disease is diagnosed at time 
t = D, when the population has 50*109 cells per blood liter. Due to treatment, 
remission will be attained at time t = R. Below 0.1 * 109 cells per blood 
liter, leukaemic cells are unobservable. After remission, a treatment resistant 
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stage of knowledge is far from being able to set up treatments considering 
rigorously all these factors. 
Virtually all patients enter remission within a month. By remission is meant 
that leukaemic cells are not detectable in blood samples by means of standard 
techniques. This happens when the number of cells per liter is under 109• 
After remission, treatment goes on until, hopefully, no leukaemic cells arc left 
in the organism. The main difficulty lies in the fact that effectiveness is not 
observable and, consequently, a new population of leukaemic cells, ressistant 
to that particular treatment, could start forming at any time with no possible 




The data set we are concerned with is of the form shown in figure 7.2. This 
data set was provided by Dr. Stephen Lowis from the Bristol Royal Hospital 
for Sick Children. For each of the 15 patients in the study, individual treatment 
details and the number of leukaemic cells in the blood are collected at certain 
time points. The first column in figure 7.2 gives the date. The second column 
accounts the number of leukaemic cells per blood liter, in 109 units. The 
remaining columns describe the administered doses of each of the five drugs 
that constitute treatment. Individual doses are calculated according to the 
body mass of the patient, which is not recorded. Dose times and frequency 
will vary between patients. 
In this data set there are three main interrelated processes that should in prin-
ciple be modelled in order to be able to estimate and predict the fate of the pop-
ulation of leukaemic cells given the treatment. It constitutes what in the previ-
ous chapter has been called as a pharmacokinetic-indirect-pharmacodynamic 
model. 
First of all the concentration of each of the drugs within the body must be 
studied. This requires a pharmacokinetic analysis for each of the substances. 
As treatment consists of a cocktail of five different drugs, the pharmacokinetic 
analysis should account for possible interactions between drugs. 
As discussed in previous chapters, given that the pharmacokinetic profiles 
generally vary between and within individuals, a population pharmacokinetic 
model could be designed in order to estimate the amount of drug that actually 
reaches the circulatory system over time for each of the patients. Note that as 
leukaemic cells are located in the circulatory system, the site of response will 
be proportional to the concentration in the central compartment. 
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Figure 7.2: Typical available data set for each of the 15 patients in the study: 
date, number of leukaemic cells per blood liter, in 10 units, and the doses of 
each of the five drugs. 
Date Cells Asp VCR Pred Dauno MTX 
24-04 6.8 2.5 30 12.5 
25-04 3.9 30 
26-04 3.8 4082 30 
27-04 30 
28-04 2.1 4082 30 
29-04 1.8 30 







The first difficulty that arises from the data set is that drug concentrations have 
not been reported. Therefore, with no observations of blood concentrations 
for the drugs, assumptions regarding the pharmacokinetic parameters need to 
be done. 
Once the evolution of the concentration of different substances within the circu-
latory system is available, the effect that these substances originate in different 
organ and tissues need to be analysed. The effect variable we are interested in 
is the death rate of leukaemic cells. Therefore, a pharmacodynamic model that 
links the concentration of the drug cocktail with the evolution of the death rate 
will be required. 
In order to establish a relationship between drugs and cell death, we need to 
understand how the cell population behaved before treatment started. There-
fore, leukaemic cell kinetics need to be studied. 
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7.3 The Structural Model 
7.3.1 The Pharmacokinetic Model 
It has already been mentioned that drug concentrations have not been reported 
in the data set. Therefore, a pharmacokinetic analysis of the substances cannot 
be performed. 
This lack of vital information will be overcome by means of assuming a one-
compartment pharmacokinetic behaviour for the concentration at the site of 
effect and arbitrarily fixing the values of the corresponding parameters. 
However, the aim of this study is not to carry out a pharmacokinetic analysis 
of the substances that constitute the treatment, but to try to associate quali-
tatively the rate of death of leukaemic cells with particular treatment schemes. 
Any quantitative link will rely upon the assumed concentration levels which 
will most probably differ substantially from the real concentraion levels. 
The chosen pharmacokinetic model for all the drugs is a one-compartment 
model (see section 2.4.2) and we assume that the concentration levels for each 
of the drugs (Asp, VCR, Pred, Dauno and MTX) are given by: 
e~sp 
'3 -













where e is the drug concentration found in the blood, d is the administered 
dose, t is the time point, subscript i = 1, ... 15 identifies the patient, j = 1, ... , 14 
the observation number and the superscript refers to the corresponding drug 
name. 
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Figure 7.3: Assumed drug concentration levels for patients 1-8 following a 
single intravenous administration of each of the administered drugs. 
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Figure 7.4: Assumed drug concentration levels for patients 9-15 following a 
single intravenous administration of each of the administered drugs. 
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There are only observations for seven time points in the data set, one per day. 
vVe have decided to add a second daily observation time in order to accommo-
date possible discrepancies in blood sample and dosing times. Therefore, we 
assume that blood samples to count the number of malignant cells are taken 
in the morning and that the administered drugs reach the circulatory system 
in the afternoon, due to either later dosing times or possible time delays in the 
pharmacokinetic processes. 
The concentration levels derived from these particular exponential equations 
are presented in figures 7.3 and 7.4. The concentration profiles differ substan-
tially between patients due to dosing differences. Patients 6 and 8 are exposed 
to particularly low concentrations. 
7.3.2 The Cell Kinetic Model 
As it has been explained in chapter 5, cells live for certain random times and 
after dying are replaced either by two newborn daughter cells or by none. 
Different cell kinetic models were presented there. 
The theory of Branching Processes presented in Section 5.6 presents the ad-
vantage that, involving a relatively moderate number of parameters, it accom-
modates general life length distributions. However, it should be kept in mind 
that all results presented there were asymptotic results. In addition, the repro-
duction mean was supposed to be constant over time, whereas our goal in this 
section is to establish a relationship between the reproduction mean and the 
concentration of drug. Changes in concentration should imply changes in the 
reproduction mean, and consequently in the evolution of the cell population. 
Let us denote the jth observed number of cells for patient i by Zij, and the time 
at which the corresponding sample was collected by tij. vVe set til = 0 and 
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take half-day as time unit 1. The model we propose to explain the evolution 
of the leukaemic cell population before treatment starts is the following: 
(7.2) 
for all i = 1,2, ... , 15 and j = 1,2, ... , 14 and where the intercept J(i and the 
slope ai are parameters to be determined. 
It is believed that the observed number of malignant cells are subject to some 
sort of measurement error. Since assay techniques are frequently observed to 
produce measurements whose precision decreases with increasing number of 
cells, we take logarithms in equation (7.2) and add a zero mean error: 
(7.3) 
Note that as we have set til = 0, Zil = J(i + fil for all i = 1, ... , 14. 
7.3.3 The Pharmacodynamic Model 
In order to relate drug doses with the cell population, equation (7.3) should 
depend on drug concentration levels. 
\Ve believe that both parameters K and a should vary according to concentra-
tion levels. Nevertheless, given that at time t = 0 treatment has not started 
yet and that the available number of observations is limitated, our first at-
tempt will be to keep the intercept constant during treatment. Consequently, 
we will model the slope parameter a as a function of drug concentration levels. 
As these change during treatment, so will do a. 
Let us assume that 
(iij = Q(i(A - L C!j) , (7.4) 
I 
1 Note that for even j blood samples were not collected, so that the number of malignant 
cells is not available. 
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where 1 = Asp, VCR, Pred, Dauno, MTX, and A is the quantity that will 
determine the sign of the slope a. In order to incorporate some degree of 
flexibility to the model, we add a zero mean error in equation (7.4) so that, 
aij = Qi(A - L CIj ) + Vij' 
I 
7.4 The Probability Model 
(7.5) 
In figure 7.5 the population cell-kinetic-pharmacodynamic model we are going 
to construct is represented as a Directed Acyclic Graph (Lauritzen, 1996). DAG 
representation has been explained in section 3.3. As it will be shown, a three-
stage hierarchical model captures all the structural relationships within the 
model. 
The first stage of the hierarchical model is constituted by: 
where the notation has already been introduced. 
(7.6) 
(7.7) 
The form of the probability distribution of each Zij given J(i, aij and Tz , the 
inverse of the residual error, fij, variance, needs to be specified. We assume 
that the residual errors iij are normally distributed independent errors, so 
that: 
(7.8) 
where as in chapter 4, we follow the notation of Gelfand and Smith (1990) for 
defining probability densities, Le., joint, conditional and marginal densities of 
the random variables x and yare denoted by [x, V], [xIY] and [x],[y] respec-
tively. A normal distribution with mean a and precision parameter b is as 
usual denoted by N (a, b). 
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Figure 7.5: DAG representation for the Cyclosporin Model. Due to the lack of 
relevant covariate information about the patients, the structure of the model 
is more simple than in the general model. Solid and dashed arrows represent 
probabilistic and deterministic relationships respectively. Circles represent un-
known random quantities whereas fixed or observed quantities are represented 
by rectangles. Stack 'plates' represent repetitive structures. 
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Equivalently, assuming that the errors Vij follow a normal distribution with 
zero mean and precision parameter To, the distribution of each of the slopes 
can be written as: 
[aijlc~i' A, e:j, To] = N(oi(A - L e:j ), Til). (7.9) 
I 
From the conditional independence assumption, denoting by z the totality of 
the observed data, by K = (Kb ... , K 15 ), by a all possible slopes and by 0 
= (01, ... , (15), it follows that, 
[zIK, a, Ty] = n:!l n~~l N(Ki + iiijtij, Tz ), 
[alo, A, To] = n:!l n~~l N(aj(A - 2:, elj ), To). 
At the second stage of the probabilistic hierarchical model, assumptions regard-
ing the distribution of the parameters K = (Kb ... , K 15 ) and 0 = (Ob ... , (15) 
are specified. We assume, following the population approach, that OJ and Ki 
are qualitatively the same for all individuals but quantitatively allowed to vary 
according to the following distributions: 
[oilop, To] = N(ap,T;l), 
[KiIKp,TK] = N(Kp,T;/), 
for i = 1, ... , 15, where op and Kp are the corresponding population means, 
and To and TK the population precision parameters. 
To complete the specification of the model, in the third stage of the hierarchy 
prior densities must be assigned to the parameters without parents: 
[Tz] = Ga(JLb VI) [Kp] = N(JL2, V2) [TK] = Ga(JL3, V3) [Op] = N(JL4, V4) 
[To] = Ga(JL5, V5) [A] = N(JL6, V6) [To] = Ga(JL7, V7) 
where the notation is the conventional used in prior chapters. 
Lastly, as discussed in chapters 3 and 4, we need to assign values to the hy-
perparameters of the model, i.e. JLrl Vn r = 1, ... , 7. As we do not have any 
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prior information available in our study we introduce very vague prior distri-
butions. The distributions we choose are N(O, 0.0001) and Ga(O.OO1, 0.001). 
These distributions are proper but very uninformative. 
7.5 Estimation 
In the former section distributional assumptions of the three-stage hierarchical 
model have been done. Applying Bayes' theorem, the joint posterior distri-
bution will be proportional to the product of the likelihood function and the 
prior densities. 
We have made use of the software WINBUGS (94) to obtain samples from 
the estimated posterior distributions of the model parameters conditional on 
the data. To sample from the posterior distributions of the precision parame-
ters the Metropolis-Hastings (Metropolis et al. 1953, Metropolis and Hastings, 
1970) algorithm is employed, whereas to get samples from the remainder pa-
rameters' posterior distributions the Gibbs sampler (Geman and Geman, 1984) 
is used. 
In WINBUGS initial values for all the chains are specified. Several different 
runs starting with different sets of initial values have been performed with 
virtually identical results. After several attempts, the first 10.000 iterations 
of the chains were discarded as 'burn-in', in order to, hopefully, guarantee 
that the stationary distribution is reached. The chains have then been run for 
additional 20.000 iterations. The computation took around 5 minutes. 
In tables 7.1 and 7.2, the estimated posterior marginal distributions of the 
population and individual slopes and intercepts are summarised. The first two 
columns give the expected value and the standard deviations of the posterior 
distributions. The Me errors in the fourth column, is the standard error of the 
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Table 7.1: Summary: Marginal Posterior Distributions for Population, Qp, and 
Individual Slopes, Qi, i = 1, ... , 15. 
I Parameter I Mean I sd I Me error I 2.5% I median I 97.5% 
I Q p I 0.08069 I 0.04552 I 0.0007694 I -0.006851 I 0.07976 I 0.1747 
QI 0.1427 0.05236 0.001192 0.0492 0.1399 0.2535 
Q2 0.0731 0.04621 0.0009793 -0.01225 0.07049 0.172 
Q3 0.04069 0.03174 0.000554 -0.01869 0.03976 0.1056 
Q4 0.05787 0.02524 0.0006497 0.0007127 0.04687 0.1007 
Q5 0.02095 0.04098 0.001731 -0.05967 0.02115 0.1013 
Q6 0.2176 0.1204 0.002723 0.03444 0.1997 0.4979 
Q7 0.09555 0.02632 0.0006203 0.04619 0.09488 0.1502 
Qs -0.02315 0.08432 0.001968 -0.1943 -0.0203 0.1332 
Qg 0.1441 0.05177 0.001169 0.04859 0.1414 0.2524 
QIO 0.03538 0.03063 0.000595 -0.02368 0.03446 0.09787 
Qu 0.1831 0.0576 0.001018 0.07971 0.1799 0.3064 
Ql2 0.04689 0.02562 0.0004419 -0.002793 0.04644 0.09862 
Ql3 0.05883 0.07494 0.001593 -0.07761 0.05351 0.2215 
Ql4 0.109 0.09183 0.005002 -0.06178 0.1042 0.3017 
Ql5 0.02 0.03053 0.0006257 -0.03829 0.01924 0.08264 
estimate of the expected value in the second column; it is estimated by con-
sidering both the sample size and the degree of autocorrelation in the sample. 
The last three columns give the quantile and the median of the corresponding 
distri bu tions. 
The values of the standard deviations and the quantiles of the posterior dis-
tributions in tables 7.1 and 7.2 suggest that these distributions are reasonably 
symmetric and concentrated around their mean values, as expected. Con-
sequently, and taking in account the small Me errors in all cases, we can 
conclude that the expected values of the posterior distributions constitute safe 
point estimators of the corresponding real values. 
In figure 7.8 we have included the estimated posterior distribution for the 
population intercept, Kp. As it can be seen, the behaviour of this function is 
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Table 7.2: Summary: Marginal Posterior Distributions for Population, Kp, 
and Individual Intercepts, Ki, i = 1, ... , 15. 
I Parameter 1 Mean 1 sd 1 Me error 1 2.5% 1 median 1 97.5% I 
I Kp 1 2.438 1 0.4454 I 0.005464 11.545 I 2.442 1 3.312 I 
Kl 2.771 0.2653 0.006477 2.221 2.78 3.273 
K2 4.993 0.2657 0.005365 4.468 4.989 5.537 
K3 1.37 0.2715 0.006133 0.8412 1.365 1.921 
K4 2.728 0.2822 0.007591 2.208 2.713 3.332 
Ks 1.747 0.6477 0.02867 0.4836 1.758 3.023 
K6 5.552 0.2373 0.005858 5.092 5.551 6.03 
K7 3.329 0.2728 0.006354 2.756 3.336 3.854 
Kg 2.149 0.2675 0.005967 1.614 2.115 2.668 
Kg 3.33 0.2779 0.00625 2.753 3.338 3.856 
KIO 1.116 0.2504 0.005757 0.6214 1.115 1.619 
Kn 3.699 0.306 0.009471 3.032 3.723 4.232 
K12 1.237 0.254 0.005058 0.7311 1.238 1.737 
K13 0.9829 0.2537 0.006055 0.4818 0.9824 1.488 
K14 0.8792 0.817 0.04519 -0.7423 0.8691 2.462 
K1S 0.7148 0.2788 0.005783 0.1805 0.7041 1.293 
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Figure 7.6: Patients 1 - 8. Dots represent observed data in log scale and solid 
lines estimated curves for patients 9 - 15. 
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very good. The kernel density estimation has been carried out using the S-Plus 
'density' function that leads to a smooth estimate that could hide local features 
of the density. The same analysis has been performed for all the parameters 
of the model, leading to satisfactory results in all cases. 
The expected values of the posterior distributions will be used as point estima-
tors of the real unknown values. Substituing these point estimators in equation 
(7.6) together with the corresponding assumed drug concentration levels, in-
dividual predicted curves are obtained. In figures 7.6 and 7.7, observed points 
are represented by dots and individual predicted curves by solid lines. 
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Figure 7.7: Patients 9 -15. Dots represent observed data in log scale and solid 
lines estimated curves for patients 9 - 15. 
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In general terms, the predicted individual curves in figures 7.6 and 7.7 are very 
encouraging. The model seem to be adequate to predict the evolution of the 
number of leukaemic cells in the organism of the patients. Keep in mind that 
the pharmacokinetic part of the model has been kept fixed as no data about 
drug concentration levels have been reported. Nevertheless, the model we have 
constructed, has proved to be able to capture the remaining variability in the 
model. In consequence, it seems that when the pharmacokinetic processes of 
all drugs involved in a particular treatment are well understood and correctly 
modelled, the model and the methodology proposed in this chapter will capture 
the the main processes involved in determining the evolution of leukaemic cell 
populations. 
However, as we have seen in chapters 3 and 4, the pharmacokinetic processes 
are extremely variable both within and between individuals, and great diffi-
coulties arise when trying to model them. In addition, when several different 
drugs are being administered simultaneously, complicated drug interactions 
might occur. We, therefore, believe that research in the pharmacokinetics of 
drug 'cocktails' plays a vital role in the study of leukaemia. 
7.6 Convergence Analysis 
As discussed in chapter 3, all the analysis presented in section 7.5 requires 
that the Gibbs sampler and the Metropolis-Hastings algorithm have effectively 
converged to their unique stationary or invariant distributions. Convergence 
diagnostics are fundamental in order to establish that the sample obtained by 
running each algorithm constitutes a sample from the corresponding posterior 
distribution. 
As briefly discussed in chapter 3, much research is being made for diagnosing 




Figure 7.8: Trace and Posterior Distribution obtained for the population in-
tercept, Kp. The first plot shows the evolution of the chain in the 20.000 
iterations after the burn-in period. The inferior figure is the corresponding 
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method of assessing convergence is universally accepted as being superior in 
different scenarios. In this work, only a graphical inspection of the chains 
has been performed. As these seem to mix rapidly over the sample space of 
the posterior distributions, we have not performed any further study. As an 
illustration, the trace obtained for the population intercept, Kp , is shown in 
figure 7.8. 
7.7 Conel us ions 
In this last chapter, the tools introduced in previous chapters have been applied 
to real data. Three interrelated complicated biological processes have been 
encompassed in a global model: pharmacokinetics, pharmacodynamics and 
cell kinetics. Due to the lack of pharmacokinetic data, an analysis of the 
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pharmacokinetic processes of the different drugs that constitute treatment has 
not been possible. 
The Bayesian population approach has proved to be remarkably appropriate in 
order to capture the variability that usually cell kinetic and pharmacodynamic 
data show. Nevertheless, when the pharmacokinetic parameters of the drugs 
involved in treatment need to be estimated, the variability and the number of 
parameters of the model would increase dramatically. 
Future work should be oriented to analysing identifiability of model parameters 
when all the three processes are being modelled simultaneously. Complicated 
pharmacokinetic models are usually needed when different drugs are being 
administered simultaneously. Poor pharmacokinetic estimations would lead to 
poor pharmacodynamic and cell kinetic estimations, and therefore, the results 




A better understanding of the treatment-effect-time relationship can lead to 
more efficient treatments based on individual characteristics and disease in-
tensity profiles. Innumerable interrelated biologically complex processes are 
involved in determining the ultimate effect that drugs initiate in the organism 
of patients.These can be grouped under the headings ofPharmacokinetic and 
Pharmacodynamic processes. 
In chapter 2 the main pharmacokinetic processes have been introduced and 
appropriate compartmental models constructed. The essential aim of these 
models is to explain and predict the evolution of drugs within the body by 
modelling the relationship between drug doses and drug concentration levels 
in the blood and other sites of interest. The compartmental approach concep-
tualises the body as a compound of different compartments and it analyses the 
kinetics between and within them. 
Pharmacokinetic data (i.e., drug concentration levels found in the blood at 
different time points) usually present considerable variability both within and 
between individuals. Due to its attempt to explain and control this variability, 
the population approach has gained prevalence over the individual pharma-
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cokinetic approach during the last two decades. In this work, the population 
pharmacokinetic/pharmacodynamic approach has been taken. 
The population approach has been studied in chapter 3 within the Bayesian 
framework that, primarily due to recent enormous advances in 'Markov chain 
Monte Carlo' techniques, offers flexible and simple methods to build and es-
timate population pharmacokinetic models. By exploiting the hierarchical 
structure of the models of interest we have easily built a general population 
pharmacokinetic model that accommodates most of the models proposed in 
the literature for different drugs. 
The strength of the population approach has been assessed in chapter 4. A 
population pharmacokinetic analyses has been performed in order to advance 
the study of the pharmacokinetics of 'cyclosporin', a drug in routine use in 
organ transplantation processes. A two-compartment model has been assumed 
to explain the evolution of cyclosporin blood concentration levels following 
certain dosing histories. A fully Bayesian population model has been specified 
and all model parameters estimated. The results support the adequacy of the 
population approach to handle sparse pharmacokinetic data. 
The ultimate aim of this work is to describe an approach to constructing a 
model that both quantitatively and qualitatively relates drug administration to 
consequent changes in complicated biological processes. We have concentrated 
our attention to the evolution of leukaemic cell populations. In order to identify 
the drug-specific effect in such populations, the kinetics of leukaemic cells 
before treatment starts need to be understood. In chapter 5 a qualitative 
description of the evolution of leukaemic cell populations has been followed by 
several models that capture the main processes that govern cell proliferation. 
Relying on different assumptions, two approaches have been taken in order 
to design stochastic models for cell proliferation. The Multi-Type Birth and 
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Death process in section 5.3.3 presents the advantage of being able to identify 
and follow the evolution of different cell subpopulations according to their role 
in the cell cycle. The underlying key assumption is that the life lengths of 
the cells are exponentially distributed so that transitions from phase to phase 
occur at random. 
The Multiple-Phase Birth and Death Process built in section 5.4 constitutes 
an alternative to exponentially distributed cell life lengths without renouncing 
the tractable continuous time Markov process theory. The main disadvantage 
of this model is that it does not allow general life length distributions either 
and that it cannot distinguish the evolution of subpopulations with different 
kinetic behaviours. 
As an attempt to overcome the limitation of constrained cell life length's dis-
tributions, a Branching process admitting general life length distributions has 
been constructed in section 5.5. A limit result has been shown for the expected 
number of cells in the population and an interesting and simple approxima-
tion obtained. This will allow the prediction of the expected evolution of a cell 
population with knowledge only about the mean and variance of individual 
cell's life length distributions. Future work would include a deeper evaluation 
of this result. 
After analysing the biological process that will be modified by the treat-
ment, we have gone to model the effect originated by drugs as a function of 
drug levels found in the body. A fully Bayesian Population Pharmacokinetic-
Pharmacodynamic model has been built in chapter 6. Several simulation stud-
ies have been performed in order to illustrate the potential of these models. 
The crucial phenomenon of drug ressistance has been acknowledged and intro-
duced in the model. 
In this work three connected processes have been modelled (i. e. pharma-
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cokinetics, cell kinetics and pharmacodynamics) and relationships between 
them considered so that a global model linking treatment and the evolution of 
leukaemic cell populations has been proposed. The population approach has 
been advocated as a powerful framework to handle real data variability. 
In the last chapter of this work a real data set has been presented. Data 
about treatment history and the number of leukaemic cells in the organism at 
different time points of a group of patients has been analysed. The absence 
of data about blood drug concentration levels has forced us to arbitrarily set 
individual pharmacokinetic parameters and, therefore, to consider a simplified 
form of the model constructed in chapter 6. Consequently, the results obtained 
cannot be used for prediction purposes as they rely on the assumed blood drug 
concentration levels. 
Nevertheless, the model has proved to be able to capture the underlying main 
pharmacodynamic and cell kinetic processes and to generate good estimators 
of the parameters. In a realistic setting, where no perfect knowledge of the 
pharmacokinetics of each of the drugs is available, parameter identifiability 
would become a complicated task. Drug interactions have shown in the litera-
ture to be complicated to model. Great difficulties arise when trying to model 
simultaneously the pharmacokinetics of different drugs. The first step would 
be to get a better understanding of individual pharmacokinetic characteristics 
of each of the drugs that constitute treatment for different patients. Then, the 
interaction of the drugs should be studied and an adequate model constructed. 
Possible identifiability problems should then be overcome. 
All this prior information would facilitate the specification and estimation of 
the general model. The better the understanding of each of the three processes 
that are considered in the general model (i.e., pharmacokinetics, pharmaco-
dynamics and cell kinetics), the better the estimation of the whole model. 
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,\Ve leave for future work the analysis of a data set containing treatment 
regimes, blood drug concentration levels and the number of leukaemic cells in 
the organism. The ambitious aim will be to get population and individual pa-
rameter estimates so that there is better knowledge when designing both new 
treatments for new patients and adjusted treatments for patients for whom 
estimates have already been obtained. 
The complexity of the task is obvious, but any tiny improvement in the ratio-















Appendix A: Individual Pharmacokinetic Parameters' Posterior Distributions 
Table A.l: Summary: Marginal Posterior Distributions for Individual Phar-
macokinetic Parameters. 
I Indiv Iln(Param) I Mean I sd I Me error I 2.5% I median I 97.5% 
Patient 1 /11 = CL -2.016 0.06841 0.002177 -2.147 -2.014 -1.895 
/12 = Q -1.12 0.2302 0.00451 -1.542 -1.128 -0.6311 
/13 = Vi 3.261 0.2731 0.00737 2.691 3.269 3.77 
/14 = V2 4.822 0.4782 0.01651 4.061 4.758 5.872 
Patient 2 /11 = CL -1.395 0.1225 0.006332 -1.719 -1.375 -1.23 
/12 = Q -0.7618 0.2138 0.004444 -1.175 -0.7631 -0.3375 
/13 = Vi 3.786 0.2699 0.007114 3.249 3.783 4.313 
/14 = V2 5.794 0.6109 0.03059 4.787 5.726 7.1037 
Patient 3 /11 = CL -0.852 0.2631 0.01915 -1.674 -0.7599 -0.6132 
/12 = Q 0.02406 0.6263 0.02811 -1.042 -0.02739 1.803 
/13 = Vi 5.422 0.2186 0.005613 4.982 5.432 5.82 
/14 = V2 6.563 1.026 0.06449 4.361 6.659 8.285 
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Table A.2: Summary: Marginal Posterior Distributions for Individual Phar-
macokinetic Parameters. 
I Indiv Iln(Param) I Mean I sd I Me error I 2.5% I median I 97.5% 
Patient 4 III = CL -1.543 0.06916 0.002078 -1.672 -1.539 -1.425 
112 = Q -0.5803 0.2675 0.006 -1.063 -0.5919 -0.001044 
III = VI 3.735 0.3365 0.00915 3.011 3.756 4.328 
114 = V2 5.118 0.5179 0.01946 4.34 5.029 6.354 
Patient 5 III = CL -1.91 0.08005 0.003757 -2.076 -1.904 -1.785 
112 = Q -1.734 0.2376 0.005676 -2.156 -1.742 -1.227 
III = VI 2.829 0.1959 0.005447 2.41 2.837 3.181 
J1.4 = V2 4.465 0.672 0.03025 3.506 4.333 6.089 
Patient 6 J1.l = CL -1.756 0.06678 0.001906 -1.882 -1.754 -1.637 
J1.2 = Q -0.6592 0.3022 0.008132 -1.195 -0.6816 -0.008874 
J1.l = VI 3.457 0.4047 0.01313 2.577 3.484 4.17 
J1.4 = V2 4.789 0.4751 0.01535 4.098 4.707 5.949 
Patient 7 III = CL -1.836 0.07362 0.002604 -1.995 -1.831 -1.714 
112 = Q -0.7082 0.2933 0.007405 -1.215 -0.7274 -0.06224 
J1.l = VI 3.568 0.329 0.00975 2.873 3.597 4.154 
J1.4 = V2 4.974 0.5306 0.01986 4.15 4.886 6.219 
Patient 8 III = CL -2.677 0.06043 0.00192 -2.808 -2.673 -2.573 
J1.2 = Q -1.972 0.245 0.005005 -2.428 -1.974 -1.459 
J1.l = VI 2.551 0.2194 0.005212 2.105 2.558 2.957 
J1.4 = V2 4.1 0.5261 0.01775 3.207 4.068 5.19 
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Table A.3: Summary: Marginal Posterior Distributions for Individual Phar-
macokinetic Parameters. 
Indiv Iln(Param) I Mean I sd I Me error I 2.5% I median I 97.5% 
Patient 9 /-LI = CL -1.195 0.08571 0.00385 -1.391 -1.189 -1.048 
/-L2 = Q -1.014 0.2319 0.005828 -1.47 -1.015 -0.5414 
/-L3 = VI 3.546 0.3559 0.0151 2.763 3.58 4.148 
J-l4 = Vi 5.189 0.7328 0.037 4.147 5.038 6.919 
Patient 10 /-LI = CL -1.788 0.06557 0.001649 -1.927 -1.785 -1.668 
/-L2 = Q -0.8363 0.2805 0.006445 -1.347 -0.8488 -0.234 
J-l3 = VI 3.503 0.3221 0.008822 2.791 3.53 4.068 
/-L4 = V2 4.977 0.4889 0.01616 4.173 4.921 6.082 
Patient 11 J-li = CL -2.032 0.07042 0.002452 -2.177 -2.027 -1.915 
J-l2 = Q -0.7425 0.4222 0.01302 -1.451 0.784 0.2196 
/-L3 = VI 3.613 0.3577 0.01183 2.807 3.647 4.223 
J-l4 = Vi 4.752 0.5482 0.02086 3.829 4.692 5.951 
Patient 12 J-li = CL -1.944 0.1035 0.004719 -2.187 -1.934 -1.77 
/-L2 = Q -2.57 0.239 0.008542 -3.047 -2.566 -2.105 
/-L3 = VI 2.387 0.204 0.008329 1.942 2.401 2.765 
J-l4 = V2 4.565 0.9825 0.05167 2.702 4.586 6.353 
Patient 13 J-li = CL -2.09 0.05698 0.001447 -2.206 -2.088 -1.98 
/-L2 = Q -0.287 0.7623 0.03913 -1.879 -0.2751 1.184 
J-l3 = VI 2.867 0.4223 0.02366 1.822 2.937 3.496 
J-l4 = V2 2.724 0.5099 0.02712 1.627 2.777 3.392 
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Table A.4: Summary: Marginal Posterior Distributions for Individual Phar-
macokinetic Parameters. 
Indiv Iln(Param) I Mean I sd I Me error I 2.5% I median I 97.5% 
Patient 14 J.LI = CL -1.703 0.06112 0.001784 -1.829 -1.702 -1.589 
J.L2 = Q -1.13 0.3043 0.009855 -1.672 -1.151 -0.4746 
J.L3 = l'I 3.182 0.3575 0.01442 2.404 3.21 3.81 
J.L4 = Vi 4.552 0.5923 0.02563 3.791 4.391 5.992 
Patient 15 J.LI = CL -1.217 0.133 0.009131 -1.613 -1.196 -1.06 
J.L2 = Q -0.9437 0.222 0.006044 -1.357 -0.9536 -0.4901 
J.L3 = VI 3.809 0.3015 0.01211 3.157 3.818 4.356 
J.L4 = V2 5.518 0.7607 0.04386 4.384 5.389 7.521 
Patient 16 J.LI = CL -2.343 0.0748 0.002941 -2.492 -2.343 -2.201 
J.L2 = Q -2.154 0.2221 0.007476 -2.587 -2.158 -1.702 
J.L3 = VI 1.801 0.3084 0.01313 1.215 1.8 2.405 
J.L4 = V2 3.872 0.511 0.023 3.135 3.775 5.152 
Patient 17 J.LI = CL -1.778 0.06267 0.001792 -1.915 -1.775 -1.666 
Jl2 = Q -1.05 0.204 0.00422 -1.438 -1.054 -0.6325 
J.L3 = l'I 3.146 0.2847 0.007367 2.559 3.156 3.682 
J.L4 = V2 5.202 0.4479 0.01638 4.416 5.164 6.169 
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